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ABSTRACT 
 
YIZHOU DONG: Design, Synthesis, and Biological Evaluation of Neo-tanshinlactone 
Analogues as Potent and Selective Anti-Breast Cancer Agents 
(Under the direction of Kenan Professor Kuo-Hsiung Lee) 
 
The overall goals of this research are to design and synthesize novel neo-
tanshinlactone analogues, to evaluate their antitumor activity and elucidate structure-activity 
relationships (SAR), to discover novel chemical entities, and to explore the mechanism(s) of 
action.  
Neo-tanshinlactone (90) and its previously reported analogues are potent and 
selective in vitro anti-breast cancer agents. In a continuing study, a highly efficient synthesis 
of 4-ethyl neo-tanshinlactone 91 was accomplished with fewer steps and higher overall yield 
than those previously reported. This synthetic route was applied to develop new lead 
compounds and establish SAR of 90. SAR studies on these compounds revealed the key 
molecular determinants of this family of anti-breast agents. Several analogues (108-110 and 
113) displayed potent and selective anti-breast cancer activity. 
We further explored how the individual rings in the molecule of 90 influence the anti-
breast cancer activity. We designed and synthesized five new classes of compounds derived 
from neo-tanshinlactone. The results led to the discovery of two novel classes of anti-breast 
cancer agents, 2-(furan-2-yl)naphthalen-1-ol and 6-phenyl-4H-furo[3,2-c]pyran-4- one 
derivatives.  
Preliminary SAR of 2-(furan-2-yl)naphthalen-1-ol derivatives was established. 
iv 
 
Compounds 172, 173, and 181 were developed as new anti-breast cancer agents with 
better selectivity than 91. Interestingly, 178 showed broad in vitro cytotoxicity against human 
cancer cell lines. Further development led to tetrahydronaphthalene-1-ol derivatives, a novel 
class of antitumor agents. 186 displayed potent activity against most tumor cell lines tested.  
Novel 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives were synthesized and 
evaluated as novel anti-breast cancer agents. We explored the SAR and optimized the 
substituents. Promising lead compounds 198-201, 211, 213, and 215 showed potent 
inhibition against the SK-BR-3 breast cancer cell line. Importantly, 213 and 215 showed the 
highest cancer cell line selectivity, being approximately 100- to 250-fold more potent against 
SK-BR-3 (0.08, and 0.14 µg/mL, respectively) compared with other cancer cell lines tested.  
Enzyme assays suggested that 91 significantly suppressed CK2α1, ABL, and AKT1, 
and 178 showed higher inhibition activity against CDC42BPB, PKG1β, and SGK1. The 
results will guide us to further explore the mechanisms of action. In addition, we 
demonstrated that 91 is a potent and selective anti-breast cancer agent both in vitro and in 
vivo.  
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CHAPTER 1 
BREAST CANCER AND TREATMENTS 
 
1.1       Introduction 
Breast cancer is the most common malignancy in women.1 Worldwide, more than 1.2 
million women are diagnosed with breast cancer every year, which accounts for one-tenth of 
all new cancers.2 In the U.S., breast cancer accounts for more than one quarter of cancers 
diagnosed in women, according to the American Cancer Society. In 2007, the estimate for 
new cases of invasive breast cancer was 170,000, as well as an estimated 60,000 additional 
cases of in situ breast cancer.3 Male breast cancer is significantly rarer than the female form 
of the disease, but still affects around 2,000 men yearly in the U.S., accounting for 1% of all 
breast cancer.3, 4  
 
1.2 Risk Factors for Breast Cancer 
A risk factor is anything that affects your chance of getting a disease, such as breast 
cancer. In 1940, the lifetime risk of a woman developing breast cancer was 5%. In 2008, the 
American Cancer Society increased that estimate to 12.3%.3  
There are different kinds of risk factors. Some factors, such as a person's age or 
race, cannot be intervened. Others are related to cancer-causing factors in the environment. 
Still other risk factors are affected by personal behaviors, including smoking, drinking, and 
diet.5  
Increasing age 
Age is one of the most important risk factors for breast cancer.3 Generally, breast 
2 
 
cancer incidence and death rates increase with age.3 Based upon statistical data from the 
National Cancer Institute, women aged 20-24 years have the lowest breast cancer incidence 
rate, and women aged 75-79 years have the highest incidence rate, which is 464.8 cases 
per 100,000.6 Age-specific incidence rates decrease in women aged 80 years and older.6 
Family history of breast cancer/genetic predisposition 
Women with a family history of breast cancer, especially in a first-degree relative 
(mother, sister, or daughter), have higher risk of developing breast cancer than those 
without a family history of breast cancer.3, 7 Approximately 5% to 10% of breast cancer 
cases result from inherited mutations or alterations in the breast cancer susceptibility genes 
BRCA1 and BRCA2.8 Based on population studies, BRCA1 mutations may cause a 65% 
risk for women to develop breast cancer by age 70; the corresponding risk for BRCA2 
mutations is 45%. However, not all familial risk is due to a BRCA1 or BRCA2 mutation.9  
Hormonal factors 
Reproductive hormones can regulate cell proliferation and DNA damage, as well as 
promote cancer growth, and thus, influence breast cancer risk.3 A woman’s risk of breast 
cancer may be increased by factors related to the levels of reproductive hormones produced 
by her body, including early menarche (<12 years), older age at menopause (>55 years), 
older age at first full-term pregnancy (>30 years), and fewer numbers of pregnancies.10  
In addition, recent studies demonstrated that the use of combination hormone 
replacement therapy (HRT), including estrogen and progestin, can be linked to increased 
breast cancer risk. A higher risk is associated with longer use.11, 12 
Clinical factors 
High breast tissue density is another strong independent risk factor for the 
development of breast cancer.3 Women with the highest levels of breast density were found 
to have a four- to six-fold increased risk of breast cancer, compared with women with the 
least dense breasts.3, 13-15  
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Some benign breast conditions are closely related to breast cancer risk.3, 16-18 There 
are three types of benign breast conditions based on the degree of risk: non-proliferative 
lesions, proliferative lesions without atypia, and proliferative lesions with atypia. Non-
proliferative lesions do not show much effect on breast cancer risk, because they are not 
associated with any overgrowth of breast tissue. Proliferative lesions without atypia may 
increase a woman’s risk of breast cancer slightly. Proliferative lesions with atypia (including 
atypical ductal hyperplasia and atypical lobular hyperplasia) have a stronger effect on breast 
cancer risk, increasing the risk four to five times higher than normal.3  
 
1.3       Treatments for Breast Cancer 
Many factors must be considered when choosing the optimal treatment for breast 
cancer, including the stage and biological characteristics of the cancer, the patient’s age and 
preferences, and the risks and benefits associated with each treatment protocol.19  
Surgery  
The primary goal of breast cancer surgery is to remove the cancer from the breast 
and to evaluate the stage of the disease.3 Surgery is one of the primary treatments for most 
women with breast cancer. Only cancerous tissue plus a rim of normal tissue is removed in 
a lumpectomy. Total mastectomy includes removal of the entire breast.3 However, breast 
cancer recurrence is still a concern after surgery.1  
Radiation therapy 
Radiation aims to destroy cancer cells remaining in the breast, chest wall, or 
underarm area after surgery or to reduce the size of a tumor before surgery.20 Radiation 
therapy is typically given for five to seven weeks, based on the patient’s condition.3 
Radiation treatment is usually prescribed with other treatments such as chemotherapy. 
Hormone therapy 
4 
 
Estrogens play crucial roles in breast cancer development and growth, and estrogen-
stimulated growth in tumor cells (as well as in normal cells) requires estrogen receptors 
(ERs).21  About two-thirds of human breast tumors express higher levels of ERs than normal 
breast tissues.22 If their breast cancers test positive for estrogen receptors, women can be 
given hormone therapy to block the effects of estrogen on the growth of breast cancer cells.3 
The most widely used therapy for antagonizing ER function is the antiestrogen tamoxifen 
(TAM), which binds to ERs and blocks downstream signaling.22 Patients may stop taking 
tamoxifen because of drug resistance or adverse effects. 
Another class of drugs known as aromatase inhibitors (AIs), which block estrogen 
production, has been approved for use in treating both early and advanced breast cancer.  
These drugs include letrozole, anastrozole, and exemestane.3, 19 They can bind aromatase 
and then reduce the amounts of estrogen in postmenopausal women. Aromatase inhibitors 
are not effective in premenopausal women, because these women produce estrogen from 
the ovaries.3 AIs are often preferred over tamoxifen as the first hormonal treatment for 
postmenopausal women, if their cancer is hormone receptor positive.3 AIs have fewer side 
effect than tamoxifen; however, they can cause osteoporosis and bone fractures.3 
Biologic therapy 
An estimated 15% to 30% of breast cancers overproduce the protein HER2/neu 
(human epidermal growth factor receptor 2), which promotes tumor growth.3 The American 
Cancer Society reported that “these tumors grow faster and are generally more likely to 
recur than tumors that do not overproduce HER2”.3 Herceptin is the first developed 
monoclonal antibody that directly targets the HER2 protein of breast tumors. Its use can 
increase the survival chance for some women with metastatic breast cancer.23-25 Recently, 
herceptin also showed potent activity in treating early-stage breast cancer that over-
expresses HER2.26 As a result, many doctors suggest all invasive breast cancers should be 
tested for the HER2 protein in order to identify women who would benefit from this therapy.27  
5 
 
Chemotherapy  
Chemotherapy refers to the use of chemicals that kill breast cancer cells after the 
tumor has been removed. Its purpose is to increase patient cure rates.3 Combinations of 
drugs are more effective than just one drug alone for breast cancer treatment.28 The drugs 
most commonly used in combination in early breast cancer are cyclophosphamide, 
methotrexate, fluorouracil, doxorubicin, epirubicin, paclitaxel, and docetaxel. Adjuvant 
chemotherapy is usually given for three to six months, based upon the combination of drugs. 
These and other chemotherapy drugs may also be used to reduce cancer size.3 Although 
new cytotoxic agents with unique mechanisms of action have been developed continuously, 
many of them have not been therapeutically useful due to low tumor selectivity.29 The toxic 
side effects, low tumor selectivity, and multidrug resistance with current cancer 
chemotherapy prompt us to develop novel potent anti-breast cancer agents. 
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CHAPTER 2 
ANTI-BREAST CANCER DRUGS (AGENTS) AND THEIR MECHANISMS OF ACTION 
 
In the previous chapter, we discussed the risk factors and general treatments for 
breast cancer. Numerous studies have demonstrated that there are many mechanisms of 
action that could lead to breast cancer including over-expression of HER2, estrogen 
receptors, aromatases, sulfatases, and others. It is important to understand the mechanisms 
of action for the discovery and development of novel anti-breast cancer drugs. In this 
chapter, we will describe the anti-breast cancer drugs in use or under development based 
on their mechanisms of action. 
 
2.1       HER2 Inhibitors 
Receptor protein tyrosine kinases play an important role in signal transduction 
pathways that mediate cell division and differentiation.1 The erbB receptor family contains 
four components: erbB-1/EGFR, erbB-2/Neu/HER2, erbB-3/HER3, and erbB-4/HER4.1 
Abnormal signaling in these pathways can have the following consequences: dysregulation 
of cell proliferation, evasion from apoptosis, angiogenesis, migration, and metastasis.2-5 
Over-expression of EGFR, as well as HER2, is a marker for poor prognosis in many human 
cancers.3, 6, 7  
Figure 2-1 shows the main pathways activated by EGFR and HER2/neu, which can 
affect cell proliferation, angiogenesis, and other signaling transduction results.8 Both the 
phosphoinositide 3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase 
(MAPK) pathway can be activated by EGFR, HER2/neu heterodimerization, and tyrosine 
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phosphorylation.9 AKT activation results in up-regulation of hypoxia-inducible factor-1α 
(HIF1α), which promotes vascular endothelial growth factor (VEGF) production and leads to 
angiogenesis. MAPK activation increases DNA synthesis to induce cell proliferation and 
tumor growth.1, 8, 10 
 
Figure 2-1. Genetic variations and therapeutic targets: HER2/neu8 
 
As shown below, many approaches have been developed to target the erbB receptor 
family, especially HER2, because of its close link to breast cancer:1  
(1)    Monoclonal antibodies (MAbs) bind the extracellular domain of the receptor;  
(2)    Small molecules inhibit kinase activity by binding at the intracellular tyrosine kinase 
domain;  
(3)    Immunotoxin conjugates deliver toxins through erbB receptor targeting;  
(4)    Antisense oligonucleotides or RNAi reduce expression; 
(5)    Adaptor proteins block downstream signaling.  
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The first two approaches have been the most extensively explored. Therapeutic 
agents that act on the HER2/neu receptor through the first two approaches will be discussed 
in more detail below.  
2.1.1    Monoclonal Antibodies 
Trastuzumab (Herceptin) is a fully humanized monoclonal antibody jointly developed 
by Genentech, and was approved for treatment of breast cancers by the U.S. FDA in 
September 1998. It binds to the extracellular domain of HER2 and exerts anti-proliferative 
activity against breast cancers that over-express HER2 (Figure 2-1).11, 12 Herceptin shows 
many effects, including antibody-mediated toxicity, prevention of downstream signaling, and 
promotion of receptor internalization.13-15 However, herceptin cannot block 
heterodimerization of HER2, because the binding site of herceptin is not involved in 
dimerization.1, 16  
Pertuzumab, another antibody, is the first in a new class of agents known as HER 
dimerization inhibitors (HDIs), being developed by Genentech. It also binds to the 
extracellular domain of HER2, but at a site distinct from that of trastuzumab.17 This binding is 
believed to sterically block the region necessary for HER2 to collaborate with other erbB 
family members.1, 18 Therefore, pertuzumab is active against tumors with low or high HER2 
expression, because pertuzumab blocks ligand-induced HER2 heterodimerization.1, 8, 17 
2.1.2   Small Molecular Inhibitors 
1. 4-Anilinoquinazolines 
4-Anilinoquinazolines constitute the most widely studied class of small molecule 
inhibitors.4 They are potent and selective reversible inhibitors of EGFR and HER2 tyrosine 
kinase, and act through competitive binding to the ATP site of the enzyme.19, 20 Although 
Iressa (1, gefitinib) failed to be approved for clinical use, Tarceva (2, erlotinib) was approved 
by the FDA in 2005 for clinical use in cancers over-expressing EGFR (Figure 2-2).21, 22 
GW572016 (3, lapatinib), developed by GSK, is a potent dual inhibitor of EGFR and HER2 
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kinases.19 Lapatinib is now in clinical use for the treatment of breast cancer. To obtain 
prolonged activity with selective kinase inhibitors, an irreversible inhibitor strategy has been 
explored by designing inhibitors to alkylate residues close to the ATP site.23 Several 
irreversible inhibitors are under development, such as CI-1033 (4), EKB-569 (5), and HKI-
272 (6).24-26  
 
 
   
Figure 2-2. Examples of 4-anilinoquinazoline inhibitors of HER2 
 
2. Tyrphostins 
Tyrphostins could be classified as ATP competitive inhibitors, but also as mixed 
competitive inhibitors.27 The characteristic feature of this class is a cis-cyano moiety, which 
13 
 
is important for HER2 inhibitory activity.28, 29 Figure 2-3 shows some examples (7-10).  
 
Figure 2-3. Examples of tyrphostin inhibitors of HER2 
 
3. Pyrrolotriazines 
The pyrrolo[2,1-f][1,2,4]triazine nucleus was developed from the quinazoline kinase 
inhibitor scaffold. Compounds 11-14 inhibited the kinase activity of EGFR, as well as 
inhibited proliferation of the human colon cancer cell line DiFi.30 BMS-599626 (15, Figure 2-
4), developed by BMS, is an effective inhibitor of both EGFR and HER2 tyrosine kinases. It 
shows superior efficacy to gefitinib in human tumor transplant models, and comparable 
activity to trastuzumab in mice with tumors over-expressing HER2.1, 31 A Phase I clinical trial 
has been completed with BMS-599626. 
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Figure 2-4. Examples of pyrrolotriazine inhibitors of EGFR or HER2 
 
4. Pyrrolopyrimidines 
AEE788 (16) and PKI166 (17) are dual EGFR/HER2 inhibitors (Figure 2-5), 
developed from 4-(phenylamino)pyrrolopyrimidines, and inhibit kinase activity in the low 
nanomolar range (Figure 2-5).32-34 These compounds are under development in clinical trials 
by Novatis. 
  
Figure 2-5. Examples of pyrrolopyrimidines as dual EGFR/HER2 inhibitors 
 
5. 5,7-Diazaindolinones 
5,7-Diazaindolinones were developed based on a combination of quinazoline and 
indolinone scaffolds (Figure 2-6). The combination of quinazoline and the five-membered 
lactam ring from the indolin-2-one core led to this class of compounds. Compounds 18-19 
have been found to be dual EGFR/HER2 inhibitors.35 
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Figure 2-6. Examples of 5,7-diazaindolinones as dual EGFR/HER2 inhibitors  
 
6. Others 
There are many natural product “HER2-inhibitors” for which no real mechanism of 
action seems to have been established; some of which may actually inhibit the enzyme. 
Nakijiquinone C (20) is reported as a modestly potent erbB-2 inhibitor, with some selectivity 
over EGFR inhibition.36 11,11’-Dideoxyverticillin (21) is a dual EGFR/HER2 inhibitor (Figure 
2-7).37 
 
Figure 2-7. Structures of nakijiquinone C and 11,11’-dideoxyverticillin 
 
2.2       Estrogen Receptor Inhibitors 
Estrogens are a group of steroidal compounds, and play key roles in development 
and maintenance of normal sexual and reproductive functions, which regulate the growth, 
differentiation, and physiology of the reproductive process.38, 39 Estrogens are also important 
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to the pathological processes of hormone-dependent cancers, such as breast, endometrial, 
prostate, ovarian, and thyroid cancers.40, 41  
Estrogens regulate signal transduction through two main pathways, genomic and 
non-genomic (Figure 2-8).41 In the genomic pathway, estrogens interact with two types of 
estrogen receptors, ERα and ERβ.39 In general, an estrogen can cross the cell membrane 
and bind to its receptor. Estrogen receptors then dimerize, at which time they can undergo 
conformational changes. The dimeric receptor-ligand complex subsequently binds to 
estrogen response element (ERE) sequences in the promoter region of estrogen-responsive 
genes, resulting in the recruitment of co-regulatory proteins (co-activators or co-repressors) 
to the promoter, which leads to an increase or decrease in mRNA levels, the production of 
associated proteins, and finally a physiological response. The genomic pathway typically 
occurs over the course of hours. 42  
Recent studies demonstrated that ERα and ERβ can regulate transcription of some 
genes independent of ERE by interacting with other DNA-bound transcription factors, rather 
than binding directly to DNA.40, 41 These factors include AP-1, SP-1, forkhead box (Fox), oct, 
nuclear factor kappaB (NF-κB), and GATA-3, which are some of the known non-ERE DNA-
bound transcription factors that interact with ERs.39, 43-45  
 
Figure 2-8. Estrogen-mediated genomic and non-genomic pathways39  
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In the non-genomic pathway, estrogens exert their biological effects either through 
the ER located in or adjacent to the plasma membrane or through other non-ER plasma 
membrane-associated estrogen-binding proteins (Figure 2-8).39, 41, 46, 47 The non-genomic 
action of estrogens could regulate a vast range of cellular responses, such as increased 
levels of calcium or nitric oxide, and the activation of multiple intracellular kinase cascades, 
including mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), 
protein kinase A (PKA), and protein kinase C (PKC).39 The non-genomic mechanism is not 
as well understood as the genomic mechanism, but has been observed in many tissues.38 
The process involves many transcription factors that regulate genes involved in many 
cellular processes, including proliferation, differentiation, cell motility, and apoptosis. The 
non-genomic effects occur within a few minutes.48, 49 
Two types of compounds have been developed to regulate estrogen receptor 
function: selective estrogen receptor modulators (SERMs) and selective estrogen receptor 
down regulators (SERDs).50 Baumann et al. summarized that “estrogens, SERMs, and 
SERDs interact with estrogen receptors in different ways: estrogens act only agonistically, 
SERMs act agonistically or antagonistically, and SERDs act only antagonistically. Estrogens 
and SERDs generally have a steroid structure, whereas SERMs lack the steroid structure of 
estrogens but have a tertiary structure that can bind to the estrogen receptors”.50 
2.2.1   Selective Estrogen Receptor Modulators (SERMs) 
Tamoxifen (22) is a selective estrogen receptor modulator (SERM) and has been 
used for more than 30 years for the treatment of breast cancer.51, 52 To improve the efficacy 
and reduce the toxicity of tamoxifen, new ‘tamoxifen-like’ analogues such as toremifene (23), 
droloxifene (24), and idoxifene (25) have been developed (Figure 2-9).50 Toremifene citrate 
is FDA approved for use in advanced (metastatic) breast cancer. Droloxifene (24) and 
idoxifene (25) are still in clinical trials. Further development of tamoxifen also led to fixed-
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ring derivatives (Figure 2-9), including raloxifene (26), arzoxifene (27), acolbifene (28), and 
EM 800 (29).50, 53 Raloxifene was approved by the FDA in 2007 for reducing the risk of 
invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal 
women at high risk for invasive breast cancer. 
 
Figure 2-9. Examples of selective estrogen receptor modulators 
 
2.2.2   Selective Estrogen Receptor Down Regulators (SERDs) 
SERDs have different molecular structures and mechanism of actions compared with 
SERMs (Figure 2-10).50 SERMs act agonistically or antagonistically, while SERDs act only 
antagonistically. Fulvestrant (30) is an analogue of estradiol with a 7α-alkyl sulfinyl chain. It 
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is used for the treatment of hormone receptor-positive metastatic breast cancer in 
postmenopausal women with disease progression following antiestrogen therapy.54 SR 
16234 (31) is a steroidal compound developed by SRI International; it shows high affinity to 
the ERα.55, 56 ZK 703 (32) and ZK 253 (33) display higher potency than tamoxifen and 
fulvestrant in vivo. Clinical studies with these two compounds are ongoing.57 
 
Figure 2-10. Examples of selective estrogen receptor down regulators 
 
2.3       Aromatase Inhibitors 
Another strategy to counteract ER function involves the reduction of estrogen levels 
by blocking a key enzyme required for their biosynthesis.58 Although the different classes of 
steroidal hormones share a common biosynthetic pathway, a characteristic feature of 
estrogen biosynthesis is the formation of the aromatic A ring, which is the final and rate-
limiting step.58, 59 The enzyme aromatase regulates this step (Figure 2-11).59 Aromatase 
belongs to the cytochrome P450 superfamily, located in the endoplasmic reticulum of cells. It 
is composed of a cytochrome P450 hemeprotein (P450 XIX, CYP19), which carries out the 
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aromatization reaction, and a NADPH-cytochrome P450 reductase, a flavoprotein required 
for the electron transfer from NADPH to the cytochrome P450 enzyme.58, 60, 61 This enzyme 
catalyzes the synthesis of estrone (E1) and estrodiol (E2) via the aromatization of the A ring 
of androgen precursors, namely androstenedione and testosterone.59 
 
Figure 2-11. The main pathways involved in production of estrogens by aromatase 
and steroid sulfatase complex59 
 
Inhibition of aromatase would selectively lead to estrogen deprivation, subsequently 
block hormone-mediated transcription, and finally result in loss of estrogenic effects, which 
cannot be achieved by the use of SERMs.62 Aromatase has always been considered the 
most promising target for estrogen-related cancers, and considerable pharmacological and 
clinical data have been devoted to the study of this enzyme complex and to the development 
of potent and selective agents able to interfere with its action. Several classes of steroidal 
(Type I) and non-steroidal (Type II) aromatase inhibitors (AIs) have been developed, and 
potent and effective agents are now in clinical use. 63, 64 
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2.3.1    Steroidal Inhibitors (Type I Inhibitors) 
1. Reversible inhibitors 
Reversible inhibitors are molecules that compete with the natural substrate for 
noncovalent binding to the active site of the enzyme. 63, 65 Steroidal inhibitors are built on the 
structure of androstenedione, with different substituents incorporated at various positions on 
the molecule.65 These inhibitors interact with the aromatase cytochrome P450 enzyme in the 
same manner as the substrate androstenedione.65 Some examples are shown in Figure 2-
12. Compound 34 is also known as formestane, and is used clinically in some countries, but 
not in the U.S. 63 
 
Figure 2-12. Examples of reversible steroidal aromatase inhibitors 
 
2. Irreversible inhibitors 
An irreversible inhibitor contains a reactive chemical moiety and reacts with the 
enzyme to produce a covalent bond between the inhibitor and the protein backbone of the 
enzyme.66, 67 These inhibitors are also classified as affinity labeling inhibitors, alkylating 
agents, or active-site directed irreversible inhibitors.65 Most irreversible aromatase inhibitors 
were designed with an alkylating moiety attached to the B-ring of androstenedione.68, 69 
Some examples are shown in Figure 2-13. 
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Figure 2-13. Examples of irreversible steroidal aromatase inhibitors 
 
3. Mechanism-based inhibitors 
A mechanism-based inhibitor, which mimics the substrate, is converted by the 
enzyme to a reactive intermediate and results in inactivation of the enzyme.65 These 
inhibitors act on the enzyme during the normal catalytic process. They are also called 
enzyme-activated irreversible inhibitors and suicide inhibitors.65 Mechanism-based inhibitors 
have distinct advantages in drug design because of they are highly enzyme specific and 
show prolonged inhibition and minimal toxicities.65 Exemestane (46) is now in clinical use for 
the treatment of advanced breast cancer (Figure 2-14).70, 71  
Figure 2-14. Examples of mechanism-based steroidal aromatase inhibitors 
 
2.3.2    Nonsteroidal Inhibitors (Type II Inhibitors) 
1. Imidazole and triazole derivatives 
Aminoglutethimide (AG, 47) is the pioneer nonsteroidal inhibitor used for the 
treatment of breast cancer. It opened the way to a different approach to the design and 
development of nonsteroidal AIs (NSAIs) inhibitors.72 Many research teams began to 
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investigate compounds containing aza-heterocycles following the hypothesis that the AG 
mode of binding could involve interaction of a nitrogen atom with the heme iron of P450.73 
Second-generation compounds containing imidazole and triazole rings were subsequently 
developed by many groups; examples are shown in Figure 2-15.72, 74 Third-generation 
agents such as letrozole (51) and anastrozole (52) are now used for the adjuvant treatment 
of hormonally-responsive breast cancer, and have proved to be more effective than 
tamoxifen in some clinical studies.75, 76  
 
Figure 2-15. Examples of NSAIs derived from imidazole and triazole  
 
2. Tetralone and tetraline derivatives 
R.W. Hartmann et al. developed many tetrahydronaphthalene leads and obtained 
remarkable results with two major compounds classes, tetralone and tetraline derivatives.77, 
78 Compounds 53-56 showed high aromatase inhibitory potency at low micromolar 
concentrations (Figure 2-16).79, 80  
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Figure 2-16. Examples of NSAIs derived from tetralone and tetraline  
3. Benzopyranone derivatives 
M. Recanatini used the method of comparative molecular analysis to develop a 
series of (di)benzopyranone derivatives.81-83 The most interesting compounds were 57-60 
(Figure 2-17), which showed strong inhibitory potency and selectivity with respect to P450.84 
 
Figure 2-17. Examples of NSAIs derived from benzopyranone  
 
2.4       Steroid Sulfatase Inhibitors 
Sulfatases are enzymes of the esterase class, which catalyze the hydrolysis of 
sulfate monoester bonds in a wide variety of physiological substrates.85 In human cells, 12 
different sulfatases have been well characterized.86-88 Steroid sulfatases (STS), a subset of 
sulfatases, are characterized by their ability to regulate the local production of estrogens and 
androgens from systemic precursors in several tissues.85, 89 Many studies are ongoing to 
develop STS inhibitors as novel therapeutics for the treatment of breast cancer. 
Estrone sulfate (E1S) is considered to be a major source of active estrogens in 
mammary tumors, especially in women after menopause (Figure 2-11).85, 90 Although E1S 
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itself does not bind to estrogen receptors,91 it is converted initially by STS to unconjugated 
E1 and then by a reducing enzyme (17β-hydroxysteroid dehydrogenase) to E2, which binds 
to the receptors with high affinity (Figure 2-11).85, 92  
The current STS inhibitors have been designed based upon the natural substrates or 
have been discovered by screening compound libraries.85 STS inhibitors can be classified 
as (i) steroidal inhibitors and (ii) non-steroidal inhibitors.58, 65 An alternative classification is (i) 
reversible inhibitors and (ii) irreversible inhibitors.85 In the following sections, the current 
status in the development of STS inhibitors will be reviewed. 
2.4.1   Steroidal STS inhibitors 
1. Reversible STS inhibitors 
Most of the reversible inhibitors feature a steroid skeleton derived from substrate or 
product. After the discovery of estrone-3-methylthiophosphonate (EMATE, 61) in the early 
1990s,93 substantial efforts began to develop novel inhibitors.85  
Many substrate-based inhibitors based upon EMATE were developed by installing 
different types of sulfate substituents, leading to E1S analogues (Figure 2-18),92 such as 62, 
which showed weak STS inhibitory activity.85 In 1998, estradiol-based inhibitors were 
discovered by Poirier and Boivin.94 Compounds 63-64 displayed STS inhibitory activity at 
nanomolar concentrations, and are still the most potent reversible inhibitors of STS known to 
date. Because compounds with a non-aromatic A-ring can be accepted by STS as 
substrates, Nussbaumer et al. investigated many steroidal non-aryl sulfamates.95 However, 
compounds 65-66 showed weak STS inhibitory activity. In addition, investigations have 
shown that progestins, such as danazol (67), promegestone (68), tibolone, and 
medrogestone, inhibit STS.96-99 Their inhibitory potency ranges from micromolar to 
nanomolar.  
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Figure 2-18. Examples of steroidal reversible STS inhibitors 
 
2. Irreversible STS inhibitors 
All irreversible inhibitors reported to date contain the arylsulfamate moiety 85, 92 
EMATE, the first irreversible inhibitor, was reported by Howarth et al. in 1994. 78 However, 
due to its potent estrogenic activity, EMATE could not be used as a therapeutic agent.100 
Further development of novel derivatives was aimed at reducing estrogenic activity, while 
retaining STS inhibitory activity.92 Structural modifications of EMATE focused on the A- and 
D-rings.101-104 Compounds 69-72 showed high STS inhibitory activity and low estrogenic 
activity (Figure 2-19). The IC50 of 70 was 1 nM, while that of EMATE was 18 nM. 
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Figure 2-19. Examples of steroidal irreversible inhibitors 
 
2.4.2    Nonsteroidal STS Inhibitors 
1. Mono-, bi-, and tri-cyclic arylsulfamates 
To mimic the A-, B-, C-rings of EMATE, mono-, bi-, and tri-cyclic arylsulfamates were 
designed by different groups (Figure 2-20).105-107 Most monocyclic arylsufamates were less 
effective than EMATE, except compound 73, which was three-fold superior to EMATE. 
Although most known bi- and tri-cyclic arylsulfamates, such as 75 and 76, were less potent 
than EMATE, they merit further development based on their simplified scaffolds and 
increased selectivity. 
 
 
Figure 2-20. Examples of nonsteroidal STS inhibitors 
 
2. STS inhibitors discovered from screening 
Novel inhibitors with different scaffolds were discovered by screening different 
28 
 
compound libraries. Compounds 77-78 were found to have STS inhibitory activity (Figure 2-
21). They were less potent than EMATE, but still provided new scaffolds without a sulfamate 
unit for possible development of novel inhibitors.92, 108  
 
Figure 2-21. Examples of nonsteroidal inhibitors from screening 
 
2.4.3    Dual Aromatase-Sulfatase Inhibitors 
Recently, dual aromatase-steroid sulfatase inhibitors (DASIs), which combine 
features of STS inhibitors and AIs, were designed to enhance the response of hormone-
dependent breast cancer both by providing more severe estrogen depletion and by reducing 
the synthesis of other steroids with estrogenic properties.58, 109, 110 Initially, the sulfamate 
pharmacophore for STS inhibition was introduced into isoflavones, which are weak AIs, and 
the resulting compounds did inhibit STS both in vitro and in vivo, confirming the feasibility of 
the DASI concept.101 Subsequent studies led to 79, the first potent dual aromatase-steroid 
sulfatase inhibitor, which acted as a reversible AI and irreversible STS inhibitor (Figure 2-
22).111 Both 79 and 80 are promising DASIs. In compounds 81 and 82, the sulfamate unit is 
incorporated into letrozole and anastrozole, respectively. Both compounds showed 
interesting inhibitory activity in vitro and in vivo.59, 112 
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Figure 2-22. Examples of dual aromatase-sulfatase inhibitors 
 
2.5       Chemotherapeutic Agents with Other Mechanisms of Action 
Many classes of chemotherapeutic drugs are available for clinical use against breast 
cancer. Table 2-1 lists some of the commonly used drugs together with their mechanisms of 
action, and their structures are shown in Figure 2-23. 
Table 2-1. Classes of therapeutic agents for the treatment of breast cancer 
Class Mechanisms of Action Examples in Clinical Use 
Anthracyclines 
Intercalate between base pairs of the 
DNA/RNA strand 
Inhibit topoiosomerase II enzyme 
Create iron-mediated free oxygen radicals
Daunorubicin 
Doxorubicin 
Epirubicin 
Idarubicin 
Valrubicin 
Taxanes Block microtubule assembly Docetaxel, Paclitaxel 
Pyrimidine 
analogues 
DNA precursors/antimetabolites 
Capecitabine and 
5-Fluorouracil 
Nucleosides  Inhibit DNA replication Gemcitabine 
Nitrogen mustard Alkylating agent Cyclophosphamide 
Alkaloid Block microtubule assembly Vinorelbine 
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Figure 2-23. Examples of chemotherapeutic agents in clinical use 
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CHAPTER 3 
DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIPS OF NOVEL NEO-
TANSHINLACTONE ANALOGUES 
 
3.1       Introduction 
Historically, natural products have been an extremely significant source of drugs and 
drug leads, which have led to numerous clinically used medicines.1-4 Accordingly, our group 
is interested in the discovery and development of novel anticancer drugs from natural plants. 
Drug discovery from medicinal plants has played an important role in the treatment of cancer, 
and about 74% of anticancer compounds are either natural products or natural product-
derived.5 Tamoxifen (TAM, Figure 1) is the most widely used selective estrogen receptor 
modulator (SERM) for the treatment of breast cancer.6 However, it has shown some acute 
and long term toxicity, such as bone metastasis.6 Other drugs, including cyclophosphamide, 
doxorubicin (adriamycin), and paclitaxel (Taxol), are also recommended to be used in 
combination in early breast cancer.7 Although the death rate from breast cancer has 
declined significantly because of earlier detection and more effective treatments, toxic side 
effects, low tumor selectivity, and multidrug resistance with cancer chemotherapy still 
prompt the development of novel potent anti-breast cancer agents.8 
Tanshen, the rhizome of Salvia miltiorrhiza Bunge, is used primarily in traditional 
Chinese medicine (TCM) for the treatment of coronary heart diseases, inflammatory 
diseases, and chronic hepatitis. Many biologically active constituents, including tanshinone I 
and tanshinone IIA, which have been studied extensively as anticancer agents, were first 
isolated from the roots of Salvia miltiorrhiza.9 Recently, Dr. Xihong Wang in our group 
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reported that neo-tanshinlactone (90) (Figure 3-1), a minor component isolated from an 
EtOH extract of S. miltiorrhiza, showed significant selective in vitro anti-breast cancer activity 
as compared to TAM. Specifically, it was 10-fold more potent and 20-fold more selective 
than TAM against ER+ and HER2++ breast cancer cells.10 Three series of analogues were 
synthesized by Dr. Wang to study the SAR (Figure 3-2).11  The A series studied the C-4 and 
-6 positions, while the B and C series explored ring-D modification. In addition, Dr. Xihong 
Wang studied three series of furanocoumarin analogues, some of which showed antitumor 
promotion activity, but weak cytotoxic activity (Figure 3-2).12 Compound 91 (Figure 3-1), a 
congener of 90, was about twice as active as 90 against MCF-7 and SK-BR-3 cell lines.11 
Preliminary structure-activity relationships (SAR) showed that a methylated furan ring-D and 
the C-4 substituent in ring A are critical for anti-breast cancer activity.11 These promising 
results encouraged us to continue the modification of this series to develop novel anticancer 
drug candidates. To increase the chemical availability, we also optimized the synthetic 
pathway. In this chapter, we describe further modifications of the A-, B-, C- and D-rings, as 
well as biological evaluation of newly synthesized analogues against several human cancer 
cell lines, including MCF-7 (estrogen receptor positive breast cancer), SK-BR-3 (estrogen 
receptor negative, HER2 over-expressing breast cancer), ZR-7-51 (estrogen receptor 
positive breast cancer), MDA-MB-231 (estrogen receptor negative breast cancer), A549 
(human lung cancer), DU145 (prostate cancer), KB (nasopharyngeal carcinoma), and KB-
vin (vincristine-resistant KB subline). 
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Figure 3-1. Structures of tamoxifen, tanshinone I, tanshinone IIA, neo-tanshinlactone 
(90) and its analogues 91-92 
 
Figure 3-2. Neo-tanshinlactone analogues and furanocoumarin analogues 
 
3.2       Design 
Our general goals in drug design are to optimize the synthesis of active analogues, 
systematically explore SAR, and develop new lead compounds. Thus, our first goal in this 
study was to optimize the synthetic route to 91. We aimed to reduce the number of steps 
and increase yields. The optimized synthetic route would then be applied to synthesize new 
analogues. Secondly, synthetic modifications of 90 were considered, because the resulting 
fundamental chemical and physical changes may affect molecular shapes, bond angles, and 
partition coefficients. Different substituents can have different hydrophobic interactions, 
sizes, and electrostatic effects that can influence interaction of a ligand with its target 
receptors. Structures of designed new neo-tanshinlactone analogues are shown in Figure 3-
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3. For our 90-analogues, we reported previously that a C-4 substituent in ring-A is critical for 
anti-breast cancer activity.11 Thus, compounds 108-116 with substituents of different sizes 
and electrostatic properties were designed to find optimal groups at this position. In ring-B, 
we changed the phenyl ring to a pyridinone ring in 121 and 122 to explore a ring system 
effect. The strategy of bioisoteric replacement can be a useful tool in analogue design. 
Based on this concept, the oxygens in ring-C were changed to sulfur and nitrogen (127-131). 
Compounds with different substituents on the furan D-ring (134-142) were also designed. 
Moreover, the degree of saturation (number of double bonds) can change the orientation of 
a molecule and affect its in vitro activity and selectivity. Consequently, we designed 152-154 
and 155-156 to have a more saturated non-aromatic ring-A and dihydrofuran ring-D, 
respectively. Finally, the furan D-ring was changed to a substituted phenyl ring in 159 to 
examine the ring system effect and interaction volume.  
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Figure 3-3. Structures of designed neo-tanshinlactone analogues 
 
3.3       Chemistry 
Synthesis of analogue 91 was achieved in five steps and an overall yield of 18%, 
compared with seven steps and 3% yield reported before12,13 (Scheme 3-1). A Grignard 
reaction of 93 in the presence of zinc chloride gave 94 in an improved yield of 85%.13 
Addition of zinc chloride increased the yield more than 25%. Analogue 95 was obtained in 
one step by oxidation of 94 with Pd/C, rather than the prior two steps (hydrochloric acid & 
Pd/C).11 Demethylation of 95 with boron tribromide gave naphthol 96. Treatment of 96 with 
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polyphosphoric acid (PPA) in the presence of 85% P2O5 and malonic acid produced 102 in 
53% yield. Phosphorus pentoxide can remove water from the reaction system and increase 
the yield and reproducibility. Finally, analogue 91 was obtained via a tandem alkylation 
/intramolecular Aldol reaction with an optimized procedure (70% yield).14 This procedure can 
increase the yield around 20%. The optimized synthetic route can be applied to synthesize 
new analogues and produce 91 in large scale for animal test. 
Scheme 3-1. Optimized synthetic pathway to 91 and analogues 108-116 
 
Reagents and conditions: (a) EtMgBr, ZnCl2, THF, rt; (b) Pd/C, triglyme, reflux; (c) BBr3, 
CH2Cl2; (d) malonic acid, PPA (85% P2O5), 75 °C, 3 h; (e) chloroacetone, HOAc/NH4OAc, 
toluene/EtOH, reflux, 24 h; (f) NBS, dibenzoyl peroxide, toluene, reflux; (g) BBr3, CH2Cl2, 
reflux, 3 h; (h) Ac2O, Et3N, 10 h; (i) 2-chloro-N,N-dimethylethanamine, K2CO3, acetone, 12h. 
 
Using the optimized synthetic pathway, target compounds 108-112 were prepared 
from various substituted 1-naphthols (97-101), as shown in Scheme 3-1. Treating naphthols 
97-101 with malonic acid in the presence of PPA (85% P2O5) provided benzochromenones 
103-107, which were converted to target compounds 108-112 under the same conditions as 
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synthesis of 91.14 Compound 113 was obtained by treatment of 91 with N-bromosuccinimide 
(NBS) and dibenzoyl peroxide.15 Removal of the methyl group of 110 with boron tribromide 
afforded 114, which was esterified with acetic anhydride, and alkylated with 2-chloro-N,N-
dimethylethanamine under basic conditions to give 115 and 116, respectively.   
B-ring modification was achieved through a two-step reaction sequence. 
Commercially available substituted anilines 117 and 118 were reacted with diethyl malonate 
at 220 °C for 8 h to give intermediates 119 and 120 (Scheme 3-2).16, 17 The desired 
compounds 121 and 122 were obtained through the tandem alkylation/intramolecular Aldol 
reaction described above and shown in Scheme 3-1.  
Scheme 3-2. Synthetic pathway to analogues 121-122 
 
Reagents and conditions: (a) diethyl malonate, 220°C, 8h; (b) chloroacetone, HOAc, 
NH4OAc, toluene/EtOH, reflux, 24 h. 
 
Target compounds 127 and 128, which are bio-isosteres of 92, were obtained by 
using the same two synthetic steps shown in Scheme 1 for 91 from naphthol 96, except that 
the starting materials were naphthalene-1-thiol 123 and naphthalen-1-amine 124 (Scheme 
3-3). Compounds 92 and 91 were converted to thiolactones 129 and 130, respectively, using 
Lawesson’s reagent.18 Compound 131 was obtained by treatment of 130 with sodium 
acetate and hydroxylamine hydrochloride.19   
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Scheme 3-3. Synthetic pathway to analogues 127-131 
 
 
d
e
131: R= Et X= NOH
O
O
O
R
O
X
O
R
92: R= H
91: R= Et
129: R= H X= S
130: R= Et X= S
 
Reagents and conditions: (a) malonic acid, PPA (85% P2O5), 75 °C, 3 h; (b) chloroacetone, 
HOAc/NH4OAc, toluene, EtOH, reflux, 24 h; (c) diethyl malonate, PPA (85% P2O5), 170 °C, 
2h; (d) Lawesson’s reagent, toluene, reflux, 5h; (e) NH2OH HCl, NaOAc, MeOH, reflux, 12 h. 
 
Target compounds 134-142 with various substituents on the D-ring were synthesized 
with the same tandem alkylation/intramolecular Aldol reaction using different bromoketones 
148 (Scheme 3-4). Compound 144 was synthesized by Negishi cross-coupling reaction of 
compound 143 with 4-methylpent-3-enyl zinc(II) bromide in 96% yield.20, 21 Treatment of 143 
with AlCl3 followed by demethylation by BBr3 gave 145 in 84% yield.21 Compounds 146 and 
147, with 5- and 6-membered A-rings, respectively, are commercially available. Compounds 
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145-147 underwent the previously reported two-step ring closure reactions to afford 152-154 
(Scheme 3-5). Reduction of 92 and 91 with palladium acetate, triethyl amine, and formic 
acid22 afforded 155 and 156, respectively (Scheme 3-6). Compound 159 was obtained from 
157 by using esterification23 and Heck reactions.24   
Scheme 3-4. Synthetic pathway to analogues 134-142 
 
 
Scheme 3-5. Synthetic pathway to analogues 152-154 
OMe
Br
OMe OH
a b
143 144 145  
 
Reactions and conditions: (a) (4-methylpent-3-enyl)zinc(II) bromide, Pd(Cl2)(dppf), THF, 
reflux, 1h; (b) (i) AlCl3, DCM, 0 °C, 15 min; (ii) BBr3, CH2Cl2; (c) malonic acid, PPA, 75 °C, 3 
h; (d) chloroacetone, HOAc/NH4OAc, toluene/EtOH, reflux, 24 h; 
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Scheme 3-6. Synthetic pathway to analogues 155-156, and 159 
 
 
Reagents and conditions: (a) Et3N, formic acid, Pd/C, acetone, 12 h; (b) 2-bromo-4-
methylbenzoyl chloride, DMAP, DIEA, THF, rt, 12h; (c) Pd(OAc)2, PPh3, NaOAc, DMA, 
reflux, 3h.  
 
3.4       Results and Discussion 
Together with 90 and previously reported analogues 91 and 92, the newly 
synthesized analogues (108-116, 121-122, 127-131, 134-142, 152-156, and 159) were 
evaluated for in vitro anti-breast cancer activity against two human tumor cell lines: MCF-7 
(ER+) and SK-BR-3 (HER2+). Compounds that had ED50 values less than 4 µg/mL were 
also examined against ZR-75-1 (ER+, HER2+) and MDA-MB-231 (ER-) breast cancer cell 
lines (Table 3-1).  
Initially, we investigated the effects of substitutions around the skeleton of 90 by 
comparing 90-92 with 108-116. The compounds displayed different degrees of activity and 
selectivity toward the four breast cancer cell lines.  
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Against the MCF-7 cell line, small alkyl groups were favored relative to other groups 
at C-4 on ring-A. Analogue 91, which has a C-4 ethyl group, was the most potent compound 
among those tested against MCF-7. Its ED50 (0.2 µg/mL) was slightly better than that (0.6 
µg/mL) of 90, which has a C-4 methyl group. The rank order of potency for all C-4 
substituted analogues was 91 (Et) > 90 (Me) > 109 (Pr) = 108 (i-Pr) > 110 (OMe) > 92 (H) > 
112 (F) > 116 [2-(dimethylamino)ethoxy] > 115 (OAc) > 114 (OH) > 111 (OEt). The 
substituents on the furan (ring-D) double bond were also investigated. A methyl group (91) 
was better than either an ethyl (136) or 4-methoxyphenyl (142) group at the R2 position. 
However, at the R3 position, a methyl group was distinctly disfavored (137-142). These 
results indicated that the optimal combination on ring-D was methyl at R2 and hydrogen at 
R3. 
Most compounds were equipotent or more potent against SK-BR-3 compared with 
MCF-7 cells. Compounds 91 and 90 were even more potent against SK-BR-3, with ED50 
values of 0.1 and 0.2 µg/mL, respectively.  However, 109 and 113 [4-(1-bromoethyl)] were 
also as potent as 91, and 108 was equipotent to 90 against this cell line.  Compounds 92, 
112, 108, and 111 showed good but lower activity (ED50 1.0, 1.1, 2.0, 2.5 µg/mL, 
respectively), while 114, 115, and 116 were even less potent. These results indicate that the 
size, orientation, and electronic effect of groups at C-4 are important to the activity. Perhaps 
even more importantly, certain substituents could greatly affect the SK-BR-3/MCF-7 
selectivity. Compounds 109-111 had approximately tenfold ratios of SK-BR-3/MCF-7 
selectivity. For the D-ring analogues (134-142), most showed similar activity against SK-BR-
3 and MCF-7. An exception was 140, which showed moderate activity against SK-BR-3 
(ED50 2.1 µg/mL), but was completely inactive against MCF-7. 
To further explore the selectivity, compounds with ED50 values less than 4 µg/mL, 
were further examined against two additional breast cancer cell lines, ZR-75-1 (ER+, HER2+) 
and MDA-MB-231 (ER-). Most compounds had similar potency against the SK-BR-3 and 
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ZR-75-1 cell lines. However, 108 had a tenfold ratio of ZR-75-1/SK-BR-3 selectivity, while 
109 had a threefold ratio. Importantly, 110 showed a 23-fold ratio of ZR-75-1/MCF-7 
selectivity. All compounds tested were not active against the MDA-MB-231 cell line, which 
confirmed that these novel analogues were highly selective.  
As indicated by ZR-75-1/SK-BR-3 selectivity ratios, we observed that some 
compounds (e.g., 109 and 110) were more sensitive to cell lines over-expressing only HER2 
(SK-BR-3 and ZR-75-1), while others (e.g., 108) were more sensitive to cell lines over-
expressing both HER2 and ER (ZR-75-1). These results will facilitate our studies on the 
mechanism(s) of action. Because ring-A is critical to activity and selectivity, we will further 
explore C1-C4 positions in the future. 
We also investigated analogues involving skeletal modifications in ring-B, -C, or –D. 
Compounds 121-122 contain a pyridinone rather than phenyl ring-B and were much less 
active than 92. Bioisosteric modifications of either lactone oxygen to nitrogen or sulfur in 
ring-C led to dramatically decreased or abolished anti-breast cancer activity (127-131). The 
results demonstrated that the lactone ring is an important feature to the activity. Compounds 
152, 154 and 155-156 with a non-aromatic ring-A and dihydrofuran ring-D, respectively, 
showed decreased activity compared with 92 and 91, respectively. Interestingly, 153 
showed moderate activity against MCF-7, SK-BR-3, and ZR-75-1 cell lines. Compound 159 
with a substituted phenyl rather than furan D-ring was inactive. These results, together with 
our previously reported data, indicated that an unsaturated furan is favored for ring-D.  
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Table 3-1. Cytotoxicity of compounds against tumor cell linesa 
Compd R1 R2 R3 X1 X2 MCF-7 SK-BR-3 ZR-75-1 MDA-MB-231 
90 Me Me H O O 0.6 0.2 0.3 10.0 
91 Et Me H O O 0.2 0.1 0.1 8.8 
92 H Me H O O 4.0 1.0 4.0 10.3 
108 iPr Me H O O 1.4 2.0 0.2 >10 
109 Pr Me H O O 1.2 0.1 0.3 >10 
110 OMe Me H O O 2.3 0.2 0.1 6.4 
111 OEt Me H O O >20 2.5 1.9 9.8 
112 F Me H O O 4.5 1.1 0.8 >10 
113 BMEb Me H O O NTc 0.1 0.1 14.1 
114 OH Me H O O 15.0 5.0 NT NT 
115 OAc Me H O O 6.0 5.7 NT NT 
116 DAEd Me H O O 5.0 5.8 NT NT 
121 Me -- -- -- -- 11.0 12.1 NT NT 
122 Pr -- -- -- -- >20 15.1 NT NT 
127 H Me H S O >20 11.7 NT NT 
128 H Me H N O NT 4.4 NT NT 
129 H Me H O S >20 >20 NT NT 
130 Et Me H O S >20 16.3 NT NT 
131 Et Me H O NOH >20 18.8 NT NT 
134 H Et H O O 2.5 1.8 2.3 >10 
135 Me Et H O O 7.5 11.3 NT NT 
136 Et Et H O O 1.3 1.5 0.6 >10 
137 H Me Me O O >20 6.9 NT NT 
138 Et Me Me O O 8.0 9.8 NT NT 
139 H H Me O O >20 12.1 NT NT 
140 Et H Me O O >20 2.1 2.2 9.6 
141 H PMPe H O O NT 5.8 NT NT 
142 Et PMP H O O >20 >20 NT NT 
152 H -- -- -- -- NT >20 NT NT 
153 H -- -- -- -- 3.7 1.32 2.09 9.81 
154 Me -- -- -- -- NT 10.09 NT NT 
155 H -- -- -- -- NT 13.7 NT NT 
156 Et -- -- -- -- NT 5.1 NT NT 
159 -- -- -- -- -- NT >20 NT NT 
a) Mean ED50 (µg/mL), Standard error of independent determinations was less than 5%; b) BME: 1-
bromoethyl; c) NT: not tested; d) PMP: 4-methoxyphenyl; e) DAE: 2-(dimethylamino)ethoxy. 
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To further investigate human tumor-tissue-type selectivity, compounds with ED50 
values less than 4 µg/mL against breast cancer cell lines were tested against four different 
human cancer cell lines, A549 (lung), DU145 (prostate), KB (nasopharnygeal), and KB-vin 
(its vincristine-resistant subline), using 91 as a positive control (Table 3-2). Except for 111 
and 153, none of the compounds were active against the four tumor cell lines tested. 
Compound 153 was active against A549 and KB-vin, but not active against DU145 and KB, 
which indicated that a cyclohexene ring-A could affect the tumor-tissue-type selectivity. In 
summary, these results demonstrated that our novel analogues were extremely selective for 
breast cancer cell lines. 
Table 3-2. Cytotoxicity of compounds against tumor cell linesa 
Compd A549 DU145 KB KB-vin
91 10.6 15.9 13.1 13.2 
108 10.8 10.5 10.5 7.3 
109 11.7 14.6 12.3 10.7 
110 10.0 14.4 13.1 11.6 
111 3.5 4.7 3.7 5.3 
112 13.5 18.2 13.1 15.3 
113 >20 17.7 12.7 >20 
134 8.2 8.7 7.5 6.6 
136 18.2 15.9 12.3 14.6 
140 11.8 14.1 13.7 12.8 
153 2.6 8.3 8.0 2.6 
aSee Table 3-1. 
 
3.5      Conclusions 
In summary, a highly efficient synthesis of 91 was accomplished with fewer steps 
and higher overall yield than those previously reported. This synthetic pathway was used to 
prepare new analogues. The SAR study led to the following observations. (1) C-4 position is 
critical for both potency and selectivity. The order of potency against SK-BR-3 was ethyl = 2-
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bromoethyl = propyl > methyl = methoxy > fluoro = hydrogen > isopropyl > ethoxy > 
dimethylamino > acetate > hydroxyl. Analogues with 4-isopropyl, -propyl and -methoxy 
groups showed high selectivity against different breast cancer cell lines. (2) The order of 
potency at the C-17 position was methyl > ethyl > hydrogen, while the order of potency at 
the C-16 position was hydrogen > methyl. (3) Pyridinone ring is not favored for ring-B. (4) 
Lactone ring-C is essential for activity. (5) Ring-D is preferably an unsaturated furan ring. 
Based upon all results, a mechanism of action study is in progress. Due to their high 
selectivity and potency, 108-110 and 113 are novel promising anti-breast cancer candidates. 
 
3.6       Experimental Section 
3.6.1    Chemistry 
Materials and Methods. Melting points were measured with a Fisher Johns melting 
apparatus without correction. 1H NMR spectra were measured on a 300 MHz Varian Gemini 
2000 spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Mass spectra were measured on a Shimadzu LC-MS2010 instrument. Thin-layer 
chromatography (TLC) and preparative TLC were performed on precoated silica gel GF 
plates purchased from Merck, Inc. Biotage Flash+ or Isco Companion systems were used 
for flash chromatography. Silica gel (200-400 mesh) from Aldrich, Inc., was used for column 
chromatography. All other chemicals were obtained from Aldrich, Inc, and Fisher, Inc. 
Intermediates 96-107 and 125-126 for target compounds 108-112 and 127-128 were 
prepared by the methods described in our previous paper.11  
Preparation of intermediates 119-120 for target compounds 121-122. 
Methylaniline or N-propylaniline (9.942 mmol) and diethyl malonate (31.65 mmol) were 
refluxed at 250 °C for 7 h so that the EtOH generated escaped freely from the top of the air 
condenser. After cooling, the mixture, which had formed a red-brown crystalline paste, was 
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diluted with light petroleum and filtered. The solid was washed with MeOH to give the 
desired compound, 119 or 120. 
4-Hydroxy-6-methyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione (119). 28% yield; 
MS: m/z 244 (M+H+); 1H NMR (300 MHz, CDCl3, ppm): δ 3.80 (s, 3H, CH3), 5.68 (s, 1H, 
COCH), 7.45-7.54 (m, 2H, aromatic), 7.78-7.83 (m, 1H, aromatic), 8.34 (d, J = 8.1 Hz, 1H, 
aromatic). 
4-Hydroxy-6-propyl-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione (120). 28% yield; 
MS: m/z 272 (M+H+); 1H NMR (300 MHz, CDCl3, ppm): δ 1.08 (t, J = 7.5 Hz, 3H, CH3), 1.82 
(h, J = 7.5 Hz, 2H, CH2CH3), 4.31 (t, J = 7.8 Hz, 2H, CH2CH2CH3), 5.67 (d, J = 0.9 Hz, 1H, 
COCH), 7.42-7.51 (m, 2H, aromatic), 7.75-7.81 (m, 1H, aromatic), 8.33-8.36 (m, 1H, 
aromatic). 
Synthesis of neo-tanshinlactone analogues 108-112, 121-122, 127-128, and 134-
142. To a solution of 102-107, or 119-120, or 125-126, or 132-133 (0.20 mmol) in toluene (8 
mL) was added a mixture of HOAc (59 mg, 1.0 mmol) and NH4OAc (75 mg, 1.0 mmol) in 
EtOH (2 mL) and chloroacetone (90 mg, 1.0 mmol) or 3-bromobutan-2-one, 2-
bromopropanal, 1-bromobutan-2-one, 2-bromo-1-(4-methoxyphenyl)ethanone. The mixture 
was stirred for 30 min at rt, and then heated to 60 °C for 30 min. Subsequently, it was 
refluxed for 24 h. After cooling, the mixture was diluted with H2O and extracted with EtOAc. 
The organic layer was dried over Na2SO4, filtered, and evaporated. The residue was purified 
by column chromatography (hexane/EtOAc) to give target compounds.  
6-Isopropyl-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (108). 65% yield; 
mp 155-157 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.42 (t, J = 6.6 Hz, 6H, (CH3)2), 2.41 (d, 
J = 1.2 Hz, 3H, CH3), 3.76 (h, J = 6.9 Hz, 1H, CH(CH3)2), 7.44 (d, J = 1.2 Hz, 1H, OCH), 
7.56-7.64 (m, 2H, aromatic), 7.87 (d, J = 9.0 Hz, 1H, aromatic), 8.05 (d, J = 9.0 Hz, 1H, 
aromatic), 8.51 (d, J = 7.8 Hz, 1H, aromatic); HRMS Calcd for C19H17O3 (M+H+):  293.1178, 
found: 293.1168. 
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1-Methyl-6-propyl-11H-benzo[h]furo[3,2-c]chromen-11-one (109). 59% yield; mp 
141-143 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.04 (t, J = 7.2 Hz, 3H, CH2CH2CH3), 1.78 
(m, 2H, CH2CH2CH3), 2.40 (d, J = 1.2 Hz, 3H, CH3), 3.06 (t, J = 7.5 Hz, 2H, CH2CH2CH3), 
7.42-7.46 (m, 2H, aromatic & OCH), 7.55 (t, J = 8.4 Hz, 1H, aromatic), 7.83 (d, J = 9.0 Hz, 
1H, aromatic), 7.94 (d, J = 9.0 Hz, 1H, aromatic), 8.49 (d, J = 8.4 Hz, 1H, aromatic); HRMS 
Calcd for C19H17O3 (M+H+): 293.1178, found: 293.1175. 
6-Methoxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (110). 29% yield; 
mp 225-227 °C ; 1H NMR (300 MHz, CDCl3, ppm): δ 2.40 (s, 3H, CH3), 4.02 (s, 3H, OCH3), 
6.95 (d, J = 7.8 Hz, 1H, aromatic), 7.42 (s, 1H, OCH), 7.54 (t, J = 7.8 Hz, 1H, aromatic), 7.78 
(d, J = 9.0 Hz, 1H, aromatic), 8.15 (d, J = 9.0 Hz, 2H, aromatic); HRMS Calcd for C17H13O4 
(M+H+): 281.0814, found: 281.0816. 
6-Ethoxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (111). 28% yield; mp 
201-203 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.56 (t, J = 7.2 Hz, 3H, CH2CH3), 2.39 (s, 
3H, CH3), 4.20 (q, J = 7.2 Hz, 2H, CH2CH3), 6.91 (d, J = 7.8 Hz, 1H, aromatic), 7.40 (s, 1H, 
OCH), 7.50 (t, J = 8.4 Hz, 1H, aromatic), 7.75 (d, J = 9.0 Hz, 1H, aromatic), 8.11 (d, J = 8.4 
Hz, 1H, aromatic), 8.16 (d, J = 9.0  Hz, 1H, aromatic); HRMS Calcd for C18H14O4 (M+H+):  
295.0970, found: 295.0970. 
6-Fluoro-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (112). 20% yield; mp 
215-217 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.42 (d, J = 1.8 Hz, 3H, CH3), 7.27-7.33 (m, 
1H, aromatic), 7.48 (d, J = 1.2 Hz, 1H, OCH), 7.55-7.62 (m, 1H, aromatic), 7.93 (d, J = 9.0 
Hz, 1H, aromatic), 8.03 (d, J = 9.0 Hz, 1H, aromatic), 8.40 (d, J = 8.7 Hz, 1H, aromatic); 
HRMS Calcd for C16H10FO3 (M+H+): 269.0614, found: 269.0616. 
5-Aza-N-methyl-1-methyl-4H-benzo[h]furo[3,2,c]chromene-4,11-dione(121). 50% 
yield; mp 265-267 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.38 (d, J = 1.5 Hz, 3H, CH3), 3.82 
(s, 3H, NCH3), 7.39 (t, J = 8.1 Hz, 1H, aromatic), 7.46 (d, J = 8.4 Hz, 1H, aromatic), 7.54 (d, 
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J = 1.5 Hz, 1H, OCH), 7.68-7.74 (m, 1H, aromatic), 8.36 (dd, J = 1.2, 8.4 Hz, 1H, aromatic); 
HRMS Calcd for C16H12NO4 (M+H+): 282.0766, found: 282.0757. 
5-Aza-N-propyl-1-methyl-4H-benzo[h]furo[3,2,c]chromene-4,11-dione(122). 55% 
yield; mp 238-240 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.08 (t, J = 7.5 Hz, 3H, 
CH2CH2CH3), 1.83 (h, J = 7.5 Hz, 2H, CH2CH2CH3), 2.38 (d, J = 0.9 Hz, 3H, CH3), 4.35 (t, J 
= 7.5 Hz, 2H, CH2CH2CH3), 7.37 (t, J = 7.8 Hz, 1H, aromatic), 7.43 (d, J = 8.7 Hz, 1H, 
aromatic), 7.53 (d, J = 1.2 Hz, 1H, OCH), 7.66-7.72 (m, 1H, aromatic), 8.35 (dd, J = 1.8, 7.8 
Hz, 1H, aromatic); HRMS Calcd for C18H16NO4 (M+H+): 310.1079, found: 310.1068. 
1-Methyl-11H-benzo[h]furo[3,2-c]thiochromen-11-one (127). 8% yield; mp 137-
139 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.42 (d, J = 1.5 Hz, 3H, CH3), 7.44 (q, J = 1.5 Hz, 
1H, OCH), 7.61-7.64 (m, 2H, aromatic), 7.85 (d, J = 8.4 Hz, 1H, aromatic), 7.88-7.92 (m, 1H, 
aromatic), 8.15 (d, J = 8.7 Hz, 1H, aromatic), 8.21-8.22 (m ,1H, aromatic); HRMS Calcd for 
C16H11O2S  (M+H+): 267.0480, found: 267.0473. 
1-Methylbenzo[h]furo[3,2-c]quinolin-11(10H)-one (128). 10% yield; mp 135-137 
°C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (d, J = 1.5 Hz, 3H, CH3), 7.47 (d, J = 1.2 Hz, 1H, 
OCH), 7.61-7.71 (m, 3H, aromatic), 7.93 (d, J = 8.4 Hz, 1H, aromatic), 7.98 (d, J = 8.7 Hz, 
1H, aromatic), 8.45 (d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C16H12NO2 (M+H+): 
250.0868, found: 250.0855. 
1-Ethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (134). 64% yield; mp 151-153 °C; 
1H NMR (300 MHz, CDCl3, ppm): δ 1.32 (t, J = 7.5 Hz, 3H, CH2CH3), 2.78 (q, J = 7.5 Hz, 2H, 
CH2CH3), 7.32 (s, 1H, OCH), 7.52-7.61 (m, 3H, aromatic), 7.66 (d, J = 8.4 Hz, 1H, aromatic), 
7.76 (d, J = 8.7 Hz, 1H, aromatic), 8.43 (d, J = 7.5 Hz, 1H, aromatic); HRMS Calcd for 
C17H13O3 (M+H+): 265.0865, found: 265.0865. 
1-Ethyl-6-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (135). 65% yield; mp 
183-185 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.33 (q, J = 7.5 Hz, 3H, CH2CH3), 2.65 (s, 
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3H, CH3), 2.81 (q, J = 7.2 Hz, 2H, CH2CH3), 7.37 (s, 2H, aromatic & OCH), 7.45 (t, J = 8.1 
Hz, 1H, aromatic), 7.71 (d, J = 8.7 Hz, 1H, aromatic), 7.78 (d, J = 9.0 Hz, 1H, aromatic), 8.36 
(d, J = 8.4 Hz, 1H, aromatic); HRMS Calcd for C18H15O3 (M+H+): 279.1021, found: 279.1017. 
1,6-Diethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (136). 75% yield; mp 101-
103 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.33 (q, J = 7.8 Hz, 6H, CH3), 2.83 (q, J = 7.5 Hz, 
2H, CH2CH3), 3.04 (q, J = 7.8 Hz, 2H, CH2CH3), 7.35-7.40 (m, 2H, aromatic & OCH), 7.48 (t, 
J = 7.5 Hz, 1H, aromatic), 7.70 (d, J = 9.3 Hz, 1H, aromatic), 7.83 (d, J = 8.7 Hz, 1H, 
aromatic), 8.37 (d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C19H17O3 (M+H+): 293.1178, 
found: 293.1169. 
1,2-Dimethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (137). 15% yield; mp 103-
105 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.32 (d, J = 0.9 Hz, 3H, OCCH3), 2.42 (d, J = 0.9 
Hz, 3H, CH3), 7.59-7.65 (m, 2H, aromatic), 7.72 (d, J = 8.7 Hz, 1H, aromatic), 7.82 (d, J = 
8.7 Hz, 1H, aromatic), 7.85-7.88 (m, 1H, aromatic), 8.58 (d, J = 8.7 Hz, 1H, aromatic); 
HRMS Calcd for C17H13O3 (M+H+): 265.0865, found: 265.0860. 
6-Ethyl-1,2-dimethyl-11H-benzo[h]furo[3,2-c]chromen-11-one (138). 29% yield; 
mp 141-143 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.29 (s, 
3H, OCCH3), 2.39(s, 3H, CH3), 3.09 (q, J = 7.5 Hz, 2H, CH2CH3), 7.42 (d, J = 6.9 Hz, 1H, 
aromatic), 7.50-7.55 (m, 1H, aromatic), 7.75-7.80 (m, 1H, aromatic), 7.88-7.91 (m, 1H, 
aromatic), 8.44 (d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C19H17O3 (M+H+): 293.1178, 
found: 293.1172. 
2-Methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (139). 12% yield; mp 229-231 
°C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (s, 3H, CH3), 6.63 (s, 1H, OCCH), 7.61-7.65 (m, 
2H, aromatic), 7.75 (d, J = 8.7 Hz, 1H, aromatic), 7.83-7.90 (m, 2H, aromatic), 8.59 (d, J = 
7.5 Hz, 1H, aromatic); HRMS Calcd for C16H11O3 (M+H+): 251.0708, found: 251.0703. 
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6-Ethyl-2-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (140). 2% yield; mp 
175-177 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.41 (t, J = 7.5 Hz, 3H, CH2CH3), 2.54 (s, 
3H, CH3), 3.15 (q, J = 7.5 Hz, 2H, CH2CH3), 6.64 (s, 1H, OCCH), 7.48 (d, J = 7.2 Hz, 1H, 
aromatic), 7.58 (t, J = 7.2 Hz, 1H, aromatic), 7.88 (d, J = 9.0 Hz, 1H, aromatic), 8.00 (d, J = 
9.0 Hz, 1H, aromatic), 8.50 (d, J = 8.4 Hz, 1H, aromatic); HRMS Calcd for C18H15O3 (M+H+): 
279.1021, found: 279.1017. 
1-(4-Methoxyphenyl)-11H-benzo[h]furo[3,2-c]chromen-11-one (141). 20% yield; 
mp 173-175 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 3.88 (s, 3H, CH3), 7.02 (d, J = 9.0 Hz, 
2H, aromatic), 7.64-7.68 (m, 2H, aromatic & OCH), 7.59-7.80 (m, 4H, aromatic), 7.90-7.94 
(m, 2H, aromatic), 8.62-8.65 (m, 1H, aromatic); HRMS Calcd for C22H15O4 (M+H+):  
343.0970, found: 343.0975. 
6-Ethyl-1-(4-methoxyphenyl)-11H-benzo[h]furo[3,2-c]chromen-11-one (142). 
34% yield; mp 185-187 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.5 Hz, 3H, 
CH2CH3), 3.11 (q, J = 7.2 Hz, 2H, CH2CH3), 3.86 (s, 3H, OCH3), 6.85-7.01 (m, 2H, aromatic), 
7.46 (d, J = 6.6 Hz, 1H, aromatic), 7.56 (t, J = 7.8 Hz, 1H, aromatic), 7.72-7.77 (m, 3H, 
aromatic & OCH), 7.86 (d, J = 8.7 Hz, 1H, aromatic), 7.95 (d, J = 8.7 Hz, 1H, aromatic), 8.47 
(d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C24H19O4 (M+H+): 371.1283, found: 371.1291. 
1-Methyl-7,8-dihydrocyclopenta[h]furo[3,2-c]chromen-10(6H)-one (152). 20% 
yield; mp 210-212 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.19 (p, J = 7.5 Hz, 2H, 
CH2CH2CH2), 2.36 (d, J = 1.5 Hz, 3H, CH3), 3.04 (t, J = 7.5 Hz, 2H, CH2CH2CH2), 3.14 (t, J = 
7.5 Hz, 2H, CH2CH2CH2), 7.19 (d, J = 7.8 Hz, 1H, aromatic), 7.36 (q, J = 1.2 Hz, 1H, OCH), 
7.63 (d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C15H13O3 (M+H+): 241.0859, found: 
241.0858. 
1-Methyl-8,9-dihydro-6H-benzo[h]furo[3,2-c]chromen-11(7H)-one (153). 13% 
yield; mp 125-127 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.80-1.86 (m, 4H, 
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CH2CH2CH2CH2), 2.35 (d, J = 1.2 Hz, 3H, CH3), 2.84 (t, J = 5.7 Hz, 2H, CH2CH2CH2CH2), 
2.94 (t, J = 6.0 Hz, 2H, CH2CH2CH2CH2), 7.01 (d, J = 8.4 Hz, 1H, aromatic), 7.34 (d, J = 0.9 
Hz, 1H, OCH), 7.51 (d, J = 8.1 Hz, 1H, aromatic); HRMS Calcd for C16H15O3 (M+H+): 
255.1016, found: 255.1012. 
1,6,6-Trimethyl-8,9-dihydro-6H-benzo[h]furo[3,2-c]chromen-11(7H)-one (154). 
38% yield; mp 101-103 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.33 (s, 6H, C(CH3)2), 1.67-
1.71 (m, 2H, CCH2CH2CH2), 1.84-1.88 (m, 2H, CCH2CH2CH2), 2.35 (d, J = 1.2 Hz, 3H, CH3),  
2.97 (t, J = 6.3 Hz, 2H, CCH2CH2CH2), 7.32 (d, J = 8.4 Hz, 1H, aromatic), 7.35 (q, J = 1.2 Hz, 
1H, OCH), 7.61 (d, J = 8.7 Hz, 1H, aromatic); HRMS Calcd for C18H19O3 (M+H+): 283.1329, 
found: 283.1315. 
6-(1-Bromoethyl)-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (113). To a 
solution of 91 (27 mg, 0.1 mmol) in CCl4 (3 mL) was added N-bromosuccinimide (18 mg, 0.1 
mmol) and dibenzoyl peroxide (2 mg). The reaction mixture was stirred and heated at reflux 
for 9 h. After the mixture was cooled in an ice bath, the solid was removed by filtration and 
washed with CCl4. Concentration and silica gel flash column chromatography (hexane-
EtOAc, 8:1) gave 113 (18 mg, 52%) as a white solid. mp 173-175 °C; 1H NMR (300 MHz, 
CDCl3, ppm): δ 2.29 (d, J = 6.9 Hz, 3H, CHBrCH3), 2.42 (d, J = 1.2 Hz, 3H, CH3), 5.97 (q, J 
= 7.5 Hz, 1H, CHCH3), 7.47 (d, J = 1.2 Hz, 1H, OCH), 7.65 (t, J = 7.8 Hz, 1H, aromatic), 
7.88 (d, J = 6.9 Hz, 1H, aromatic), 8.00 (d, J = 9.0 Hz, 1H, aromatic), 8.15 (d, J = 8.7 Hz, 1H, 
aromatic), 8.65 (d, J = 8.7 Hz, 1H, aromatic); HRMS Calcd for C18H14BrO3 (M+H+): 357.0126, 
found: 357.0120. 
6-Hydroxy-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one (114). To a solution 
of 110 (32 mg, 0.114 mmol) in DCM (3 mL) was added BBr3 (1.12 mL, 1.12 mmol) dropwise 
at 0 °C. The reaction mixture was stirred and warmed to rt for 12 h. Water was added to 
quench the reaction. The solution was extracted with CHCl3. The organic layer was 
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concentrated and purified with flash chromatography, eluting with DCM-MeOH, 15:1, to give 
114. 52% yield; 1H NMR (300 MHz, DMSO, ppm): δ 2.30 (s, 3H, CH3), 7.06 (d, J = 8.7 Hz, 
1H, aromatic), 7.53 (t, J = 8.4 Hz, 1H, aromatic), 7.82-7.86 (m, 2H, aromatic), 7.97 (d, J = 
1.2 Hz, 1H, OCH), 8.11 (d, J = 9.3 Hz, 1H, aromatic), 10.58 (s, 1H, OH); HRMS Calcd for 
C16H11O4 (M+H+): 265.0501, found: 265.0505. 
1-Methyl-11-oxo-11H-benzo[h]furo[3,2-c]chromen-6-yl acetate (115). Compound 
114 (0.1 mmol) was dissolved in acetic anhydride under argon. Triethylamine (0.14 mL, 1.0 
mmol) was added to the solution. After stirring overnight at 60 °C, the solution was washed 
with water and extracted with DCM, and dried (MgSO4). Removal of solvent under reduced 
pressure yielded a residue, which was purified by column chromatography, eluting with 
EtOAc–hexane (1:4). 43% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, CH3), 2.50 
(s, 3H, COCH3), 7.39 (d, J = 6.9 Hz, 1H, aromatic), 7.46 (s, 1H, OCH), 7.65 (t, J = 8.1 Hz, 
1H, aromatic), 7.80 (d, J = 8.7 Hz, 1H, aromatic), 7.90 (d, J = 8.7 Hz, 1H, aromatic), 8.52 (d, 
J = 8.4  Hz, 1H, aromatic); HRMS Calcd for C18H13O5 (M+H+): 309.0763, found: 309.0762. 
6-(2-(Dimethylamino)ethoxy)-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one 
(116). Compound 114 (0.1 mmol) was dissolved in acetone under argon. K2CO3 (235 mg, 
1.7 mmol) was added to the solution. After stirring for 10 min, 2-chloro-N,N-
dimethylethylamine hydrochloride (30 mg, 0.2 mmol) was added to the mixture. After 
refluxing for 10 h, the mixture was filtrated and concentrated. The residue was purified by 
column chromatography, eluting with EtOAc–hexane (1:2). 9% yield; mp 209-211 °C; 1H 
NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, CH3), 2.44 (s, 6H, N(CH3)2), 2.96 (t, J = 5.1 Hz, 
2H, OCH2CH2), 4.31 (t, J = 5.1 Hz, 2H, OCH2CH2), 6.98 (d, J = 7.5 Hz, 1H, aromatic), 7.45 
(s, 1H, OCH), 7.55 (t, J = 8.1 Hz, 1H, aromatic), 7.83 (d, J = 8.7 Hz, 1H, aromatic), 8.20 (dd, 
J = 7.2, 8.7 Hz, 2H, aromatic); HRMS Calcd for C20H20NO4 (M+H+): 338.1392, found: 
338.1389. 
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Synthesis of neo-tanshinlactone analogues 129-130. A mixture of compound 92 
or 91 (0.1 mmol) and Lawesson’s reagent (81 mg, 0.2 mmol) in dry toluene (5 mL) was 
heated to reflux for 7 h. After cooling, toluene was removed in vacuo, and the red residue 
was dissolved in EtOAc and partitioned with H2O. The organic phase was separated and 
dried over MgSO4. Removal of solvent in vacuo afforded an oily residue, which was purified 
by column chromatography (EtOAc–hexane) to give a yellow solid. 
1-Methyl-11H-benzo[h]furo[3,2-c]chromene-11-thione (129). 90% yield; mp 267-
269 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.53 (s, 3H, CH3), 7.46 (s, 1H, OCH), 7.67-7.69 
(m, 2H, aromatic), 7.79-7.92 (m, 3H, aromatic), 8.75 (d, J = 7.2 Hz, 1H, aromatic); HRMS 
Calcd for C16H11O2S (M+H+): 267.0480, found: 267.0471. 
6-Ethyl-1-methyl-11H-benzo[h]furo[3,2-c]chromene-11-thione (130). 84% yield; 
mp 189-191 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.49 
(d, J = 1.2 Hz, 3H, CH3), 3.09 (q, J = 7.5 Hz, 2H, CH2CH3), 7.40 (d, J = 1.5 Hz,  1H, OCH), 
7.46 (d, J = 7.2 Hz, 1H, aromatic), 7.56 (t, J = 7.2, 8.1 Hz, 1H, aromatic), 7.78 (d, J = 9.0 Hz, 
1H, aromatic), 7.95 (d, J = 9.0 Hz, 1H, aromatic), 8.55 (d, J = 8.7 Hz, 1H, aromatic); HRMS 
Calcd for C18H15O2S (M+H+): 295.0793, found: 295.0779. 
6-Ethyl-1-methyl-11H-benzo[h]furo[3,2-c]chromen-11-one oxime (131). A mixture 
of 130 (22 mg. 0.075 mmol), hydroxylamine hydrochloride (10.4 mg, 0.15 mmol), sodium 
acetate (12 mg, 0.15 mmol), and MeOH (5 mL) was refluxed overnight and then filtered. The 
filtrate was concentrated under reduced pressure to give an oily residue. Purification by the 
column chromatography (EtOAc–hexane) gave 131 in 87% yield. mp 211-213 °C; 1H NMR 
(300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.2 Hz, 3H, CH2CH3), 2.28 (d, J = 0.9 Hz, 3H, CH3), 
3.11 (q, J = 7.5 Hz, 2H, CH2CH3), 7.18 (s, 1H, OH), 7.33 (d, J = 1.2 Hz, 1H, OCH), 7.40 (d, J 
= 6.9 Hz, 1H, aromatic), 7.52 (dd, J = 7.2, 8.4 Hz, 1H, aromatic), 7.71 (d, J = 9.0 Hz, 1H, 
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aromatic), 7.86 (d, J = 9.0 Hz, 1H, aromatic), 8.40 (d, J = 8.7 Hz, 1H, aromatic); HRMS 
Calcd for C18H16NO3 (M+H+): 294.1130, found: 294.1118. 
1-Methoxy-2-(4-methylpent-3-enyl)benzene (144). Preparation of (4-methylpent-3-
enyl)zinc(II) bromide: Zinc powder (0.98 g, 15 mmol) was stirred and heated to 70 °C under 
high vacuum for 30 minutes. N,N'-Dimethylimidazolidinone (DMI) (to give a total volume of 
10 mL) and iodine (0.13 g, 0.50 mmol) were added under the protection of argon. After the 
red color of iodine had faded, the 5-bromo-2-methyl-2-pentene (10 mmol) was added. The 
colorless reaction mixture was stirred for 12 h at 70 °C, and then it was cooled to rt.  
1-Bromo-2-methoxybenzene (1.0 mmol), Pd(Cl2)(dppf) (0.1 mmol), and 10 mL THF 
were stirred  in a 25 mL bottle. (4-Methylpent-3-enyl)zinc(II) bromide (2.0 mmol) was added. 
The mixture was refluxed for 1 h and cooled to rt. The reaction was quenched by addition of 
4 N HCl (5 mL).  The mixture was extracted with diethyl ether, and the organic layer dried 
over MgSO4. Removal of solvent under reduced pressure yielded a light yellow liquid, which 
was purified by column chromatography, eluting with EtOAc–hexane (1:10). 96% yield; 1H 
NMR (300 MHz, CDCl3, ppm): δ 1.57 (s, 3H, CH3), 1.68 (d, J = 0.9 Hz, 3H, CH3), 2.24 (q, J = 
7.5 Hz, CHCH2CH2), 2.62 (q, J = 7.8 Hz, 2H, CHCH2CH2), 3.82, (s, 3H, OCH3), 5.18-5.23 (m, 
1H, CHC(CH3)2), 6.83-6.90 (m, 2H, aromatic), 7.11-7.20 (m, 2H, aromatic). 
5,5-Dimethyl-5,6,7,8-tetrahydronaphthalen-1-ol (145). 143 (8.66 g, 46 mmol) was 
dissolved in 250 mL of CH2Cl2 and cooled at 0 °C while AlCl3 (6.13 g, 46 mmol) was added 
in one portion. The resulting orange solution was stirred at 0 °C for 15 min and then poured 
into 300 mL of ice-water. The aqueous phase was separated and extracted with two portions 
of Et2O and dried to obtain pure 5-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene. 
[99% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.28 (s, 6H, (CH3)2), 1.61-1.65 (m, 2H, 
CCH2), 1.76-1.80 (m, 2H, CCH2CH2), 2.65 (t, J = 6.3 Hz, 2H, CCH2CH2CH2), 3.81 (s, 3H, 
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OCH3),  6.64 (d, J = 8.1 Hz, 1H, aromatic), 6.97 (d, J = 7.8 Hz, 1H, aromatic), 7.13 (t, J = 8.1 
Hz, 1H, aromatic).] 
To a solution of 5-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene (2 mmol) in 
DCM (3 ml) was added BBr3 (6 mmol) dropwise at 0 °C. The reaction mixture was stirred 
and warmed to rt for 12 h. Water was added to quench the reaction. The solution was 
extracted with CHCl3. The organic layer was concentrated and purified with flash 
chromatography, eluting with hexane: EtOAc=10:1, to give 145 as a solid. 85% yield; 1H 
NMR (300 MHz, CDCl3, ppm): δ 1.28 (s, 6H, (CH3)2), 1.62-1.66 (m, 2H, CCH2), 1.79-1.88 (m, 
2H, CCH2CH2), 2.63 (t, J = 6.6 Hz, 2H, CCH2CH2CH2), 4.63 (s, 1H, OH),  6.59 (q, J = 6.6 Hz, 
1H, aromatic), 6.95 (d, J = 7.8 Hz, 1H, aromatic), 7.04 (t, J = 7.8 Hz, 1H, aromatic). 
Synthesis of neo-tanshinlactone analogues 149-151. A mixture of 146 (or 147, 
145) (1.0 g, 6.33 mmol), malonic acid (658 mg, 6.33 mmol), and PPA (85% P2O5, 10 g) was 
heated at 75 °C for 3 h. After cooling, ice-water was added to the black residue. The mixture 
was filtered, and the solid dissolved in MeOH. The organic layer was concentrated and 
purified with flash chromatography, eluting with DCM: MeOH=10:1, to yield 149 (or 150, 151) 
as a yellow solid. 
4-Hydroxy-8,9-dihydrocyclopenta[h]chromen-2(7H)-one (149). 35% yield; 1H 
NMR (300 MHz, CD3OD, ppm): δ 2.16-2.23 (m, 2H, CH2CH2CH2), 3.01-3.08 (m, 4H, 
CH2CH2CH2), 6.64 (d, J = 8.1 Hz, 1H, COCH), 7.20 (d, J = 8.1 Hz, 1H, aromatic), 7.68 (d, J 
= 8.1 Hz, 1H, aromatic); MS: m/z 201 (M-H+). 
4-Hydroxy-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (150). 32% yield; 1H 
NMR (300 MHz, CD3OD, ppm): δ 2.64-2.73 (m, 4H, (CH2)4), 2.85 (t, J = 2.7 Hz, 4H, (CH2)4), 
6.40 (s, 1H, COCH), 7.03 (d, J = 8.1 Hz, 1H, aromatic), 7.60 (d, J = 8.1 Hz, 1H, aromatic); 
MS: m/z 215 (M-H+). 
4-Hydroxy-7,7-dimethyl-7,8,9,10-tetrahydro-2H-benzo[h]chromen-2-one (151). 
42% yield; 1H NMR (300 MHz, CD3OD, ppm): δ 1.33 (s, 6H, (CH3)2), 1.69-1.73 (m, 2H, 
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CCH2), 1.88-1.89 (m, 2H, CCH2CH2), 2.87 (t, J = 6.6 Hz, 2H, CCH2CH2CH2), 7.38 (d, J = 8.4 
Hz, 1H, aromatic), 7.68 (d, J = 8.4 Hz, 1H, aromatic); MS: m/z 243 (M-H+). 
Synthesis of neo-tanshinlactone analogues 155-156. Compound 92 or 91 (0.2 
mmol) was dissolved in acetone at 40 °C under argon. Pd/C (81 mg, 10%), triethylamine 
(0.33 mL, 2.40 mmol) and formic acid (0.075 mL, 2.00 mmol) were added to the solution. 
After stirring overnight, TLC showed some substrate remained unreacted. The solution was 
filtered through Celite and solvent removed in vacuo to yield a dark oily residue. The residue 
was dissolved in DCM before washing with saturated aqueous sodium bicarbonate (5 mL), 
aqueous citric acid (5 mL, 10% v/v), water (5 mL) and brine (5 mL), and then dried (MgSO4). 
Removal of solvent under reduced pressure yielded a white solid, which was purified by 
column chromatography, eluting with EtOAc–hexane (1:4).  
1-Methyl-1H-benzo[h]furo[3,2-c]chromen-11(2H)-one (155). 30% yield (recovered); 
mp 143-145 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.46 (d, J = 6.9 Hz, 3H, CHCH3), 3.68-
3.77 (m, 1H, CHCH3), 4.47 (q, J = 6.3 Hz, 1H, CH2), 5.00 (t, J = 6.6 Hz, 1H, CH2), 7.62-7.71 
(m, 4H, aromatic), 7.87-7.90 (m, 1H, aromatic), 8.59-8.62 (m, 1H, aromatic); HRMS Calcd 
for C16H13O3 (M+H+): 253.0865, found: 253.0856. 
6-Ethyl-1-methyl-1H-benzo[h]furo[3,2-c]chromen-11(2H)-one (156). 56% yield 
(recovered); mp 83-85 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.8 Hz, 3H, 
CH2CH3), 1.46 (d, J = 7.5 Hz, 3H, CHCH3), 3.13 (q, J = 7.5 Hz, 2H, CH2CH3), 3.66-3.78 (m, 
1H, CHCH3), 4.47 (q, J = 6.0 Hz, 1H, CH2), 5.00 (t, J = 6.6 Hz, 1H, CH2), 7.50-7.60 (m, 2H, 
aromatic), 7.64 (d, J = 9.3 Hz, 1H, aromatic), 7.91 (d, J = 9.3 Hz, 1H, aromatic), 8.49 (d, J = 
8.7 Hz, 1H, aromatic); HRMS Calcd for C18H19O3 (M+H+): 281.1178, found: 281.1163. 
Naphthalen-1-yl 2-bromo-4-methylbenzoate (158). Thionyl chloride (0.17ml, 2.40 
mmol) was added to 2-bromo-4-methylbenzoic acid (430 mg, 2 mmol) in DCM (3 mL) and 
DMF (0.1 mL), and the mixture was refluxed under nitrogen atmosphere for 1 h. After 
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cooling to rt, it was concentrated in vacuo to give the title compound as a pale yellow solid, 
which was used directly in the next step. 
Naphthalen-1-ol (288 mg, 2.00 mmol) was dissolved in THF (5 mL), then DMAP (5 
mg) and ethyldiisopropylamine (0.36 mL, 2.05 mmol) were added, and the mixture was 
cooled to 0 °C for 10 min. Freshly prepared 2-bromo-4-methylbenzoyl chloride in dry THF 
(10 mL) was added to the mixture via cannula, and the resulting mixture was stirred at 25 °C 
for 2 h, diluted with diethyl ether (150 mL), and quenched by the addition of water (15 mL). 
The organic layer was washed with HCl and NaHCO3 and then dried (Na2SO4) and 
concentrated in vacuo. The residue was purified with flash chromatography, eluting with 
hexane: EtOAc=10:1, to give 158. 96% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.41 (s, 3H, 
CH3), 7.27 (dd, J = 0.9, 8.1 Hz, 1H, aromatic), 7.40 (dd, J = 1.2, 7.5 Hz, 1H, aromatic), 7.48-
7.52 (m, 3H, aromatic), 7.60 (d, J = 0.9 Hz, 1H, aromatic), 7.77 (d, J = 8.1 Hz, 1H, aromatic), 
7.87-7.90 (m, 1H, aromatic), 7.96-7.99 (m, 1H, aromatic), 8.13 (d, J = 8.1 Hz, 1H, aromatic). 
9-Methyl-6H-dibenzo[c,h]chromen-6-one (159). A mixture of 158 (68 mg, 0.2 
mmol), Pd(OAc)2 (4.5 mg, 0.02 mmol), PPh3 (10.5 mg, 0.04 mmol), and NaOAc (32.8 mg, 
0.4 mmol) was dissolved in dry dimethylacetamide (10 mL), and the solution was degassed 
and then heated to 150 °C for 3 h. On cooling to rt, the solution was diluted with diethyl ether 
(50 mL) and washed with HCl, and the organice extracts were dried over Na2SO4. The 
solution was filtered, the filtrate condensed in vacuo, and the resulting oil purified by flash 
chromatography (hexane:EtOAc 4:1) to give the title compound as a white solid. 
65% yield; mp 193-195 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.55 (s, 3H, CH3), 7.35-7.38 
(m, 1H, aromatic), 7.57-7.63 (m, 2H, aromatic), 7.71 (d, J = 9.0 Hz, 1H, aromatic), 7.82-7.85 
(m, 1H, aromatic), 7.91 (s, 1H, aromatic), 8.00 (d, J = 9.3 Hz, 1H, aromatic), 8.30 (d, J = 7.8 
Hz, 1H, aromatic), 8.53-8.56 (m, 1H, aromatic); HRMS Calcd for C18H13O2 (M+H+): 261.0916, 
found: 261.0909. 
3.6.2    Biological Assay-Cell Growth Inhibition Assay. 
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All stock cultures are grown in T-25 flasks. Freshly trypsinized cell suspensions were 
seeded in 96-well microtiter plates with compounds added from DMSO-diluted stock. The 
plates were incubated for an additional 72 h after attachment and drug addition, and the 
assay was terminated by 10% TCA. Then, 0.4% SRB dye in 1% HOAc was added to stain 
the cells for 10 min. Unbound dye was removed by repeated washing with 1% HOAc and the 
plates were air dried. Bound stain was subsequently solved with 10 mM trizma base, and the 
absorbance read at 515 nm. Growth inhibition of 50% (ED50) was calculated as the drug 
concentration that caused a 50% reduction in the net protein increase in control cells during 
the drug incubation. The mean ED50 is the concentration of agent that reduces cell growth by 
50% under the experimental conditions and is the average from at least three independent 
determinations. Variation between replicates was no more than 5% of the mean. The 
following human tumor cell lines were used in the assay: A549 (non-small cell lung cancer), 
MCF-7 (estrogen receptor positive breast cancer), MDA MB-231 (estrogen receptor negative 
breast cancer), SK-BR-3 (estrogen receptor negative, HER-2 over-expressing breast 
cancer), ZR-75-1 (estrogen receptor positive breast cancer, HER-2 over-expressing breast 
cancer), KB (nasopharyngeal carcinoma), KB-vin (vincristineresistant KB subline). All cell 
lines were obtained from the Lineberger Cancer Center (UNC-CH) or from ATCC (Rockville, 
MD). Cells were propagated in RPMI-1640 supplemented with 10% FBS, penicillin (100 
IU/mL), streptomycin (1 μg/mL), and amphotericin B (0.25 µg/mL), and were cultured at 
37 °C in a humidified atmosphere of 95% air/5% CO2. 
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CHAPTER 4 
DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL 2-(FURAN-2-YL) 
NAPHTHALEN-1-OL AND TETRAHYDRONAPHTHALENE-1-OL DERIVATIVES 
 
4.1       Introduction 
Natural products continue to be an excellent source of new medicinal leads.1-3  
However, the structural complexity of natural products, including their intricate ring systems 
and numerous chiral centers, may hamper mechanism of action studies and clinical 
development.4 For that reason, structural simplification of natural products is a powerful and 
highly productive tool for lead development and analogue design.5 A well-known example is 
the simplification of morphine, which led to the clinically used medicines levophanol and 
meperidine.6 Neo-tanshinlactone (90) is a steroid-like tetracyclic natural product originally 
isolated from the traditional Chinese medicine Tanshen (Figure 4-1). Structure-activity 
relationships of neo-tanshinlactone analogues were described in the previous chapter.7, 8  
However, several questions remained unanswered: how does the skeletal planarity affect 
activity and selectivity, how do each of the four individual rings contribute to activity, and 
how will the activity and selectivity change by simplification of the tetracyclic molecule of 90. 
In this chapter, we will discuss our chemical and biological strategies to investigate 
structurally simplified neo-tanshinlactone (90) analogues to answer these questions. 
 
4.2       Design 
To study the individual contribution of the A-, C-, and D-rings of 90 to the selective 
activity against breast cancer cells, scaffolds 1-4 were designed as ring-opened model 
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compounds by breaking bonds 1-4 respectively (Figure 4-2). Different R groups were also 
incorporated to explore preliminary SAR of the four scaffolds. Designed analogues are 
shown in Figure 4-3 and Figure 4-4.  
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Figure 4-1. Scaffolds 1-4 derived through structural simplification of 90 
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Figure 4-2. Structures of designed target compounds 160-171 with scaffolds 1-4 
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Figure 4-3. Structures of designed target compounds 172-194 derived from scaffold 2 
 
4.3      Chemistry 
4.3.1   Synthesis of compounds with scaffold 1 
Intermediate 161 was obtained via a tandem alkylation/intramolecular Aldol reaction 
with commercially available 195 (Scheme 4-1).9 Demethylation of 161 by BBr3 generated 
160, which was converted to isopropyl and hexyl ethers, 162 and 163, respectively. 
Scheme 4-1. Synthetic pathway to analogues 160-163 with scaffold 1 
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Reagents and conditions: (a) HOAc, NH4OAc, chloroacetone, toluene, EtOH, reflux, 65%; (b) 
BBr3, DCM, 50 °C, 42%; (c) 2-iodopropane for 162, 1-bromohexane for 163, Cs2CO3, DMF, 
acetone, 50 °C, 30% and 29%, respectively. 
 
4.3.2    Synthesis of compounds with scaffold 2  
Previously synthesized neo-tanshinlactone analogues, 91-92, 110-111, 136, and 138, 
were hydrolyzed to cleave the lactone ring and derive the related carboxylic acids, 164, 172-
174, and 182-183, respectively (Scheme 4-2).10 After hydrolysis of 92 and 91, MeI and 18-
crown-6 ether were added directly to the crude mixture, without work up, to provide selective 
methylation of the hydroxy group of 164 and 172.11 The resulting methyl ethers 175-176 
were converted to methyl esters (177-178) with thionyl chloride and methanol at room 
temperature.12 Alcohols 179-180 were obtained by reduction of 91-92 with lithium aluminum 
hydride. Treatment of 180 with iodomethane in the presence of potassium carbonate gave 
181.  
Scheme 4-2. Synthetic pathway to analogues 164 and 172-183 with scaffold 2 
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Reagents and conditions: (a) 5% NaOH (aq), reflux; (b) MeI, NaOH, 18-crown-6, CH3CN, 90 
°C; (c) SOCl2, MeOH, rt; (d) LiAlH4, THF; (e) MeI, K2CO3, acetone, rt. 
 
4.3.3    Synthesis of compounds with scaffold 3 
Compounds 157 and 196 were esterified with the appropriate acyl chlorides to give 
165-169 (Scheme 4-3).  
Scheme 4-3. Synthetic pathway to analogues 165-169 with scaffold 3 
 
 
4.3.4    Synthesis of compounds with scaffold 4 
Propargyl ether 170 and dimethylcarbamothioester 171 were synthesized from 132 
by using 3-bromoprop-1-yne in the presence of K2CO3, and dimethylcarbamothioic chloride 
in the presence of NMP and DABCO, respectively (Scheme 4-4).13, 14  
Scheme 4-4. Synthetic pathway to analogues 170-171 with scaffold 4 
 
Reagents and conditions: (a) 3-bromoprop-1-yne for 170, K2CO3, acetone, reflux, 40%; (b) 
dimethylcarbamothioic chloride for 171, NMP, DABCO, 50 °C, 85%. 
 
4.4      Results and Discussion 
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Initially, compounds 160-171 were tested for in vitro anticancer activity against two 
human breast cancer cell lines, MCF-7 (ER+) and SK-BR-3 (HER2+) (Table 4-1). 
Compounds with scaffolds 1 (160-163), 3 (165-169), and 4 (170-171) showed no activity 
against the two tested cancer cell lines. Compound 164 with scaffold 2 was less potent than 
91, but more potent than the remaining compounds. Thus, the results demonstrated that 
both the A-ring and D-ring are important in maintaining the biological activity of this 
compound type, while compounds with an opened ring-C could retain activity.  
 
Table 4-1. In vitro anticancer activity of 160-171 against MCF-7 and SK-BR-3 tumor 
cell linesa 
91
O
O
O
HOOC
OH
O
R
O
O
O
OR
R'O
O
R
O
O
O
R
scaffold 1 scaffold 4scaffold 3scaffold 2
Et
 
 
Compd scaffold R R’ MCF7 (ER+) 
SK-BR-3 
(HER2+)
91    0.2 0.1 
160 1 OH --- >20 7.8 
161 1 Me --- >20 10.5 
162 1 iPr --- 12.0 10.8 
163 1 Hexyl --- >20 15.9 
164 2 H --- 6.0 7.0 
165 3 H >20 >20 
166 3 Me >20 >20 
167 3 H  11.0 >20 
168 3 H  15.5 >20 
169 3 H >20 >20 
170 4 --- >20 17.9 
171 4 --- 15.5 10.9 
a) Mean ED50 (µg/mL), Standard error of independent determinations was less than 5% 
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In addition, we performed conformational analysis to study the molecular geometries 
of the four different scaffolds of 162, 164, 166, and 170. As seen in Figure 4-4, compounds 
162, 164, 166, and 170 possess most of the pharmacophore features present in the 
reference compound 91, including an aromatic center, hydrophobic region, and hydrogen 
bond donor and acceptor groups. However, several key features are also missing in 162, 
164, 166, and 170 in comparison with 91, i.e., one aromatic center in 162 and 170, and a 
closed ring in 164 and 166. The cytotoxicity results demonstrated that both the A- and D-ring 
are important in maintaining the molecule’s biological activity. Interestingly, although 164 
lacks a C-ring, an additional intramolecular hydrogen bond can form between –COOH and –
OH groups in the lowest energy conformer of 164. This hydrogen bond could ‘lock’ the 
structure into a conformation that is close to that of the tetracyclic scaffold. Thus, 
intramolecular hydrogen bonding in 164 may help the compound retain its biological potency.  
 
Figure 4-4. Pharmacophore analysis of 162, 164, 166, and 170 with reference to 91 
using the PCH annotation scheme.  
77 
 
(Purple: H-bond donor; Blue: H-Bond acceptor; Light green: Aromatic ring center; Deep 
green: Hydrophobic region.) The structures of the global energy minima are shown by stick 
models.  
 
Compound 164 was selected for further structure optimization in order to establish 
SAR correlations and to identify more active derivatives with the desired biological 
properties. Substituents on the 164-scaffold will likely affect the molecule’s overall three-
dimensional structure and, thus, the compound’s interaction with its target, which will 
translate into increased or decreased anti-breast cancer activity.  
In order to test for a potential relationship between the intramolecular hydrogen bond 
(COOH- and OH-groups) and the selective in vitro anti-breast cancer activity, a specific 
target sub-set (172, 176 and 178) was designed. Compound 172, with OH at position R4 and 
COOH at position R5, can form an intramolecular hydrogen bond. However, in 176, one 
hydrogen donor has been effectively removed by methylation of the OH in 172, and in 178, 
both hydrogen bond donors are blocked with methyl groups. Compounds 172-183 were 
designed to further study the SAR of various substituents on the molecule. The newly 
synthesized analogues (172-183) were tested initially for in vitro anticancer activity against 
two human breast cancer cell lines: MCF-7 (ER+) and SK-BR-3 cells (HER2+) (Table 4-2). 
Both 172 and 178 showed similar activity to TAM against MCF-7 (ED50 values of 3.3 and 2.5 
µg/mL, respectively), while 172 showed fivefold better activity than TAM against SK-BR-3 
cells (ED50 value of 1.0 µg/mL) and 178 showed about fourfold better activity than TAM 
against SK-BR-3 cells (ED50 value of 1.2 µg/mL). Compound 176 displayed similar activity to 
TAM against both cell lines. From the ED50 values of 164, 172, 173, and 174, the SAR study 
suggested that R1 substituents influenced the in vitro anticancer activity and hydrophobic 
groups were favored at this position. At the R2 position, a methyl group was preferable to 
ethyl (172 vs 183), and at the R3 position, hydrogen was favored over methyl (172 vs 182). 
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Proper combinations of R4 and R5 (hydroxy group, carboxylic acid, and alkoxy group) could 
lead to potent analogues (172, 178, and 181).  
Table 4-2. Structure and cytotoxicity of analogues 172-183a 
 
Compd R1 R2 R3 R4 R5 MCF-7 SK-BR-3  
TAM      5 5 
164 H Me H OH COOH 6 7.0 
172 Et Me H OH COOH 3.3 1.0 
173 OMe Me H OH COOH 23 3.5 
174 OEt Me H OH COOH 7.5 6.0 
175 H Me H OMe COOH 18 16.7 
176 Et Me H OMe COOH 4.3 8.5 
177 H Me H OMe COOMe 8.5 6.5 
178 Et Me H OMe COOMe 2.5 1.2 
179 H Me H OH CH2OH 7 9.5 
180 Et Me H OH CH2OH 12 12.8 
181 Et Me H OMe CH2OH -- 0.8 
182 Et Me Me OH COOH 8.5 10.4 
183 Et Et H OH COOH 5.1 5.4 
aSee Table 4-1. 
 
To examine human tumor-tissue-type selectivity, active compounds 172, 173, 178, 
and 181 (ED50 values >4.0 µg/mL were considered not active) were selected for testing 
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against a limited but diverse set of human cancer cell lines, using 91 as a positive control 
and “gold-standard” (Table 4-3). Compounds 172 and 173 were active only against certain 
breast cancer cell lines and not active against other tumor tissue cells tested, such as A549 
lung cancer or DU145 prostate cancer cell lines. Thus, these two compounds had high 
tissue selectivity. More interestingly, 172 and 173 also showed high potency (ED50 0.3 and 
0.6 µg/mL, respectively) and selectivity toward the ZR-7-51 (ER+, HER2+) cell line. 
Compound 172 was two times less potent against SK-BR-3 (HER2+) (ED50 0.9 µg/mL) and 
ten times less potent against MCF-7 (ER+) (ED50 3.3 µg/mL). Compound 173 was six times 
less potent against SK-BR-3 (HER2+) (ED50 3.5 µg/mL) and 33 times less potent against 
MCF-7 (ER+) (ED50 >20 µg/mL). Meanwhile, compound 91 showed similar potency against 
ZR-7-51 and SK-BR-3 and was only three times less potent against MCF-7 than ZR-7-51. In 
summary, 172 and 173 were more potent against ZR-75-1 than cell lines over-expressing 
either ER or HER2 (MCF-7 or SK-BR-3), and much more potent than cell lines not over-
expressing ER or HER2 (remaining cell lines in the panel). More importantly, 181 showed 
extremely high selectivity against SK-BR-3 cell line (ED50 0.8 µg/mL) compared with other 
cell lines tested (eight- to eleven-fold difference). This high selectivity could be applied for 
further analogue design and mechanism of action study. Unexpectedly, compound 178 was 
active against all cancer cell lines tested. 
Table 4-3. Cytotoxicity of compounds against tumor cell linesa 
 MCF-7 SK-BR-3 ZR-75-1 MDA MB-231 A549 DU145 KB KBvin
91 0.2 0.1 0.1 >10 10.6 15.9 13.1 13.2 
172 3.3 1.0 0.3 >10 10.6 8.7 9.1 7.0 
173 >20 3.5 0.6 >10 10.1 8.2 9.7 8.9 
178 2.5 1.2 1.3 2.3 1.5 2.2 1.7 1.3 
181 -- 0.8 6.5 9.1 9.6 7.2 7.0 6.6 
aSee Table 4-1. 
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To further explore the physicochemical basis for the different selectivity profiles 
between 172 and 178, dihedral energy analyses between the naphthalene and furan rings 
were performed over 360° (Figure 4-5). Compared with 91, compound 172 retains three 
aromatic centers and possesses one additional intramolecular hydrogen bond. This 
hydrogen bond helps to ‘lock’ the conformation close to that of 91, which may explain why 
the activity pattern of 172 is similar to that of 91, but with increased selectivity. The narrow 
shape of the potential energy well for the dihedral angle between the naphthalene and furan 
rings implies that it is difficult to vary the angle from the minimum of -135° (Figure 4-5). Thus, 
the compound’s structure is fairly rigid, leading to a small probability for 172 to bind to a 
diverse set of targets. Compound 178 also retains three aromatic centers and hydrogen 
bond acceptors, in common with the tetracyclic compound 91. However, the intramolecular 
hydrogen bond found in 172 cannot form in 178. The dihedral angle between the 
naphthalene ring and the furan ring is more flexible as seen in Figure 4-5.15 In comparison to 
172, the potential energy surface around the minimum is much flatter and there are fewer 
energy barriers (Figure 4-5). As a result, the increased structural flexibility in 178 could 
permit multi-target interactions and account for the compound’s observed broader activity 
spectrum.  
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Figure 4-5. Dihedral energy analyses of compounds between the naphthalene ring 
and the furan ring of 172 (Top panel) and 178 (Bottom panel). The structure of the 
global energy minimum is shown by a ball and stick model. 
 
4.5      Tetrahydronaphthalene-1-ol (TNO) Derivatives as Antitumor Agents 
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We further studied the effect of a non-aromatic ring-A in scaffold 2 on antitumor 
activity. Novel tetrahydronaphthalene-1-ol (TNO) derivatives were designed and eleven new 
analogues were synthesized as shown in Scheme 4-5. Compounds 152-154 were 
hydrolyzed by sodium hydroxide to give ring-opened compounds 184-186. From a 
comparison of the activity data for 184-186 (Table 4-4), a gem-dimethyl group on ring-A 
seems to be important for activity. To study the functions of the hydroxyl and carboxylic acid 
groups of 186, analogues 187-194 were designed and synthesized. Selective methylation of 
186 generated methyl ether 187, which was converted to methyl ester 188 through the same 
sequence as for the synthesis of 177 and 178.11 Meanwhile, reduction of 154 with lithium 
aluminum hydride afforded diol 189, which was treated with iodomethane and iodoethane in 
the presence of Cs2CO3 to generate phenylethers 190 and 191, respectively. Alkylation of 
the remaining primary alcohol was accomplished with iodomethane and iodoethane in the 
presence of NaH to give 192 and 193, respectively. Acetate 194 was obtained by acetylation 
of 190 with Ac2O. 
Scheme 4-5. Synthetic pathway to tetrahydronaphthalene-1-ol derivatives 184-194 
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Reagents and conditions: (a) 5% NaOH (aq), reflux; (b) MeI, NaOH, 18-crown-6, CH3CN, 90 
°C; (c) SOCl2, MeOH, rt; (d) LiAlH4, THF; (e) MeI or EtI, Cs2CO3, acetone, 50 °C; (f) MeI or 
EtI, NaH, THF, rt; (g) Ac2O, Et3N, DMAP, CH2Cl2. 
 
The newly synthesized analogues 184-194 were tested in vitro for their cytotoxic 
activity against a panel of human tumor cell lines: SK-BR-3 (estrogen receptor negative, 
HER2 over-expressing breast cancer), ZR-75-1 (estrogen receptor positive breast cancer), 
MDA-MB-231 (estrogen receptor negative breast cancer), A549 (non-small cell lung cancer), 
DU145 (prostate cancer cell line), KB (nasopharyngeal carcinoma), KB-vin (vincristine-
resistant KB subline).  
Tetrahydronaphthalene-1-ol (TNO) derivatives 184 and 185 displayed only weak 
antitumor activity, while 186 showed potent and broad antitumor activity against the tumor 
cell line panel (ED50 0.23 µg/mL against SK-BR-3 cell line; 0.49 µg/mL against ZR-75-1 cell 
line). The results demonstrated that analogues with a non-aromatic six-membered ring-A 
and gem-dimethyl substitution could retain significant activity. As to the tumor-tissue-type 
selectivity, 186 was highly active against all tumor cell lines tested (ED50 0.23–1.44 µg/mL), 
except MDA-MB-231 (ED50 7.42 µg/mL), while 91 and 172 were selectively active against 
certain breast cancer cell lines. These results demonstrated that introduction of a non-
aromatic ring-A could greatly influence the selective antitumor activity, most likely by 
changing the molecular conformation and orientation. In our prior SAR studies of neo-
tanshinlactone (91) and the ring-opened analogue 172, the presence of two functional 
groups from the opened lactone ring-C was critical to the antitumor activity, which 
encouraged us to study additional derivatives of 186. We synthesized a series of analogues 
with ether and ester substituents of various sizes. As seen in Table 4-4, 187-194 showed 
only weak to marginal activity against all tumor cell lines tested, which led to low selectivity 
ratios between MDA-MB-231 and other tumor cell lines. For example, 191 and 194 showed 
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only four-fold higher potency against SK-BR-3 than MDA-MB-231, while 186 was 33-fold 
more potent against SK-BR-3 than MDA-MB-231. Thus, the current SAR study indicated 
that the optimal substituent combination is hydroxyl and carboxylic acid. The preliminary 
results indicated that the combination of gem-dimethylated ring-A, hydroxyl, and carboxylic 
acid is important to antitumor activity and selectivity. More analogues will be synthesized 
and evaluated to establish detailed SAR of this new compound series.  
Table 4-4. Cytotoxicity of compounds 184-194 against tumor cell linesa 
Compd SK-BR-3 ZR-75-1 MDA-MB-231 A549 DU145 KB KB-vin
91 0.1 0.1 >10 10.6 15.9 13.1 13.2 
172 1.0 0.3 >10 10.6 8.7 9.1 7.0 
184 7.8 7.8 11.5 10.7 9.9 8.1 7.8 
185 8.79 5.87 20 15.52 11.02 13.64 7.95 
186 0.23 0.49 7.42 0.97 0.87 1.39 1.44 
187 8.0 13.0 >20 16.8 10.7 13.6 15 
188 8.9 11.3 20 20 11 17.5 17.1 
189 6.1 7.3 11.3 7 6.5 6.25 5.7 
190 7.1 4.5 8.5 7 6.5 7.6 6.5 
191 3.1 4.5 12.5 7.2 5.5 5.3 4.8 
192 5.8 4.5 15.0 6.1 5.5 3.6 6.3 
193 6.5 6.5 14.0 7.5 5.8 7.1 5.4 
194 4.8 5.3 19.0 9.8 5.7 8.7 8.5 
aSee Table 4-1. 
 
4.6      Conclusion 
In summary, current data have led to new developments and insights about neo-
tanshinlactone-based compounds that are active and selective against breast cancer cell 
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lines. We demonstrated that rings A and D were important for the activity. Importantly, we 
discovered that the lactone ring C could be opened through hydrolysis of the ester bond, 
while keeping the desired biological activity. A new class of active C-ring opened 
compounds, 2-(furan-2-yl) naphthalen-1-ol derivatives, was subsequently developed. 
Compounds 172-173 and 181 exhibited much higher selectivity against certain breast 
cancer cell lines than neo-tanshinlactone analogue 91. In addition, compound 178 was 
active against all cell lines tested, suggesting a different mechanism of action from its 
structural derivatives. Conformational and dihedral energy analyses of 172 and 178 
suggested that intramolecular hydrogen bonding was important to form a rigid conformation 
and improved the in vitro anticancer selectivity of 172. We also discovered another novel 
class of antitumor agents, tetrahydronaphthalene-1-ol (TNO) derivatives. Compound 186 
was the most potent analogue with ED50 0.23 µg/mL against SK-BR-3 cell line and showed 
broader antitumor activity compared with 91 and 172. Overall, these results establish two 
new scaffolds as promising structures for the development of promising anti-breast cancer 
agents.  
 
4.7       Experimental Section 
4.7.1    Chemistry 
Materials and Methods. Melting points were measured with a Fisher Johns melting 
apparatus without correction. 1H NMR spectra were measured on a 300 MHz Varian Gemini 
2000 spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Mass spectra were measured on a Shimadzu LC-MS2010 instrument. Thin-layer 
chromatography (TLC) and preparative TLC were performed on precoated silica gel GF 
plates purchased from Merck, Inc. Biotage Flash+ or Isco Companion systems were used 
for flash chromatography. Silica gel (200-400mesh) from Aldrich, Inc. was used for column 
chromatography. All other chemicals were obtained from Aldrich, Inc, and Fisher, Inc. 
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7-Methoxy-3-methyl-4H-furo[3,2-c]chromen-4-one (161). To a solution of 195 (199 
mg, 1.04 mmol) in toluene (9 mL) was added a mixture of HOAc (0.30 mL, 5.20 mmol) and 
NH4OAc (400 mg, 5.20 mmol) in EtOH (3 mL) and chloroacetone (0.42 mL, 5.20 mmol). The 
mixture was refluxed for 24 h. After cooling, the mixture was diluted with H2O and extracted 
with EtOAc. The organic layer was dried over Na2SO4, filtered, and evaporated. The residue 
was purified by column chromatography to give 161 as a white solid. 65% yield; 1H NMR 
(300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.2 Hz, 3H, CH3), 3.88 (s, 3H, OCH3), 6.88-6.93 (m, 
2H, aromatic), 7.33 (d, J = 1.5 Hz, 1H, OCH), 7.71-7.74 (m, 1H, aromatic). 
7-Hydroxy-3-methyl-4H-furo[3,2-c]chromen-4-one (160). To a solution of 161 (46 
mg, 0.2 mmol) in DCM (3 mL) was added BBr3 (0.6 mL, 0.6 mmol) dropwise at 0 °C. The 
reaction mixture was refluxed for 3 h. Water was added to quench the reaction. The solution 
was extracted with CHCl3, concentrated, and purified with column chromatography. 42% 
yield; 1H NMR (300 MHz, CD3OD, ppm): δ 2.88 (d, J = 1.2 Hz, 3H, CH3), 6.81-6.88 (m, 2H, 
aromatic), 7.53 (d, J = 1.2 Hz, 1H, OCH), 7.72 (d, J = 8.7 Hz, 1H, aromatic). 
General procedure for synthesis of 162-163. Compound 160 (0.2 mmol) was 
dissolved in DMF (1 mL) and acetone (3 mL). Cesium carbonate (195 mg, 0.6 mmol) and 2-
iodopropane or 1-bromohexane (0.6 mmol) were added to the above solution. The reaction 
mixture was stirred at rt for 12 h.  After removal of solvent in vacuo, the residue was purified 
by column chromatography to give 162 or 163 as a white solid.  
7-Isopropoxy-3-methyl-4H-furo[3,2-c]chromen-4-one (162). 30 % yield; mp 85-
87°C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (d, J = 6.0 Hz, 6H, CH(CH3)2), 2.34 (s, 3H, 
CH3), 4.61 (h, J = 6.0 Hz, 1H, CH), 6.86-6.90 (m, 2H, aromatic), 7.33 (s, 1H, OCH), 7.71 (d, 
J = 8.4 Hz, 1H, aromatic); HRMS Calcd for C15H15O4 (M+H+): 259.0965, found: 259.0961. 
7-(Hexyloxy)-3-methyl-4H-furo[3,2-c]chromen-4-one (163). 29% yield; 1H NMR 
(300 MHz, CDCl3, ppm): δ 0.92 (t, J = 6.9 Hz, 3H, (CH2)5CH3), 1.33-1.51 (m, 6H, (CH2)3), 
1.81 (p, J = 6.6 Hz, 2H, OCH2CH2), 2.34 (d, J = 0.9 Hz, 3H, CH3), 4.01 (t, J = 6.6 Hz, 2H, 
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OCH2), 6.88-6.91 (m, 2H, aromatic), 7.28 (d, J = 1.2 Hz, 1H, OCH), 7.71 (d, J = 9.3 Hz, 1H, 
aromatic). 
General procedure for synthesis of 165-169. Thionyl chloride (0.08 mL, 1.20 mmol) 
was added to the carboxylic acid (1.00 mmol) in CH2Cl2 (3 mL) and DMF (0.1 mL), and the 
mixture was refluxed under nitrogen atmosphere for 1 h. After cooling to rt, the mixture was 
concentrated in vacuo to give the corresponding acid chloride as a pale yellow solid, which 
was used directly in the next step. Naphthalen-1-ol or 5-methylnaphthalen-1-ol (1.00 mmol) 
was dissolved in THF (5 mL), then DMAP (5 mg) and ethyldiisopropylamine (0.18 mL, 1.02 
mmol) were added, and the mixture was cooled to 0 °C for 10 min. Freshly prepared acid 
chloride in dry THF (10 mL) was added to the mixture via cannula, and the resulting mixture 
was stirred at 25 °C for 2 h, diluted with diethyl ether (150 mL), and quenched by the 
addition of water (15 mL). The organic layer was washed with HCl and NaHCO3 and then 
dried (Na2SO4) and concentrated in vacuo. The residue was purified with flash 
chromatography eluting with hexane: EtOAc=10:1 to give 165-169. 
Naphthalen-1-yl furan-3-carboxylate (165). 87% yield; 1H NMR (300 MHz, CDCl3, 
ppm): δ 6.96 (d, J = 1.8 Hz, 1H, aromatic), 7.33 (dd, J = 1.5, 7.5 Hz, 1H, aromatic), 7.46-
7.55 (m, 4H, aromatic), 7.76 (d, J = 8.1 Hz, 1H, aromatic), 7.86-7.92 (m, 2H, aromatic), 8.32 
(t, J = 0.9 Hz, 1H, aromatic). 
5-Methylnaphthalen-1-yl furan-3-carboxylate (166). 46% yield; mp 53-55°C; 1H 
NMR (300 MHz, CDCl3, ppm): δ 2.72 (s, 3H, CH3), 6.97 (dd, J = 0.6, 5.2 Hz, 1H, aromatic), 
7.33-7.42 (m, 3H, aromatic), 7.51-7.56 (m, 2H, aromatic), 7.79 (d, J = 8.1 Hz, 1H, aromatic), 
7.93 (d, J = 8.4 Hz,1H, aromatic), 8.32-8.33 (m, 1H, aromatic). HRMS Calcd for C16H13O3 
(M+H+): 253.0859, found: 253.0869. 
Naphthalen-1-yl 3-methylbenzoate (167). 67% yield; 1H NMR (300 MHz, CDCl3, 
ppm): δ 2.49 (s, 3H, CH3), 7.36 (dd, J = 0.9, 8.1 Hz, 1H, aromatic), 7.4-7.55 (m, 5H, 
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aromatic), 7.79 (d, J = 8.1 Hz, 1H, aromatic), 7.89-7.95 (m, 2H, aromatic), 8.13-8.15 (m, 1H, 
aromatic). 
Naphthalen-1-yl 2-bromo-4-methylbenzoate (168). 96% yield; 1H NMR (300 MHz, 
CDCl3, ppm): δ 2.41 (s, 3H, CH3), 7.27 (dd, J = 0.9, 8.1 Hz, 1H, aromatic), 7.40 (dd, J = 1.2, 
7.5 Hz, 1H, aromatic), 7.48-7.52 (m, 3H, aromatic), 7.60 (d, J = 0.9 Hz, 1H, aromatic), 7.77 
(d, J = 8.1 Hz, 1H, aromatic), 7.87-7.90 (m, 1H, aromatic), 7.96-7.99 (m, 1H, aromatic), 8.13 
(d, J = 8.1 Hz, 1H, aromatic). 
Naphthalen-1-yl benzo[d][1,3]dioxole-5-carboxylate (169). 76% yield; 1H NMR 
(300 MHz, CDCl3, ppm): δ 6.11 (s, 2H, CH2), 6.96 (d, J = 8.1 Hz, 1H, aromatic), 7.35 (dd, J = 
0.9, 7.8 Hz, 1H, aromatic), 7.48-7.54 (m, 3H, aromatic), 7.74 (d, J = 1.5 Hz, 1H, aromatic), 
7.78 (d, J = 8.1 Hz, 1H, aromatic), 7.88-7.93 (m, 2H, aromatic), 7.96 (dd, J = 1.5, 8.1 Hz, 1H, 
aromatic). 
4-(Prop-2-ynyloxy)-2H-benzo[h]chromen-2-one (170). To a mixture of 132 (212 
mg, 1.00 mmol mmol), K2CO3 (300 mg, 2.17 mmol) in acetone (8 mL) was added 3-
bromoprop-1-yne (0.17 mL, 1.50 mmol). The mixture was refluxed 12 h. After cooling, the 
mixture was filtered, concentrated, diluted with H2O and extracted with EtOAc. The organic 
layer was dried over Na2SO4, filtered, and evaporated. The residue was purified by column 
chromatography to give 170 as a light yellow solid. 40% yield; mp 205-207 °C; 1H NMR (300 
MHz, CDCl3, ppm): δ 2.70 (t, J = 2.4 Hz, 1H, CCH), 4.92 (d, J = 2.4 Hz, 2H, OCH2), 5.93 (s, 
1H, COCH), 7.62-7.71 (m, 3H, aromatic), 7.80-7.90 (m, 2H, aromatic), 8.54-8.58 (m, 1H, 
aromatic); HRMS Calcd for C16H11O3 (M+H+): 251.0703, found: 251.0697. 
O-2-oxo-2H-benzo[h]chromen-4-yl dimethylcarbamothioate (171). 4-Hydroxy-2H-
benzo[h]chromen-2-one (7.5 mmol) and 1,4-diazabicyclo[2.2.2]octane (DABCO) (9.75 mmol, 
1.3 equiv) were heated in N-methylpyrrolidone (NMP) (6 mL) to 50 °C to give a dark brown 
solution. Dimethylthiocarbamoyl chloride (8.25 mmol, 1.1 equiv) was dissolved in NMP (1.5 
mL) and added dropwise to the previous solution over 18 min. Some fine precipitate formed 
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in the dark red solution during this addition. The reaction was monitored by LC and was 
complete within 90 min at 50 °C. Water was added over 15 min at 50 °C. The original solid 
dissolved readily, but a yellow precipitate formed later in the addition, which persisted to the 
end. The reaction mixture was cooled to 20 °C and the precipitate isolated by filtration. The 
product cake was washed twice with water and dried in vacuo at 50 °C to yield the title 
compound as a solid. 85% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 3.46 (s, 3H, N(CH3)2), 
3.52 (s, 3H, N(CH3)2), 6.30 (s, 1H, COCH), 7.51 (d, J = 9.0 Hz, 1H, aromatic), 7.64-7.70  (m, 
3H, aromatic), 7.86-7.90 (m, 1H, aromatic), 8.56-8.59 (m, 1H, aromatic). 
General procedure for synthesis of 164, 172-174, 182-183, 184-186. Lactone 91-
92, 110-111, 136, 138, 152-154 (0.1 mmol) was refluxed in ethanolic aqueous potassium 
hydroxide (5%; 5 mL) for 3.5 h. Then the reaction mixture was cooled and quenched by 
pouring into ice, acidified with 6N HCl, and extracted with CHCl3. Removal of solvent, drying 
(Na2SO4), and chromatographic purification (DCM-MeOH) gave the hydrolyzed product as a 
light yellow solid. 
2-(1-Hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (164). 93% yield; 
mp 194-196 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.27 (d, J = 1.2 Hz, 3H, CH3), 
7.51-7.55 (m, 5H, aromatic & OCH), 7.86-7.89 (m, 1H, aromatic), 8.40-8.44 (m, 1H, 
aromatic). HRMS Calcd for C16H11O4 (M-H+): 267.0657, found: 267.0663. 
2-(5-Ethyl-1-hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (172). 
90% yield; mp 151-153 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 1.35 (t, J = 7.5 Hz, 3H, 
CH2CH3), 2.25 (d, J = 0.9 Hz, 3H, CH3), 3.08 (q, J = 7.5 Hz, 2H, CH2CH3), 7.35-7.37 (m, 2H, 
aromatic), 7.41 (d, J = 1.2 Hz, 1H, OCH), 7.48 (d, J = 8.7 Hz, 1H, aromatic), 7.62 (d, J = 9.0 
Hz, 1H, aromatic), 8.24-8.28 (m, 1H, aromatic). HRMS Calcd for C18H15O4 (M-H+): 295.0976, 
found: 295.0972. 
2-(1-Hydroxy-5-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (173). 
80% yield; mp 173-175 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.41 (s, 3H, CH3), 4.00 
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(s, 3H, OCH3), 6.98 (d, J = 7.5 Hz, 1H, aromatic), 7.38 (t, J = 8.1 Hz, 1H, aromatic), 7.51 (d, 
J = 9.0 Hz, 1H, aromatic), 7.64 (s, 1H, OCH) 7.78 (d, J = 8.7 Hz, 1H, aromatic), 7.94 (d, J = 
8.7 Hz, 1H, aromatic). HRMS Calcd for C17H13O5 (M-H+): 297.0768, found: 297.0765. 
2-(5-Ethoxy-1-hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (174). 
56% yield; mp 208-210 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 1.51 (t, J = 7.8 Hz, 3H, 
CH2CH3), 2.33 (s, 3H, CH3), 4.23 (q, J = 6.9 Hz, 2H, CH2CH3), 6.97 (d, J = 7.8 Hz, 1H, 
aromatic), 7.38 (t, J = 8.7 Hz, 1H, aromatic), 7.48 (d, J = 8.7 Hz, 1H), 7.59 (s, 1H, OCH), 
7.82 (d, J = 8.7 Hz, 1H, aromatic), 7.82 (d, J = 8.7 Hz, 1H, aromatic). HRMS Calcd for 
C18H15O5 (M-H+): 311.0919, found: 311.0940. 
2-(5-Ethyl-1-hydroxynaphthalen-2-yl)-4,5-dimethylfuran-3-carboxylic acid (182). 
66% yield; mp 158-160 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 1.35 (t, J = 7.8 Hz, 3H, 
CH2CH3), 2.17 (s, 3H, CH3), 2.26 (s, 3H, CH3), 3.07 (q, J = 7.8 Hz, 2H, CH2CH3), 7.32-7.38 
(m, 2H, aromatic), 7.49 (d, J = 9.0 Hz, 1H, aromatic), 7.60 (d, J = 9.0 Hz, 1H, aromatic), 
8.23-8.26 (m, 1H, aromatic). HRMS Calcd for C19H17O4 (M-H+): 309.1132, found: 309.1140. 
4-Ethyl-2-(5-ethyl-1-hydroxynaphthalen-2-yl)furan-3-carboxylic acid (183). 90% 
yield; mp 153-155 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 1.24 (t, J = 7.5 Hz, 3H, CH2CH3), 
1.35 (t, J = 7.5 Hz, 3H, CH2CH3), 2.78 (q, J = 7.5 Hz, 2H, CH2CH3), 3.07 (q, J = 7.5 Hz, 2H, 
CH2CH3), 7.34-7.36 (m, 2H, aromatic), 7.39 (s, 1H, OCH), 7.49 (d, J = 9.3 Hz, 1H, aromatic), 
7.60 (d, J = 9.3 Hz, 1H, aromatic), 8.24-8.27 (m, 1H, aromatic). HRMS Calcd for C19H17O4 
(M-H+): 309.1132, found: 309.1124. 
2-(4-Hydroxy-2,3-dihydro-1H-inden-5-yl)-4-methylfuran-3-carboxylic acid (184). 
90 % yield; 1H NMR (300 MHz, CD3OD, ppm): δ 2.06 (p, J = 7.5 Hz, 2H, CH2CH2CH2), 2.20 
(d, J = 0.9 Hz, 3H, CH3), 2.89 (q, J = 7.5 Hz, 4H, CH2CH2CH2), 4.94 (s, 1H, OH), 6.83 (d, J = 
7.8 Hz, 1H, aromatic), 7.14 (d, J = 7.8 Hz, 1H, aromatic), 7.30 (d, J = 0.9 Hz, 1H, OCH); MS: 
m/z 257 (M-H+). 
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2-(1-Hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-carboxylic 
acid (185). 59% yield; mp 115-117 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 1.75-1.77 
(m, 4H, CH2), 2.20 (d, J = 1.2 Hz, 3H, CH3),  2.69-2.75 (m, 4H, CH2) 6.67 (d, J = 8.4 Hz, 1H, 
aromatic), 7.10 (d, J = 8.4 Hz, 1H, aromatic), 7.43 (s, 1H, OCH); HRMS Calcd for C16H15O4 
(M-H+): 271.0970, found: 271.0971. 
2-(1-Hydroxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-
carboxylic acid (186). 76% yield; mp 105-107 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 1.28 
(s, 6H, C(CH3)2), 1.62-1.66 (m, 2H, CH2), 1.78-1.82 (m, 2H, CH2), 2.21(d, J = 1.5 Hz, 3H, 
CH3),  2.70 (t, J = 6.3 Hz, 2H, CH2), 6.96 (d, J = 8.4 Hz, 1H, aromatic), 7.13 (d, J = 8.4 Hz, 
1H, aromatic), 7.33 (d, J = 1.2 Hz, 1H, OCH); HRMS Calcd for C18H19O4 (M-H+): 301.1434, 
found: 301.1425. 
General procedure for synthesis of methyl ethers. Compound 91, 92, or 154 (0.1 
mmol) was refluxed in ethanolic aqueous potassium hydroxide (5%; 5 mL) for 3.5 h. The 
solution was washed with CHCl3 and evaporated to give the dipotassium salt, which was 
refluxed for 24 h with 18-crown-6 (4.35 mg, 0.0145 mmol) and methyl iodide (0.01 mL, 0.159 
mmol) in acetonitrile (5 mL). The acetonitrile was removed in vacuo. After dilution with 
CHCl3, the mixture was washed with water (10 mL), dried, and concentrated to give an oily 
residue. The residue was purified with flash chromatography, eluting with DCM:MeOH= 10:1, 
to give the methyl ether derivative. 
2-(1-Methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (175). 46% yield; 
mp 118-120 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 0.9 Hz, 3H, CH3), 3.74 (s, 
3H, OCH3), 7.35 (d, J = 1.5 Hz, 1H, OCH), 7.47 (d, J = 8.7 Hz, 1H, aromatic), 7.51-7.54 (m, 
2H, aromatic), 7.62 (d, J = 8.4 Hz, 1H, aromatic), 7.83-7.86 (m, 1H, aromatic), 8.18-8.22 (m, 
1H, aromatic). HRMS Calcd for C17H13O4 (M-H+): 281.0814, found: 281.0827. 
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2-(5-Ethyl-1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (176). 
39% yield; mp 128-130 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.37 (t, J = 7.8 Hz, 3H, 
CH2CH3), 2.46 (d, J = 1.2 Hz, 3H, CH3), 3.09 (q, J = 7.8 Hz, 2H, CH2CH3), 3.73 (s, 3H, 
OCH3), 7.35-7.52 (m, 4H, aromatic & OCH), 7.82 (d, J = 9.3 Hz, 1H, aromatic), 8.08 (d, J = 
9.9 Hz, 1H, aromatic). HRMS Calcd for C19H17O4 (M-H+): 309.1127, found: 309.1139. 
2-(1-Methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-
carboxylic acid (187). 32 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, (CH3)2), 
1.63-1.67 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, CCH2CH2CH2), 2.36 (d, J = 0.9 Hz, 3H, 
CH3), 2.76 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 3.52 (s, 3H, OCH3), 7.16 (d, J = 8.4 Hz, 1H, 
aromatic), 7.23 (d, J = 8.4 Hz, 1H, aromatic), 7.29 (d, J = 1.5 Hz, 1H, OCH); MS: m/z 315 
(M+H+). 
General procedure for synthesis of methyl esters. Thionyl chloride (0.05 mL, 0.45 
mmol) was added dropwise at 0 °C to a solution of 175, 176, or 187 (0.14 mmol) in MeOH 
(15 mL). The solution was then stirred at rt for 12 h. The solvent was evaporated, and the 
residue was dissolved in EtOAc and washed successively with saturated aqueous NaHCO3 
and brine. The organic phase was dried over Na2SO4 and evaporated under reduced 
pressure to give the methyl ester derivative. 
Methyl 2-(1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylate (177). 32% 
yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 1.2 Hz, 3H, CH3), 3.69 (s, 3H, OCH3), 
3.71 (s, 3H, COOCH3), 7.35 (d, J = 1.5 Hz, 1H, OCH), 7.50-7.57 (m, 3H, aromatic), 7.64 (d, 
J = 8.4 Hz, 1H, d, J = 1.5 Hz, 1H, OCH), 7.84-7.88 (m, 1H, aromatic), 8.19-8.23 (m, 1H, 
aromatic). HRMS Calcd for C18H15O4 (M-H+): 297.1121, found: 297.1110. 
Methyl 2-(5-ethyl-1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylate (178). 
82% yield; mp 121-123 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.8 Hz, 3H, 
CH2CH3), 2.52 (s, 3H, CH3), 3.11 (q, J = 7.5 Hz, 1H, CH2CH3), 3.68 (s, 3H, OCH3), 3.69 (s, 
3H, COOCH3), 7.34-7.49 (m, 3H, aromatic & OCH), 7.54 (d, J = 8.7 Hz, 1H, aromatic), 7.85 
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(d, J = 8.7 Hz, 1H, aromatic), 8.10 (d, J = 8.4 Hz, 1H, aromatic). HRMS Calcd for C20H19O4 
(M-H+): 325.1434, found: 325.1430. 
Methyl 2-(1-methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methyl 
furan-3-carboxylate (188). 23 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, 
(CH3)2), 1.63-1.67 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, CCH2CH2CH2), 2.20 (d, J = 1.2 
Hz, 3H, CH3), 2.75 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 3.46 (s, 3H, OCH3), 3.72 (s, 3H, 
COOCH3), 7.14 (d, J = 8.1 Hz, 1H, aromatic), 7.23 (d, J = 8.1 Hz, 1H, aromatic),7.27 (d, J = 
0.9 Hz, 1H, OCH); MS: m/z 329 (M+H+). 
General procedure for synthesis of 179-180, and 189. LiAlH4 (60 mg, 16 mmol) 
was added at 0 °C to a solution of 91, 92, or 154 (0.1 mmol) in THF (5 mL). The solution 
was then refluxed for 5 h. Then the reaction mixture was cooled and quenched by pouring 
into ice, acidified with 2N HCl, and extracted with diethyl ether: DCM= 2:1 (3×5 mL). The 
solvent was evaporated after drying (Na2SO4). Chromatographic purification (hexane: 
EtOAc= 4:1) gave the product as a white solid. 
2-(3-(Hydroxymethyl)-4-methylfuran-2-yl)naphthalen-1-ol (179). 87% yield; mp 
95-97 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.13 (s, 3H, CH3), 4.58 (s, 2H, CH2OH), 
7.45-7.56 (m, 5H, aromatic & OCH), 7.83-7.87 (m, 1H, aromatic), 8.33-8.36 (m, 1H, 
aromatic); HRMS Calcd for C16H13O3 (M-H+): 253.0870, found: 253.0863. 
5-Ethyl-2-(3-(hydroxymethyl)-4-methylfuran-2-yl)naphthalen-1-ol (180). 95% 
yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.14 (s, 3H, CH3), 
3.08 (q, J = 7.8 Hz, 2H, CH2CH3), 4.64 (s, 2H, CH2OH), 7.35-7.44 (m, 3H, aromatic), 7.54 (d, 
J = 8.7 Hz, 1H, aromatic), 7.64 (d, J = 9.3 Hz, 1H, aromatic), 7.99 (br, 1H, OH), 8.25 (d, J = 
8.1 Hz, 1H, aromatic). HRMS Calcd for C18H17O3 (M-H+): 281.1183, found: 281.1197. 
2-(3-(Hydroxymethyl)-4-methylfuran-2-yl)-5,5-dimethyl-5,6,7,8-tetrahydronaph 
thalene-1-ol (189). 93% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, (CH3)2), 1.63-
1.67 (m, 2H, CCH2CH2CH2), 1.80-1.84 (m, 2H, CCH2CH2CH2), 2.11 (d, J = 0.9 Hz, 3H, CH3), 
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2.71 (t, J = 6.3 Hz, 2H, CCH2CH2CH2), 4.58 (s, 1H, CH2OH), 6.97 (d, J = 8.4 Hz, 1H, 
aromatic), 7.20 (d, J = 8.4 Hz, 1H, aromatic), 7.28 (d, J = 0.9 Hz, 1H, OCH); MS: m/z 385 
(M-H+). 
General procedure for synthesis of 181, and 190-191. Compound 180 or 189 (0.1 
mmol) was dissolved in acetone. Methyl iodide or ethyl iodide (0.3 mmol) and potassium 
carbonate (for 180) or cesium carbonate (for 189) (1.0 mmol) were added to the above 
solution. The mixture was stirred overnight and purified with flash chromatography to obtain 
the ethers. 
(2-(5-Ethyl-1-methoxynaphthalen-2-yl)-4-methylfuran-3-yl)methanol (181). 79% 
yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.5 Hz, 3H, CH2CH3), 2.17 (d, J = 1.2 
Hz, 3H, CH3), 2.75 (t, J = 6.3 Hz, 1H, OH), 3.12 (q, J = 7.5 Hz, 2H, CH2CH3), 3.70 (s, 3H, 
OCH3), 4.48 (d, J = 6.0 Hz, 2H, CH2OH), 7.37 (d, J = 1.2 Hz, 1H, OCH), 7.40(d, J = 6.3 Hz, 
1H, aromatic), 7.49 (dd, J = 7.2, 8.1 Hz, 1H, aromatic), 7.55 (d, J = 8.7 Hz, 1H, aromatic), 
7.90 (d, J = 9.0 Hz, 1H, aromatic), 8.09 (d, J = 8.4 Hz, 1H, aromatic); HRMS Calcd for 
C19H21O3 (M+H+): 297.1485, found: 297.1470. 
(2-(1-methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-
yl)methanol (190). 100 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, (CH3)2), 
1.64-1.68 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, CCH2CH2CH2), 2.12 (d, J = 0.9 Hz, 3H, 
CH3), 2.69 (t, J = 6.3 Hz, 1H, CH2OH), 2.77 (t, J = 6.3 Hz, 2H, CCH2CH2CH2), 3.46 (s, 3H, 
OCH3), 4.41 (d, J = 5.7 Hz, 2H, CH2OH), 7.16-7.22 (m, 2H, aromatic), 7.27 (d, J = 0.9 Hz, 
1H, OCH); MS: m/z 323 (M+Na+). 
(2-(1-Ethoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-
yl)methanol (191). 94 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.18 (t, J = 7.2 Hz, 3H, 
CH2CH3), 1.30 (s, 6H, (CH3)2), 1.64-1.68 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, 
CCH2CH2CH2), 2.12 (d, J = 0.9 Hz, 3H, CH3), 2.76 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 2.87 
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(br, 1H, CH2OH), 3.58 (q, J = 7.2 Hz, 2H, CH2CH3), 4.39 (s, 2H, CH2OH), 7.18 (s, 2H, 
aromatic), 7.26 (d, J = 0.3 Hz, 1H, OCH); MS: m/z 313 (M-H+). 
General procedure for synthesis of 192-193. Compound 190 or 191 (0.05 mmol) 
was dissolved in THF. Methyl iodide (0.5 mmol) and NaH (1.0 mmol) were added to the 
above solution. The mixture was stirred for 2 h and then poured into ice water. The solution 
was acidified and extracted with CH2Cl2. The organic phase was dried (Na2SO4) and 
concentrated. The residue was purified with flash chromatography eluting with hexane: 
EtOAc=10:1 to give 192-193. 
2-(1-Methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-(methoxymethyl) 
-4-methylfuran (192). 44 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, (CH3)2), 
1.64-1.67 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, CCH2CH2CH2), 2.10 (d, J = 1.2 Hz, 3H, 
CH3), 2.77 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 3.33 (s, 3H, CH2OCH3), 3.49 (s, 3H, OCH3), 
4.32 (s, 2H, CH2OCH3), 7.17 (dd, J = 8.4 Hz, 2H, aromatic), 7.28 (d, J = 1.2 Hz, 1H, OCH); 
MS: m/z 315 (M+H+). 
2-(1-Ethoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-(methoxymethyl)-
4-methylfuran (193). 61 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.19 (t, J = 7.2 Hz, 3H, 
CH2CH3), 1.30 (s, 6H, (CH3)2), 1.64-1.67 (m, 2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, 
CCH2CH2CH2), 2.09 (d, J = 0.9 Hz, 3H, CH3), 2.77 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 3.32 (s, 
3H, CH2OCH3),  3.59 (q, J = 6.9 Hz, 2H, CH2CH3), 4.32 (s, 2H, CH2OCH3), 7.16 (dd, J = 8.1 
Hz, 2H, aromatic), 7.26 (d, J = 0.9 Hz, 1H, OCH); MS: m/z 329 (M+H+). 
 (2-(1-Methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-4-methylfuran-3-
yl)methyl acetate (194). Compound 190 (0.05 mmol) was dissolved in CH2Cl2. Acetic 
anhydride (0.50 mmol), Et3N (0.65 mmol), and DMAP (5 mg) were added to the above 
solution. The mixture was stirred overnight and purified with flash chromatography to obtain 
the ester. 82 % yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.30 (s, 6H, (CH3)2), 1.63-1.67 (m, 
2H, CCH2CH2CH2), 1.77-1.83 (m, 2H, CCH2CH2CH2), 2.06 (s, 3H, CH2OCOCH3), 2.06 (d, J 
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= 0.9 Hz, 3H, CH3), 2.76 (t, J = 6.3 Hz, 1H, CCH2CH2CH2), 3.48 (s, 3H, OCH3), 5.01 (s, 2H, 
CH2OCOCH3), 7.13-7.19 (m, 2H, aromatic), 7.30 (d, J = 1.2 Hz, 1H, OCH); MS: m/z 365 
(M+Na+). 
4.7.2    Biological Assay. 
The assay methods and description of cell lines are described in Chapter 3.  
4.7.3    Computational Methods 
A conformational analysis was conducted to study the molecular geometries of 
compounds 162, 164, 166, and 170 and their potential SAR relevance. The X-ray structure 
(CSD Refcode: VOBVIR) of 8-ethyl-4,10,12-trimethoxy-6H-benzo(d)naphtho(1,2-b)pyran-6-
one was obtained by searching the Cambridge Structural Database version 5.29 and 
employed as the template by which compounds 162, 164, 166, and 170 were aligned to 
obtain their starting conformations.16 Systematic conformational searches were then carried 
out for compounds 162, 164, 166, and 170. The lowest energy conformers were further 
minimized by PM3 Hamiltonian. The final structures were rendered for pharmacophore 
elucidation and dihedral energy analysis. All calculations were conducted using the MOE 
2007.09 package. 
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CHAPTER 5 
NOVEL SUBSTITUTUED 6-PHENYL-4H-FURO[3,2-C]PYRAN-4-ONE DERIVATIVES AS 
POTENT AND HIGHLY SELECTIVE ANTI-BREAST CANCER AGENTS 
 
5.1         Introduction 
  In the previous chapter, we reported a study on how the individual A, C, and D rings 
of neo-tanshinlactone (90) analogues influence in vitro anti-breast cancer activity.1 The 
results revealed that 2-(furan-2-yl)-naphthalen-1-ol derivatives (e.g., 172),1 in which ring-C of 
90 is missing, are a new class of potent and selective anti-breast cancer agents. These 
results encouraged us to further simplify the scaffold of 90 and develop novel analogues as 
potential anti-breast cancer agents.  
 
Figure 5-1. Structures of neo-tanshinlactone (90), 2-(furan-2-yl)-naphthalen-1-ol 
derivative 172, and a newly designed scaffold 5 
 
5.2       Design 
We designed scaffold 5 by removing ring-B of 90 to investigate how this ring affects 
the anti-breast cancer activity (Figure 5-1). Twenty-four new analogues were designed to 
explore the SAR and develop new leads. Firstly, new analogues with various substitutents 
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around ring-A were designed including mono-, di-, and tri-substituted analogues, as shown 
in Figure 5-2. Hydrogen, methyl, methoxy, ethoxy, hydroxy, and fluorine groups were 
incorporated at different positions (3’ and 4’ positions) of the phenyl ring (197-206) to study 
the effects of position, group size, halogen, etc. We also designed di-substituted analogues 
(2’,3’; 3’,4’; and 3’,5’; 207-214) and a tri-substituted analogue (3’,4’,5’; 215). We further 
designed compounds 216-220, which have a modified ring-C or -D, as shown in Figure 5-2. 
Insertion of an ethyl (216) or two methyl (217) groups rather than a single methyl group on 
the furan, as well as bioisosteric replacement of sulfur (thiolactone 218-219) for oxygen in 
the lactone carbonyl, and reduction of the furan ring (220) were also investigated for their 
impact on anti-breast cancer activity.  
 
Figure 5-2. Structures of designed 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives  
 
5.3      Chemistry 
101 
 
All target compounds (197-220) were synthesized through a three- to five-step 
sequence (Scheme 5-1). Various substituted esters 221 were reacted with a dianion 
intermediate generated from ethyl acetoacetate with LDA and TMEDA to give diketoesters 
222 as tautomeric mixtures. Pyrones 223-235 were prepared by heating 222 at 170 °C 
under reduced pressure.2 The resulting yellow solid was isolated by vacuum filtration, and 
the compound used directly in the next step.2 Target compounds 197-199, 202-205, 207, 
209-210, 212-213, and 215-217 were obtained via a tandem alkylation/intramolecular Aldol 
reaction of 223-235.3, 4 Removal of the methyl group in 199, 205, 207, 210, and 213 by BBr3 
gave 201, 206, 208, 211, and 214, respectively. Ethyl ether 200 was obtained by treatment 
of 201 with iodoethane under basic conditions (Scheme 5-1). Compounds 210 and 213 was 
reacted with Lawesson's reagent to afford 218 and 219, respectively, 5 and 220 was 
synthesized by hydrogenation of 210 with formic acid.6 
Scheme 5-1 Synthetic pathway to analogues 197-220 
 
 
5.4       Results and Discussion 
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Together with 90, the newly synthesized 6-phenyl-4H-furo[3,2-c]pyran-4-one 
analogues (197-220) were evaluated for in vitro anti-breast cancer activity against the SK-
BR-3 human tumor cell line. Results from 197–215 (Table 5-1) showed that different 
substituents around the phenyl ring were critical to the potency and selectivity. Modifications 
in the furopyranone ring system were also explored with 216–220 (Table 5-2). Selected 
active compounds with ED50 values less than 4 µg/mL against SK-BR-3 were further 
examined against ZR-7-51 (estrogen receptor positive breast cancer), MDA-MB-231 
(estrogen receptor negative breast cancer), A549 (human lung cancer), DU145 (prostate 
cancer), KB (nasopharyngeal carcinoma), and KB-vin (vincristine-resistant KB subline) 
cancer cell lines (Table 5-3). 
 
Table 5-1. Cytotoxicity of 197-215 against SK-BR-3 tumor cell linea 
Compd 2’ 3’ 4’ 5’ SK-BR-3 
90 - - - - 0.25 
197 H H H H 3.5 
198 H Me H H 1.7 
199 H OMe H H 0.66 
200 H OEt H H 0.18 
201 H OH H H 0.39 
202 H F H H 5.0 
203 H H F H 4.7 
204 H H Me H >20 
205 H H OMe H >20 
206 H H OH H 8.7 
207 OMe OMe H H 18.6 
208 OH OH H H 8.8 
209 H Me Me H 3.7 
210 H OMe OMe H 14.8 
211 H OH OH H 0.12 
212 H Me H Me 5.7 
213 H OMe H OMe 0.08 
214 H OH H OH 9.9 
215 H OMe OMe OMe 0.14 
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amean ED50 (µg/mL), Standard error of independent determinations was less than 5%. 
 
Structurally, both 90 and 198 have a methyl substituent at corresponding positions on 
their phenyl rings. Thus, the two compounds are identical, except that 198 has no ring-B. 
Interestingly, although 198 showed potent activity against SK-BR-3 breast cancer cell line 
with an ED50 value of 1.74 µg/mL, it was much less active than 90. Addition of methyl (198), 
methoxy (199), ethoxy (200), and hydroxy (201) at the 3’-position of the phenyl ring 
increased activity against the SK-BR-3 cell line, compared with 197. The rank order of 
potency of the five compounds was 200 > 201 > 199 > 198 > 197. Especially, 3’-OEt analog 
200 displayed slightly greater activity (ED50 0.18 µg/mL) than 90. In contrast, fluorine at the 
3’-position (202), as well as 4’-position (203), led to somewhat decreased potency compared 
with the unsubstituted analogue 197. Addition of methyl, methoxy, or hydroxy at the phenyl 
4’-position (204-206) reduced potency significantly. Compounds 207-214 and 215 are di- 
and tri-substituted derivatives, respectively, with one substituent always present at the 
phenyl 3’-position. Neither 2’,3’-disubstituted compound (207, 208) showed significant 
activity, leading us to speculate that a substituent in the 2’-position may have a steric effect 
on the orientation of the lactone ring and reduce the ligand-receptor interaction. Analogues 
with the same substituent at both the 3’- and 4’-positions showed increased potency relative 
to the corresponding 4’-monosubstituted analogue (204 vs 209, 205 vs 210, 206 vs 211). 
Thus, alkyl, alkoxy, and hydroxy groups are favored at the 3’-position, while they are not 
favored at the 4’-position. Comparison of 213 with 212 and 211 indicated that a methoxy 
group is favored at the 5’-position, while methyl and hydroxy groups are not. Furthermore, 
the 3’,4’,5’-trimethoxy (215) and 3’,5’-dimethoxy (213) analogues showed dramatically 
enhanced potency compared with the 3’-methoxy compound (199), while the 3’,4’-dimethoxy 
(210) and 2’,3’-dimethoxy (207) analogues showed decreased potency. In fact, the 3’,5’-
dimethoxy analogue 213 (ED50 0.08 µg/mL) was the most active analogue among the 19 
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substituted phenyl A-ring analogues (197–215). It was also approximately three-fold more 
potent than 90. 
We also investigated the cytotoxic activity of 216-220, which have a modified ring-C 
or -D, as shown in Table 5-2. Insertion of an ethyl (216) or two methyl (217) groups rather 
than a single methyl group on the furan, as well as bioisosteric replacement of sulfur 
(thiolactones 218-219) for oxygen in the lactone carbonyl, and reduction of the furan ring-D 
(220) led to greatly reduced or no anti-breast cancer activity (Table 5-2).  
 
Table 5-2. Cytotoxicity of 216-220 against SK-BR-3 cell linea 
Compd 216 217 218 219 220 
SK-BR-3 16.7 >20 >20 10.6 20 
aSee Table 5-1. 
 
To examine the human tumor-tissue-type selectivity, active compounds 198-201, 211, 
213, and 215 were tested against a limited but diverse panel of human cancer cell lines, 
using 90 as a positive control (Table 5-3). Compounds 198-200 and 211 displayed similar 
and significant inhibition of the ZR-75-1 and SK-BR-3 cell lines. Interestingly, 213 and 215 
showed only weak activity against ZR-75-1, although they were very active against SK-BR-3. 
Analogue 211 showed marginal inhibition, while the other six lead compounds had no 
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activity against MDA-MB-231 breast cancer or the remaining four non-breast cancer cell 
lines tested, which suggested high tumor-tissue-type selectivity. Importantly, 213 and 215 
showed unique selectivity against the SK-BR-3 breast cancer cell line (HER2+), with 
approximately 100-250 fold differences compared with the other cancer cell lines tested. The 
unique selectivity of these novel lead compounds could be exploited to develop novel anti-
breast cancer trials candidates and explore the mechanism(s) of action.  
Table 5-3. Cytotoxicity of selected compounds against human tumor cell linesa 
Compd ZR-75-1 MDA-MB-231 A549 DU145 KB KBvin 
90 0.25 10.0 14.3 15.4 >10 >20 
198 1.5 >20 12.9 5.9 10.5 9.6 
199 1.4 >10 14.9 >20 >20 18.2 
200 0.60 >10 15.6 20 17.4 >20 
201 0.21 >10 16.6 20 15.8 14.6 
211 0.31 5.9 5.0 6.6 5.2 6.0 
213 8.8 >20 >20 18.7 >20 >20 
215 9.2 >10 20 >20 >20 >20 
aSee Table 5-1. 
 
5.5      Conclusion 
In conclusion, this study discovered a novel class of promising anti-breast cancer 
agents, substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives. The ED50 values of the 
two most potent analogues (213 and 215) against SK-BR-3 were 0.08 and 0.14 µg/mL, 
respectively. More importantly, 213 and 215 showed extremely high cancer cell line 
selectivity, being approximately 100- to 250-fold more potent against SK-BR-3 compared 
with six additional tested cancer cell lines. Preliminary SAR studies led to the following 
observations. (1) 3’-Methyl, methoxy, ethoxy, and hydroxy groups, but not a 3’-fluoro group, 
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could increase potency. (2) Among di-substituted phenyl compounds, 2’-, 4’-, or 5’-methyl 
groups, 2’- or 4’-methoxy groups, and 5’-hydroxy groups decreased potency; while a 4’-
hydroxy or 5’-methoxy group increased potency. (3) Current modifications in ring-C and -D 
were not preferred. The SAR profile established from the current study is different from that 
with the neo-tanshinlactone series, which is a four-ring system. Thus, skeletal planarity is not 
indispensable for the entire molecule, though it may be important to some extent. Focused 
studies will continue to develop promising novel analogues as clinical trials candidates for 
anti-breast cancer treatment. 
 
5.6       Experimental Section 
5.6.1    Chemistry 
Materials and Methods. Melting points were measured with a Fisher Johns melting 
apparatus without correction. 1H NMR spectra were measured on a 300 MHz Varian Gemini 
2000 spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Mass spectra were measured on a Shimadzu LC-MS2010 instrument. Thin-layer 
chromatography (TLC) and preparative TLC were performed on precoated silica gel GF 
plates purchased from Merck, Inc. Biotage Flash+ or Isco Companion systems were used 
for flash chromatography. Silica gel (200-400 mesh) from Aldrich, Inc. was used for column 
chromatography. All other chemicals were obtained from Aldrich, Inc. and Fisher, Inc. 
Preparation of intermediates 223-235 were reported by Douglas et al.2 
General procedure for preparation of 223-235. To a solution of diisopropylamine 
(8.9 mL, 63.7 mmol, 2.5 eq) in 100 mL of THF at -10 °C (ice in acetone) was added n-BuLi 
(2.5 M in hexane) (25.5 mL, 63.7 mmol, 2.5 eq) via a syringe. This solution was stirred at -
10 °C for 45 min. In a separate flask, a solution of ethyl acetoacetate (3.32 g, 25.5 mmol) in 
50 mL of THF was cooled to -78 °C and the LDA solution was carefully transferred to the 
ethyl acetoacetate solution dropwise via a cannula. A yellow cloudy solution formed initially, 
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but the mixture quickly turned homogeneous. After completing the addition of the LDA 
solution, freshly distilled TMEDA (3.84 mL, 25.5 mmol, 1.0 eq) was added in one aliquot via 
a syringe. The reaction mixture was then stirred for 3 h at -78 °C. The reaction mixture 
turned orange when a solution of 219 (25.5 mmol, commercially available) was added via 
cannulation, and a yellow precipitate was observed. The reaction mixture was warmed to rt 
and stirred for 48 h. When the reaction was completed, 4 mL of HOAc was added to the 
reaction mixture, which was subsequently concentrated under reduced pressure. The 
resulting crude residue was filtered through a small bed of silica gel eluted with ample 
CH2CI2. After removal of the solvent in vacuo, the crude diketoester was purified using silica 
gel column chromatography eluting with a gradient of EtOAc in hexane to obtain 220. In 
each case, numerous keto and enol tautomers could be found in many fractions. These 
tautomers also frequently equilibrated upon isolation. Hence, it was difficult to isolate one 
pure isomer and characterization was complicated. The mixtures of tautomers from different 
fractions were used directly for the pyrone formation without further characterization or 
purification. Compounds 220 were added to a flask equipped with an adaptor connected to a 
manifold and maintained under argon. The flask was then connected to a vacuum set at 5 
mmHg pressure and heated over an oil bath at 170 °C. It was kept at this temperature for 
0.5-1 h, and then cooled to rt. Diethyl ether was added to the reaction mixture, which was 
then filtered, and the solid residue was washed with diethyl ether. The solid was dried in 
vacuo and used in the next step.  
4-Hydroxy-6-phenyl-2H-pyran-2-one (223). 58% yield; 1H NMR (300 MHz, CD3OD, 
ppm): δ 5.48 (d, J = 2.1 Hz, 1H, COCH), 6.70 (d, J = 1.8 Hz, 1H, OCCH), 7.48-7.51 (m, 3H, 
aromatic), 7.85-7.88 (m, 2H, aromatic); MS: m/z 187 (M-H+). 
4-Hydroxy-6-m-tolyl-2H-pyran-2-one (224). 26% yield; 1H NMR (300 MHz, CD3OD, 
ppm): δ 2.40 (s, 3H, CH3), 5.47 (d, J = 2.4 Hz, 1H, COCH), 6.67 (s, 1H, OCCH), 7.30-7.39 
(m, 2H, aromatic), 7.64-7.69 (m, 2H, aromatic); MS: m/z 201 (M-H+). 
108 
 
4-Hydroxy-6-(3-methoxyphenyl)-2H-pyran-2-one (225). 45% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 3.85 (s, 3H, OCH3), 5.46 (d, J = 1.8 Hz, 1H, COCH), 6.56 (s, 1H, 
OCCH), 7.01-7.05 (m, 1H, aromatic), 7.33-7.41 (m, 3H, aromatic); MS: m/z 217 (M-H+). 
6-(3-Fluorophenyl)-4-hydroxy-2H-pyran-2-one (226). 41% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 5.50 (d, J = 1.5 Hz, 1H, COCH), 6.75 (s, 1H, OCCH), 7.21-7.27 (m, 
1H, aromatic), 7.48-7.71 (m, 3H, aromatic); MS: m/z 205 (M-H+). 
6-(4-Fluorophenyl)-4-hydroxy-2H-pyran-2-one (227). 46% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 5.46 (d, J = 1.8 Hz, 1H, COCH), 6.67 (s, 1H, OCCH), 7.20-7.26 (m, 
2H, aromatic), 7.89-7.93 (m, 2H, aromatic); MS: m/z 207 (M+H+). 
4-Hydroxy-6-p-tolyl-2H-pyran-2-one (228). 52% yield; 1H NMR (300 MHz, CD3OD, 
ppm): δ 2.39 (s, 3H, CH3), 5.44 (d, J = 2.1 Hz, 1H, COCH), 6.63 (s, 1H, OCCH), 7.29 (d, J = 
8.1 Hz, 2H, aromatic), 7.74 (d, J = 8.4 Hz, 2H, aromatic); MS: m/z 201 (M-H+). 
4-Hydroxy-6-(4-methoxyphenyl)-2H-pyran-2-one (229). 48% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 3.84 (s, 3H, OCH3), 6.55 (s, 1H, OCCH), 7.01 (d, J = 8.7 Hz, 2H, 
aromatic), 7.79 (d, J = 8.7 Hz, 2H, aromatic); MS: m/z 217 (M-H+). 
6-(2,3-Dimethoxyphenyl)-4-hydroxy-2H-pyran-2-one (230). 14% yield; 1H NMR 
(300 MHz, DMSO, ppm): δ 3.77 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 5.38 (d, J = 1.8 Hz, 1H, 
COCH), 6.38 (d, J = 2.1 Hz, 1H, OCCH), 7.21-7.23 (m, 3H, aromatic), 11.82 (s, 1H, OH); MS: 
m/z 247 (M-H+). 
6-(3,4-Dimethylphenyl)-4-hydroxy-2H-pyran-2-one (231). 24% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 2.26 (s, 6H, CH3), 5.40 (d, J = 1.5 Hz, 1H, COCH), 6.53 (s, 1H, 
OCCH), 7.16 (d, J = 7.8 Hz, 1H, aromatic), 7.48 (d, J = 7.8 Hz, 1H, aromatic), 7.54 (s, 1H, 
aromatic); MS: m/z 215 (M-H+). 
6-(3,4-Dimethoxyphenyl)-4-hydroxy-2H-pyran-2-one (232). 85% yield; 1H NMR 
(300 MHz, CD3OD, ppm): δ 3.88 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 5.42 (d, J = 2.1 Hz, 1H, 
COCH), 6.62 (s, 1H, OCCH), 7.05 (d, J = 8.4 Hz, 1H, aromatic), 7.41-7.50 (m, 2H, aromatic); 
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MS: m/z 247 (M-H+). 
6-(3,5-Dimethylphenyl)-4-hydroxy-2H-pyran-2-one (233). 27% yield; 1H NMR (300 
MHz, CD3OD, ppm): δ 2.26 (s, 6H, CH3), 5.03 (s, 2H, COCH & OH), 6.48 (s, 1H, OCCH), 
7.01 (s, 1H, aromatic), 7.30 (s, 2H, aromatic); MS: m/z 215 (M-H+). 
6-(3,5-Dimethoxyphenyl)-4-hydroxy-2H-pyran-2-one (234). 27% yield; 1H NMR 
(300 MHz, CD3OD, ppm): δ 3.83 (s, 6H, OCH3), 5.47 (d, J = 2.1 Hz, 1H, COCH), 6.61 (t, J = 
2.1 Hz, 1H, aromatic), 6.68 (s, 1H, OCCH), 6.99 (d, J = 2.1 Hz, 2H, aromatic); MS: m/z 247 
(M-H+). 
4-Hydroxy-6-(3,4,5-trimethoxyphenyl)-2H-pyran-2-one (235). 50% yield; 1H NMR 
(300 MHz, CD3OD, ppm): δ 81 (s, 3H, OCH3), 3.90 (s, 6H, OCH3), 5.45 (d, J = 1.8 Hz, 1H, 
COCH), 6.70 (d, J = 1.8 Hz, 1H, OCCH), 7.17 (s, 2H, aromatic); MS: m/z 277 (M-H+). 
General procedure of preparation of 197-199, 202-205, 207, 209-210, 212-213, 
215. To a solution of 223-235 (1.04 mmol) in toluene (9 mL) was added a mixture of HOAc 
(0.30 ml, 5.20 mmol) and NH4OAc (400 mg, 5.20 mmol) in EtOH (3 mL) and chloroacetone 
(0.42 mL, 5.20 mmol; or 1-bromobutanone and 3-bromobutan-2-one for preparation of 216 
and 217, respectively). The mixture was stirred for 30 min at rt, and then heated to 60 °C for 
30 min. Subsequently, it was refluxed for 24 h. After cooling, the mixture was diluted with 
H2O and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered, and 
evaporated in vacuo. The residue was purified by column chromatography to give a white 
solid.  
3-Methyl-6-phenyl-4H-furo[3,2-c]pyran-4-one (197). 50% yield; mp 105-107 °C; 1H 
NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 7.00 (s, 1H, OCH), 7.28-7.29 
(m, 1H, C7-H), 7.43-7.46 (m, 3H, aromatic), 7.83-7.87 (m, 2H, aromatic); HRMS Calcd for 
C14H11O3 (M+H+): 227.0708, found: 227.0696. 
3-Methyl-6-m-tolyl-4H-furo[3,2-c]pyran-4-one (198). 52% yield; mp 135-137 °C; 1H 
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NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 6.99 (s, 1H, 
C7-H), 7.23-7.36 (m, 3H, aromatic), 7.62 (d, J = 7.2 Hz, 1H, aromatic), 7.69 (d, J = 1.5 Hz, 
1H, OCH); HRMS Calcd for C15H13O3 (M+H+): 241.0865, found: 241.0851. 
6-(3-Methoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (199). 44% yield; mp 
119-121 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.87 (s, 3H, 
OCH3), 6.96-7.00 (m, 2H), 7.29-7.44 (m, 4H); HRMS Calcd for C15H13O4 (M+H+): 257.0814, 
found: 257.0800. 
6-(3-Fluorophenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (202). 34%yield; mp 158-
160 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 7.01 (s, 1H, C7-H), 
7.10-7.17 (m, 1H, aromatic), 7.31 (d, J = 1.2 Hz, 1H, OCH), 7.39-7.46 (m, 1H, aromatic), 
7.54-7.58 (m, 1H, aromatic), 7.61-7.65 (m, 1H, aromatic); HRMS Calcd for C14H10FO3 
(M+H+): 245.0614, found: 245.0603. 
6-(4-Fluorophenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (203). 52% yield; mp 175-
177 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 6.94 (s, 1H, C7-H), 
7.12-7.18 (m, 2H, aromatic), 7.29 (d, J = 1.2 Hz, 1H, OCH), 7.82-7.87 (m, 2H, aromatic); 
HRMS Calcd for C14H10FO3 (M+H+): 245.0614, found: 245.0603. 
3-Methyl-6-p-tolyl-4H-furo[3,2-c]pyran-4-one (204). 62% yield; mp 153-155 °C; 1H 
NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.2 Hz, 3H, CH3), 2.40 (s, 3H, CH3), 6.95 (s, 1H, 
C7-H), 7.24-7.27 (m, 3H, aromatic & OCH), 7.74 (d, J = 8.1 Hz, 2H, aromatic); HRMS Calcd 
for C15H13O3 (M+H+): 241.0865, found: 241.0848. 
6-(4-Methoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (205). 60% yield; mp 
146-148 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.5 Hz, 3H, CH3), 3.87 (s, 3H, 
OCH3), 6.88 (s, 1H, C7-H), 6.97 (d, J = 9.0 Hz, 2H,  aromatic), 7.26 (d, J = 1.5 Hz, 1H, OCH), 
7.80 (d, J = 9.0 Hz, 2H,  aromatic); HRMS Calcd for C15H13O4 (M+H+): 257.0808, found: 
257.0816. 
111 
 
6-(2,3-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (207). 40% yield; 
mp 111-113 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.2 Hz, 3H, CH3), 3.87 (s, 
3H, OCH3), 3.92 (s, 3H, OCH3), 7.00 (dd, J = 1.2, 8.1 Hz, 1H, aromatic), 7.16 (t, J = 8.1 Hz, 
1H, aromatic), 7.34 (q, J = 1.2 Hz, 1H, OCH), 7.48 (s, 1H, C7-H), 7.54 (dd, J = 1.2, 8.1 Hz, 
1H, aromatic); HRMS Calcd for C16H15O5 (M+H+): 287.0919, found: 287.0906. 
6-(3,4-Dimethylphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (209). 67% yield; mp 
182-184 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.30 (s, 3H, CH3) 2.32 (s, 3H, CH3), 2.33 (d, 
J = 1.5 Hz, 3H, CH3), 6.95 (s, 1H, C7-H), 7.20 (d, J = 8.1 Hz, 1H, aromatic), 7.26 (d, J = 1.2 
Hz, 1H, OCH), 7.57 (d, J = 8.1 Hz, 1H, aromatic), 7.64 (s, 1H, aromatic); HRMS Calcd for 
C16H15O3 (M+H+): 255.1016, found: 255.1010. 
6-(3,4-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (210). 83% yield; 
mp 154-156 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 1.5 Hz, 3H, CH3), 3.94 (s, 
3H, OCH3), 3.98 (s, 3H, OCH3), 6.90 (s, 1H, C7-H), 6.92 (d, J = 8.7 Hz, 1H, aromatic), 7.27 
(t, J = 1.5 Hz, 1H, OCH), 7.34 (d, J = 2.1 Hz, 1H, aromatic), 7.43 (dd, J = 2.1, 8.4 Hz, 1H, 
aromatic); HRMS Calcd for C16H15O5 (M+H+): 287.0919, found: 287.0900. 
6-(3,5-Dimethylphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (212). 30% yield; mp 
171-173 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.33 (d, J = 0.9 Hz, 3H, CH3),  2.37 (s, 6H, 
CH3), 6.98 (s, 1H, C7-H), 7.07 (s, 1H, aromatic), 7.28 (d, J = 0.9 Hz, 1H, OCH), 7.48 (s, 2H, 
aromatic); HRMS Calcd for C16H15O3 (M+H+): 255.1021, found: 255.1010. 
6-(3,5-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (213). 38%, yield; 
mp 153-155 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.86 (s, 
6H, OCH3), 6.54 (t, J = 2.1 Hz, 1H, C7-H), 6.98 (s, 1H, aromatic), 6.99 (d, J = 2.7 Hz, 2H, 
aromatic), 7.30 (d, J = 1.5 Hz, 1H, OCH); HRMS Calcd for C16H15O5 (M+H+): 287.0919, 
found: 287.0898. 
3-Methyl-6-(3,4,5-trimethoxyphenyl)-4H-furo[3,2-c]pyran-4-one (215). 40% yield; 
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mp 201-203 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.5 Hz, 3H, CH3), 3.91 (s, 
3H, OCH3), 3.95 (s, 6H, OCH3), 6.94 (s, 1H, C7-H), 7.06 (s, 2H, aromatic), 7.29 (d, J = 1.2 
Hz, 1H, OCH); HRMS Calcd for C17H17O6 (M+H+): 317.1025, found: 317.1037. 
6-(3,5-Dimethoxyphenyl)-3-ethyl-4H-furo[3,2-c]pyran-4-one (216). 51% yield; mp 
131-133 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.31 (t, J = 7.2 Hz, 3H, CH2CH3), 2.77 (q, J 
= 7.5 Hz, 2H, CH2CH3), 3.86 (s, 6H, OCH3), 6.54 (t, J = 2.1 Hz, 1H, C7-H), 6.98 (d, J = 2.1 
Hz, 3H, aromatic), 7.30 (t, J = 1.2 Hz, 1H, OCH); HRMS Calcd for C17H17O5 (M+H+): 
301.1076, found: 301.1057. 
6-(3,5-Dimethoxyphenyl)-2,3-dimethyl-4H-furo[3,2-c]pyran-4-one (217). 12% 
yield; mp 163-165 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 0.6 Hz, 3H, CH3), 2.33 
(d, J = 0.6 Hz, 3H, CH3), 3.86 (s, 6H, OCH3), 6.53 (t, J = 2.1 Hz, 1H, aromatic), 6.93 (s, 1H, 
OCH), 6.97 (d, J = 2.1 Hz, 2H, aromatic); HRMS Calcd for C17H17O5 (M+H+): 301.1071, 
found: 301.1067. 
General procedure of preparation of 201, 206, 208, 211, and 214. To a solution of 
199, 205, 207, 210, or 213 (0.2 mmol) in DCM (3 ml) was added BBr3 (0.6 ml, 0.6 mmol) 
dropwise at 0 °C. The reaction mixture was stirred overnight. Water was added to quench 
the reaction. The solution was extracted with CHCl3 and concentrated. The residue was 
purified by column chromatography to give a white solid.  
6-(3-Hydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (201). 78% yield; mp 
225-227 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.29 (d, J = 1.5 Hz, 3H, CH3), 6.86-6.90 (m, 
1H, C7-H), 7.26-7.31 (m, 3H, aromatic & OCH), 7.35-7.39 (m, 1H, aromatic), 7.52 (dd, J = 
1.2, 2.7 Hz, 1H, aromatic); HRMS Calcd for C14H11O4 (M+H+): 243.0657, found: 243.0659. 
6-(4-Hydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (206). 80% yield; mp 
258-260 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.27 (d, J = 1.5 Hz, 3H, CH3), 6.86 (d, J = 
9.0 Hz, 2H, aromatic) 7.18 (s, 1H, C7-H), 7.46 (d, J = 1.2 Hz, 1H, OCH), 7.75 (d, J = 9.3 Hz, 
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2H, aromatic); HRMS Calcd for C14H11O4 (M+H+): 243.0657, found: 243.0641. 
6-(2,3-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (208). 66% yield; 
mp 239-241 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.28 (d, J = 0.9 Hz, 3H, CH3), 6.76 (t, J 
= 1.5 Hz, 1H, aromatic), 6.86 (dd, J = 1.5, 1.8 Hz, 1H, aromatic), 7.38 (dd, J = 1.2, 1.5 Hz, 
1H, aromatic), 7.48 (q, J = 1.2 Hz, 1H, OCH), 7.75 (s, 1H, C7-H); HRMS Calcd for C14H11O5 
(M+H+): 259.0606, found: 259.0602. 
6-(3,4-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (211). 60% yield; 
mp 259-261 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.69 (d, J = 1.5 Hz, 3H, CH3), 6.83 (d, 
J = 7.8 Hz, 3H, C7-H), 7.12 (s, 1H, aromatic), 7.26-7.31 (m, 2H, aromatic), 7.46 (dd, J = 1.2 
Hz, 1H, OCH); HRMS Calcd for C14H11O5 (M-H+): 257.0450, found: 257.0464. 
6-(3,5-Dihydroxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (214). 70% yield; 
mp >300 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 2.86 (d, J = 1.2 Hz, 3H, CH3), 6.35 (t, J = 
2.1 Hz, 1H, aromatic), 6.80 (d, J = 2.1 Hz, 2H, aromatic), 7.21 (s, 1H, C7-H), 7.51 (d, J = 1.2 
Hz, 1H, OCH); HRMS Calcd for C14H11O5 (M+H+): 259.0601, found: 259.0594. 
6-(3-Ethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-one (200). To a mixture of 201 
(212 mg, 1.00 mmol), K2CO3 (300 mg, 2.17 mmol) in actone (8 mL) was added iodoethane 
(0.4 mL, 5.00 mmol). The mixture was stirred for 12 h. The mixture was concentrated and 
diluted with H2O and extracted with EtOAc. The organic layer was dried over Na2SO4, 
filtered, and evaporated. The residue was purified by column chromatography to give a 
white solid. 35% yield; mp 128-130 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.45 (t, J = 6.9 
Hz, 3H, CH2CH3), 2.33 (d, J = 1.5 Hz, 3H, CH3), 4.10 (d, J = 7.2 Hz, 2H, CH2CH3), 6.95-6.96 
(m, 1H, aromatic), 6.98 (s, 1H, C7-H), 7.29 (d, J = 1.5 Hz, 1H, OCH), 7.32-7.43 (m, 3H, 
aromatic); HRMS Calcd for C16H13O4 (M+H+): 271.0965, found: 271.0962. 
General preparation of 218-219. A mixture of 210 or 213 (0.1 mmol) and 
Lawesson’s reagent (81 mg, 0.2 mmol) in dry toluene (5 mL) was heated to reflux for 12 h. 
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Toluene was removed and the red residue was dissolved in EtOAc and partitioned with H2O. 
The organic phase was separated and dried over Na2SO4. Removal of solvent in vacuo 
afforded an oily residue, which was purified by column chromatography resulting in a yellow 
solid. 
6-(3,5-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-thione (218). 60% yield; 
mp 147-149 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.46 (d, J = 1.5 Hz, 3H, CH3), 3.87 (s, 
6H, OCH3), 6.57 (t, J = 2.1 Hz, 1H, C7-H), 7.02 (s, 1H, aromatic), 7.03 (s, 1H, aromatic), 
7.17 (s, 1H, aromatic), 7.32 (d, J = 1.5 Hz, 1H, OCH); HRMS Calcd for C16H14O4S (M+H+): 
303.0691, found: 303.0702. 
6-(3,4-Dimethoxyphenyl)-3-methyl-4H-furo[3,2-c]pyran-4-thione (219). 50% yield; 
mp 157-159 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.46 (s, 3H, CH3),  3.96 (s, 3H, OCH3), 
3.96 (s, 3H, OCH3), 6.95 (d, J = 8.7 Hz, 1H, aromatic), 7.11 (s, 1H, aromatic), 7.30 (s, 1H, 
OCCH), 7.40 (d, J = 2.1 Hz, 1H, OCH), 7.52 (m, 1H, aromatic); HRMS Calcd for C16H14O4S 
(M+H+): 303.0691, found: 303.0681. 
6-(3,4-Dimethoxyphenyl)-3-methyl-2H-furo[3,2-c]pyran-4(3H)-one (220). 210 (57 
mg, 0.2 mmol) was dissolved in acetone at 40 °C under argon. Pd/C (81 mg, 10%), 
triethylamine (0.33 mL, 2.4 mmol) and formic acid (0.075 mL, 2 mmol) were added to the 
solution. The solution was stirred overnight and filtered through celite and removal of solvent 
yielded a dark oily residue. The residue was dissolved in DCM before washing with 
saturated aqueous sodium bicarbonate and dried. Removal of solvent in vacuo afforded an 
oily residue, which was purified by column chromatography resulting in a white solid. 13% 
recovered yield; mp 95-97 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 6.6 Hz, 3H, 
CHCH3), 3.55 (m, 1H, CHCH3), 3.94 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 4.29 (dd, J = 6.0, 
9.0 Hz, 1H, OCHH), 4.82 (t, J = 9.3 Hz, 1H, OCHH), 6.46 (s, 1H, OCCH), 6.91 (d, J = 8.7 Hz, 
1H, aromatic), 7.33 (d, J = 2.1 Hz, 1H, aromatic), 7.41 (dd, J = 2.1, 8.7 Hz, 1H, aromatic); 
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HRMS Calcd for C16H17O5 (M+H+): 289.1076, found: 289.1079. 
5.6.2    Biological Assay 
The assay methods and description of cell lines are described in Chapter 3.  
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CHAPTER 6 
MECHANISM OF ACTION STUDY AND IN VIVO EVALUATION 
 
Mechanism of Action Study 
6.1       Cell Assays (MD Anderson Cancer Center) 
6.1.1    Introduction 
The MTT assay1 was applied to examine the effect of the compounds on cell growth, 
cytotoxicity, and tumor-tissue-type selectivity. Twenty-nine tumor cell lines from different 
tissues and two normal cell lines treated with compound 91 were evaluated with this assay.   
6.1.2    Methodology of MTT assay 
The MTT assay was used to assess the killing effect of the drugs. Cells were seeded 
into 96-well plates at a density of 5000 cells in media per well. The drug was dissolved in 
DMSO. The drug was added into wells after overnight incubation. After 72 hours of 
incubation at 37 °C in 5% CO2, 20 μL of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] reagent was added to each well and incubated for two hours. Then, the 
plates were read on a plate reader at OD 570 nM. The cell killing efficiency was determined 
by plotting the percent of survival cells with different concentrations of the compounds in the 
same family, which were tested side-by-side. The MTT reading derived from the cells 
treated with DMSO only was set as 100%. The following human cell lines were used in the 
assay. Breast cancer cell lines: MDA-MB-453, BT-483, MDA-MB-435, BT-549, MDA-MB-
436, HBL100, Hs578t, BT20, BT474, MDA-MB-468, MCF7, Au565, ZR-75-1, T-47D, SK-BR-
3; Prostate cancer cell lines: PC3, DU145, LnCAP; Ovarian cancer cell line: SKOV3ip1, 
Hey8, 2774; Esophagus cancer cell line: SKGF4, BE3, BIC1; Liver cancer cell line: Hep3B, 
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HepG2; Pancreatic cancer cell line: Panc1, Capan1; Lung cancer cell line: H1299; 
Pancreatic normal cell line: E6E7; Human lung fibroblast cell line: WI38. 
6.1.3   Results and Discussion 
As shown in Figure 6-1, 91 was effective in about 40% of human breast cancer cell 
lines (total 15 cell lines), was ineffective or weakly effective in ovarian, liver, pancreatic, lung, 
and esophagus cancer cell lines (total 11 cell lines), and promoted the cell growth in some 
prostate cancer cell lines (total 3 cell lines). Importantly, 91 was not active against E6E7, a 
pancreatic normal cell line and WI38, a human lung fibroblast cell line. The results 
demonstrated that 91 is highly selective against breast cancer cell lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1. In vitro anticancer profiles of 91 
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Compound 91 was effective in ER+/HER2+ positive cell lines, and also inhibited the 
ER-/HER2- MDA-MB-468 cell line, but did not affect ER+/HER2+ BT474 and MDA-MB-453 
cell lines (Table 6-1). From the results in the cell-based assay, we postulated ER or HER2 is 
not the primary target of 91 in human breast cancer cell lines. 
Table 6-1. In vitro anticancer profiles of 91 
 MCF-7 SK-BR-3 ZR-75-1 AU565 T-47D MDA-MB-468 MDA-MB-453 BT474
ER + - + - + - + + 
HER2 - ++ - ++ + - ++ ++ 
Effective + + + + + + - - 
     
Compound 91 showed better killing effects compared to exemestane or tamoxifen in 
91-sensitive human breast cancer cell lines, but not in BT549, a human breast cancer cell 
line, and WI38, a human lung fibroblast cell line (Table 6-2). 
Table 6-2. In vitro anticancer profiles of tamoxifen, exemestane, and 91 
Cell lines Tamoxifen Exemestane 91 
MCF7 ± + ++ 
SK-BR-3 ± + ++ 
ZR-75-1 ND ± ++ 
Au565 ND + ++ 
T-47D + + ++ 
MDA-MB-468 + + +± 
BT549 ND ± ± 
WI38 ND ± ± 
ND: not detected. 
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6.2       Enzyme Assays (MDS Pharma Services) 
6.2.1    Introduction 
With over 500 kinases in the human kinome and numerous drugs in phase 3 clinical 
trials and beyond, kinase inhibitors have become very attractive for drug design and 
development. To identify the targets of neo-tanshinlactone derivatives, compounds 91 and 
173 were examined for inhibitory activity against 58 kinases. This investigation was 
performed by MDS Pharma Services.2 
6.2.2    Methods 
Methods employed in this study have been adapted from the scientific literature to 
maximize reliability and reproducibility. Reference standards were run as an integral part of 
each assay to ensure the validity of the results obtained. Assays were performed under 
conditions described in the experimental section.  
6.2.3    Results and Discussion 
A summary of results meeting the significance criteria is presented in the following 
tables. Compound 178 showed higher inhibition activity against CDC42BPB, PKG1β, and 
SGK1 (Table 6-4), while 91 significantly suppressed CK2α1, ABL, and AKT1 (Table 6-3). 
The results suggested that these two compounds may have different mechanisms of action. 
More studies are focusing on these pathways to identify the possible targets. 
 
 
 
 
 
 
 
121 
 
Table 6-3. Enzyme assay profiles of 91 
Primary Biochemical Assay Species % INH 
Protein Serine/Threonine Kinase, AURKA (Aurora-A) Human 73 
Protein Serine/Threonine Kinase, CDC42BPB Human 82 
Protein Serine/Threonine Kinase, CSNK2A1 (CK2α1) Human 99 
Protein Serine/Threonine Kinase, MAPK8 (JNK1) Human 64 
Protein Serine/Threonine Kinase, MAPKAPK2 Human 50 
Protein Serine/Threonine Kinase, PDK1 Human 59 
Protein Serine/Threonine Kinase, PIM1 Human 71 
Protein Serine/Threonine Kinase, PRKG1 (PKG1β) Human 74 
Protein Serine/Threonine Kinase, SGK1 Human 82 
Protein Serine/Threonine Kinase, SGK2 Human 85 
Protein Serine/Threonine Kinase, TSSK2 (STK22B) Human 51 
Protein Tyrosine Kinase, ABL1 (ABL) Mouse 93 
Protein Tyrosine Kinase, ERBB2 (HER2) Human 69 
Protein Tyrosine Kinase, Insulin Receptor Human 83 
Protein Serine/Threonine Kinase, GSK3B Human 57 
Protein Serine/Threonine Kinase, AKT1 (PRKBA) Human 93 
 
Table 6-4. Enzyme assay profiles of 178 
Primary Biochemical Assay Species % INH 
Protein Serine/Arginine-rich Kinase, SRPK1 Human 55 
Protein Serine/Threonine Kinase, CDC42BPB Human 90 
Protein Serine/Threonine Kinase, CSNK2A1 (CK2α1) Human 66 
Protein Serine/Threonine Kinase, MARK1 Human 68 
Protein Serine/Threonine Kinase, MAPKAPK2 Human 84 
Protein Serine/Threonine Kinase, PDK1 Human 86 
Protein Serine/Threonine Kinase, PIM1 Human 83 
Protein Serine/Threonine Kinase, PKD2 Human 63 
Protein Serine/Threonine Kinase, PRKG1 (PKG1β) Human 92 
Protein Serine/Threonine Kinase, SGK1 Human 96 
Protein Serine/Threonine Kinase, TSSK2 (STK22B) Human 60 
Protein Serine/Threonine Kinase, GSK3B Human 59 
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6.2.4    Experimental Section 
Protein Serine/Arginine-rich Kinase, CLK2. Source: Human recombinant insect 
cells; Substrate: 50 µM S6 kinase/Rsk2 substrate peptide 2; Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C;  
Incubation Buffer: 20 mM MOPS, pH 7.2, 25 mM β-Glycerophosphate, 1 mM DTT, 5 mM 
EGTA, 20 mM MgCl2, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P]S6 
kinase/Rsk2 substrate peptide 2; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Arginine-rich Kinase, SRPK1. Source: Human recombinant E. Coli; 
Substrate: 5 µM SRPK1tide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 
37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 7.2, 
25 mM β-Glycerophosphate, 1 mM DTT, 5 mM EGTA, 20 mM MgCl2, 1 mM Na3VO4; 
Quantitation Method: Quantitation of [32P]SRPK1tide; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, AKT1 (PRKBA). Source: Human recombinant 
insect Sf21 cells; Substrate: 15 µg/mL Crosstide; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 25 °C; Incubation Time/Temp: 60 minutes at 25 °C; Incubation 
Buffer: 50 mM HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT; Quantitation 
Method: ELISA quantitation of Crosstide-P; Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Serine/Threonine Kinase, AURKA (Aurora-A). Source: Human 
recombinant insect Sf21 cells; Substrate: 100 µM Kemptide; Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 25 mM β-Glycerophosphate, 1 mM DTT, 5 mM 
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EGTA, 20 mM MgCl2, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P]S6 
kinase/Rsk2 substrate peptide 2; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, Ca2+/Calmodulin-Dep. II. Source: Rat brain; 
Substrate: 50 µM BB40; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 37 
°C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM HEPES, pH 7.4, 
1 mM EGTA, 10 mM MgCl2, 0.1 mM DTT, 1.5 mM CaCl2, 0.02 mg/ml Calmodulin; 
Quantitation Method: Quantitation of [32P]BB40; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, CAMK2D (KCC2D). Source: Human 
recombinant insect cells; Substrate: 50 µM Autocamtide-2; Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C;  
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM MgCl2, 1.5 mM CaCl2·2H2O, 20 µg/mL Calmodulin; Quantitation 
Method: Quantitation of [32P] Autocamtide-2; Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Serine/Threonine Kinase, CDC42BPB. Source: Human recombinant insect 
Sf21 cells; Substrate: 50 µM S6 kinase/Rsk2 substrate peptide 2; Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C;  
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P]S6 kinase/Rsk2 
substrate peptide 2; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, CHK2. Source: Human recombinant E. Coli; 
Substrate: 10 µM CHKtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 
37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 7.2, 
5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM Na3VO4; 
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Quantitation Method: Quantitation of [32P] CHKtide; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, CSNK1A1 (CK1). Source: Human recombinant 
E. Coli; Substrate: 9 µM CK1 substrate peptide; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] CK1 substrate 
peptide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, CSNK2A1 (CK2α1). Source: Human 
recombinant insect Sf21 cells; Substrate: 100 µM CK2 substrate peptide; Vehicle: 1% 
DMSO; Pre-Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes 
at 37 °C; Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 
25 mM β-Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] CK2 
substrate peptide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, Dyrk1a. Source: Rat recombinant E. Coli; 
Substrate: 50 µM Woodtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 
37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 7.2, 
5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM Na3VO4; 
Quantitation Method: Quantitation of [32P] Woodtide; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, GSK3B. Source: Human recombinant insect 
Sf21 cells; Substrate: 5 µM Phospho-glycogen synthase peptide-2; Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
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Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] Phospho-
glycogen synthase peptide-2; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, IKK-1. Source: Human recombinant insect Sf21 
cells; Substrate: 20 µM IKKtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes 
at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 
7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM Na3VO4; 
Quantitation Method: Quantitation of [32P] IKKtide; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, IRAK4. Source: Human recombinant insect Sf21 
cells; Substrate: 50 µg/mL Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, LIMK1. Source: Human recombinant insect Sf21 
cells; Substrate: 0.7 µM Cofilin-1; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] Cofilin-1; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, MAP2K1 (MEK1). Source: Human recombinant 
E. Coli; Substrate: 50 µg/mL Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
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Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, MAP3K5 (ASK1). Source: Human recombinant 
E. Coli; Substrate: 50 µg/mL Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, MAPK8 (JNK1). Source: Human recombinant 
insect Sf21 cells; Substrate: 1.5 µM ATF2; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 
15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] ATF2; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, MAPKAPK2. Source: Human recombinant E. 
Coli; Substrate: 50 µM MAPKAPK substrate peptide; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MAPKAPK 
substrate peptide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, MARK1. Source: Human recombinant insect 
Sf21 cells; Substrate: 10 µM CHKtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
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Na3VO4; Quantitation Method: Quantitation of [32P] CHKtide; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, MYLK (MLCK). Source: Human recombinant 
insect Sf21 cells; Substrate: 50 µM ZIPtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 
15 minutes at 37 °C; Incubation Time/Temp: 4 hours at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 1.5 mM CaCl2, 0.02 mg/ml Calmodulin, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] ZIPtide; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, NEK2. Source: Human recombinant insect Sf21 
cells; Substrate: 50 µg/ml Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PDK1. Source: Human recombinant insect Sf21 
cells; Substrate: 5.3 µM PDKtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] PDKtide; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PHKG2. Source: Human recombinant insect Sf9 
cells; Substrate: 50 µM ZIPtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes 
at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 
7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM Na3VO4; 
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Quantitation Method: Quantitation of [32P] ZIPtide; Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Serine/Threonine Kinase, PIM1. Source: Human recombinant E. Coli; 
Substrate: 50 µM S6 kinase/Rsk2 substrate peptide 2; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] S6 
kinase/Rsk2 substrate peptide 2; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PKD2. Source: Human recombinant insect Sf21 
cells; Substrate: 50 µM MAPKAPK; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] MAPKAPK; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PLK1. Source: Human recombinant insect Sf9 
cells; Substrate: 20 µG/ml Casein; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] Casein; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PRKCG (PKCγ). Source: Human recombinant 
insect Sf21 cells; Substrate: 250 µg/ml Histone; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 50 mM HEPES, pH 7.4, 1 mM EGTA, 10 mM MgCl2, 0.1 mM DTT, 50 µg/ml 
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Phosphatidylserine, 8 µg/mL Diacylglycerol; Quantitation Method: Quantitation of [32P] 
Histone; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PRKCG (PKCŋ). Source: Human recombinant 
insect Sf9 cells; Substrate: 250 µg/ml Histone; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 50 mM HEPES, pH 7.4, 1 mM EGTA, 10 mM MgCl2, 0.1 mM DTT, 50 µg/mL 
Phosphatidylserine, 8 µg/mL Diacylglycerol; Quantitation Method: Quantitation of [32P] 
Histone; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, PRKG1 (PKG1β). Source: Human recombinant 
insect Sf9 cells; Substrate: 50 µM BPDEtide; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4, 5 µM cGMP; Quantitation Method: Quantitation of [32P] 
BPDEtide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, RIPK2 (RIP2). Source: Human recombinant 
insect Sf21 cells; Substrate: 50 µg/ml Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, RPS6KA2 (RSK3). Source: Human recombinant 
insect Sf21 cells; Substrate: 50 µg/ml MAPKAPK substrate peptide; Vehicle: 1% DMSO; 
Pre-Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 
°C; Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 
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mM β-Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] 
MAPKAPK substrate peptide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, RPS6KA5 (MSK1). Source: Human recombinant 
insect Sf21 cells; Substrate: 10 µM Crosstide KK; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] Crosstide KK; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, SGK1. Source: Human recombinant insect Sf21 
cells; Substrate: 10 µM Crosstide KK; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] Crosstide KK; Significance Criteria: 50% 
of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, SGK2. Source: Human recombinant insect Sf21 
cells; Substrate: 10 µM Crosstide KK; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
Na3VO4; Quantitation Method: Quantitation of [32P] Crosstide KK; Significance Criteria: 50% 
of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, STK17A (DRAK1). Source: Human recombinant 
insect cells; Substrate: 50 µM ZIPtide; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM 
MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM 
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Na3VO4; Quantitation Method: Quantitation of [32P] ZIPtide; Significance Criteria: 50% of 
max stimulation or inhibition. 
Protein Serine/Threonine Kinase, STK3 (MST2). Source: Human recombinant 
insect Sf21 cells; Substrate: 50 µg/ml Myelin basic protein (MBP); Vehicle: 1% DMSO; Pre-
Incubation Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; 
Incubation Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation of [32P] MBP; 
Significance Criteria: 50% of max stimulation or inhibition. 
Protein Serine/Threonine Kinase, TSSK2 (STK22B). Source: Human recombinant 
insect Sf21 cells; Substrate: 10 µM CHKtide; Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 20 mM MOPS, pH 7.2, 5 mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-
Glycerophosphate, 1 mM Na3VO4; Quantitation Method: Quantitation Method: Quantitation 
of [32P] CHKtide; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Tyrosine Kinase, ABL1 (ABL). Source: Mouse recombinant E. coli; 
Substrate: 10 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 25 °C; Incubation Time/Temp: 60 minutes at 25 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT; Quantitation Method: ELISA 
quantitation of Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or inhibition. 
Protein Tyrosine Kinase, ALK. Source: Human recombinant insect cells; Substrate: 
200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 37 
°C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 20 mM MOPS, pH 7.2, 5 
mM EGTA, 20 mM MgCl2, 1 mM DTT, 25 mM β-Glycerophosphate, 1 mM Na3VO4; 
Quantitation Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max 
stimulation or inhibition. 
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Protein Tyrosine Kinase, BTK. Source: Human recombinant insect sf21 cells; 
Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Tyrosine Kinase, CSK. Source: Human recombinant E. coli; Substrate: 200 
µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 minutes at 37 °C; 
Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM HEPES, pH 7.4, 20 
mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2mM MnCl2; Quantitation Method: Quantitation of 
[32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or inhibition. 
Protein Tyrosine Kinase, EPHA4 (EphA4). Source: Human recombinant insect 
sf21 cells; Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 50 mM HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; 
Quantitation Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Tyrosine Kinase, ERBB2 (HER2). Source: Human recombinant insect sf9 
cells; Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 
15 minutes at 25 °C; Incubation Time/Temp: 5 minutes at 25 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT; Quantitation Method: ELISA 
quantitation of Poly(Glu:Tyr-P); Significance Criteria: 50% of max stimulation or inhibition. 
Protein Tyrosine Kinase, FER (TYK3). Source: Human recombinant insect sf21 
cells; Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 
15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
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HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Tyrosine Kinase, FGFR1. Source: Human recombinant insect sf21 cells; 
Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Tyrosine Kinase, FLT1 (VEGFR-1). Source: Human recombinant insect 
sf21 cells; Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation 
Time/Temp: 15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation 
Buffer: 50 mM HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; 
Quantitation Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max 
stimulation or inhibition. 
Protein Tyrosine Kinase, FLT3. Source: Human recombinant insect sf21 cells; 
Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Tyrosine Kinase, Insulin Receptor. Source: Human recombinant insect sf9 
cells; Substrate: 10 µg/mL Histone H1; Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 25 °C; Incubation Time/Temp: 60 minutes at 25 °C; Incubation Buffer: 50 mM 
134 
 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT; Quantitation Method: ELISA 
quantitation of Histone H1-P; Significance Criteria: 50% of max stimulation or inhibition. 
Protein Tyrosine Kinase, LYN A. Source: Human recombinant insect cells; 
Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 15 
minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
Protein Tyrosine Kinase, MET (HGFR); Protein Tyrosine Kinase, NTRK1 (TRKA); 
Protein Tyrosine Kinase, PTK2B; Protein Tyrosine Kinase, RET; Protein Tyrosine 
Kinase, ROS1; Protein Tyrosine Kinase, TEK;Protein Tyrosine Kinase, TYRO3 
(RSE);Protein Tyrosine Kinase, ZA70 (ZAP-70). Source: Human recombinant insect sf21 
cells; Substrate: 200 µg/mL Poly(Glu:Tyr); Vehicle: 1% DMSO; Pre-Incubation Time/Temp: 
15 minutes at 37 °C; Incubation Time/Temp: 30 minutes at 37 °C; Incubation Buffer: 50 mM 
HEPES, pH 7.4, 20 mM MgCl2, 0.2 mM Na3VO4, 1 mM DTT, 2 mM MnCl2; Quantitation 
Method: Quantitation of [32P] Poly(Glu:Tyr); Significance Criteria: 50% of max stimulation or 
inhibition. 
 
6.3  In Vivo Evaluation of Neo-tanshinlactone Analogue 91 
6.3.1    Introduction 
To examine the efficacy, tumor-tissue-type selectivity, and breast cancer subtype 
selectivity of 91, it was tested for in vivo activity against human ZR-75-1 breast ductal 
carcinoma, PC-3 human prostate adenocarcinoma, and MDA-MB-231 breast ductal 
carcinoma xenografts, with paclitaxel as positive control. This work was performed in 
cooperation with Professor Che-Ming Teng at National Taiwan University. 
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6.3.2    Methodology3 
Mice  
Male (for PC-3) and female (for MDA-MB-231 and ZR-75-1) SCID mice (NTUH 
Animal Facility) were 5 weeks old, and had a body weight (BW) range of 20-24 g on D1 of 
the study. The animals were fed ad libitum water (reverse osmosis, 1 ppm Cl) and PicoLab 
Rodent Diet 20 Modified and Irradiated Lab Diet® consisting of 20.0% crude protein, 9.9% 
crude fat, and 4.7% crude fiber. The mice were housed on National Taiwan University 
Laboratory Animal Center, NTUMC, on a 12-hour light cycle at 21–23 °C and 60–85% 
humidity. Nude-athymic mice were maintained in accordance with the Institutional Animal 
Care and Use Committee procedures and guidelines. 
Tumor Cell Culture    
All human cancer cells were maintained in RPMI 1640 medium containing 100 
units/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, 0.25 μg/mL amphotericin B, 
and 25 μg/mL gentamicin. The medium was supplemented with 10% heat-inactivated fetal 
bovine serum and 2 mM glutamine. The cells were cultured in tissue culture flasks in a 
humidified incubator at 37 °C, in an atmosphere of 5% CO2 and 95% air. 
In Vivo Implantation and Tumor Growth 
All human cancer cells used for implantation were harvested during log phase growth 
and resuspended in phosphate-buffered saline at 5 x 107 cells/mL. Each mouse was 
injected s.c. in the right flank with 1 x 107 cells (0.2 mL cell suspension). Tumors were 
monitored twice weekly and then daily as their volumes approached 80-150 mm3. Tumor 
size, in mm3, was calculated from:  
Tumor Volume = w2 × l /2 
where w = width and l = length in mm of the tumor. Tumor weight can be estimated 
with the assumption that 1 mg is equivalent to 1 mm3 of tumor volume. 
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Time to Endpoint (TTE) and Tumor Growth Delay (TGD) 
Each animal was euthanized when the tumors reached the predetermined endpoint 
size. The time to endpoint (TTE) for each mouse was calculated by the following equation: 
m
bvolume) (endpoint log
  TTE 10
−=  
where TTE is expressed in days, endpoint volume is in mm3, b is the intercept, and m is the 
slope of the line obtained by linear regression of a log-transformed tumor growth data set. 
The data set was comprised of the first observation that exceeded the study endpoint 
volume and the three consecutive observations that immediately preceded the attainment of 
the endpoint volume. The calculated TTE was usually less than the day on which an animal 
is euthanized for tumor size. Animals that did not reach the endpoint were euthanized at the 
end of the study, and assigned a TTE value equal to the last day. An animal classified as 
having died from a treatment-related (TR) or non-treatment-related metastasis (NTRm) 
cause was assigned a TTE value equal to the day of death.  An animal classified as having 
died from a non-treatment-related (NTR) cause was excluded from TTE calculations.  
Treatment efficacy was determined from tumor growth delay (TGD), which is defined 
as the increase in the median TTE for a treatment group compared to the control group 
(expressed in days): 
TGD = T – C, 
, or as a percentage of the median TTE of the control group: 
100*
C
CT%TGD −=  
where: T = median TTE for a treatment group, C = median TTE for control Group 1. 
6.3.3    Results and Discussion 
We have examined the anticancer activity of compound 91 in several xenograft 
models, such as PC-3 (androgen-independent human prostate carcinoma cells), MDA-MB-
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231 (estrogen receptor negative breast cancer cells), and ZR-75-1 (estrogen receptor 
positive breast cancer cells). Compound 91 was administered intraperitoneally (i.p.) in a 4% 
benzyl alcohol/6% cremophor/90% D5W solution and was given at 10 mg/kg every other 
day to endpoint (qod to end). A positive reference group received paclitaxel i.p. at 20 mg/kg 
once daily every fourth day for 5 doses (q4d x 5). A control group received vehicle i.p. on a 
qod to end schedule. As shown in Figure 6-2, the treatment of SCID mice with compound 91 
resulted in inhibition of estrogen-positive ZR-75-1 tumor xenograft growth. There was 
significant reduction in growth of estrogen-positive breast tumors in compound 91-treated 
animals as compared with the control group. Treatment results were presented as percent 
tumor growth delay (%TGD), which is the percent increase in the mean time to endpoint 
(TTE) for drug-treated versus control mice. Logrank tests determine significance of the 
differences between TTE values for compound 91-treated and control mice, at P ≤ 0.05. In 
ZR-75-1 xenograft model, the mean TTE for the control group was 15.1 days. Paclitaxel 
produced a mean TTE of 35.0 days, corresponding to a %TGD of 132. Compound 91 at 10 
mg/kg produced a mean TTE of 29.5 days, corresponding to a %TGD of 95 (p = 0.0067, 
logrank). However, compound 91 could not be evaluable statistically due to toxicity (data not 
shown). Of the xenografts studied, only estrogen-dependent breast cancer was suppressed 
by compound 91 treatment. With the PC-3 (androgen-independent human prostate 
carcinoma cells) and MDA-MB-231 (estrogen receptor negative breast cancer cells), 91 did 
not exert an effect.  
In summary, 91 showed potent inhibition activity against the ZR-75-1 human breast 
ductal carcinoma xenograft, while it did not display any antitumor activity against PC-3 
human prostate adenocarcinoma and MDA-MB-231 breast ductal carcinoma xenografts. 
The results proved that compound 91 is a selective anti-breast cancer agent in vivo. These 
findings suggest that compound 91 may be selectively used to inhibit the growth of 
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hormone-dependent breast cancers, particularly regrowth of residual tumor in 
postmenopausal breast cancer survivors receiving estrogen replacement therapy. 
 
Figure 6-2. In vivo anticancer activity of compound 91. 
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CHAPTER 7 
CONCLUDING REMARKS AND PERSPECTIVES FOR FUTURE STUDIES 
 
7.1       Conclusions 
7.1.1    Elucidation of SAR of New Neo-tanshinlactone Analogues 
In this study, the synthetic pathway to 4-ethyl neo-tanshinlactone 91 was optimized 
by reducing the number of steps and increasing yields. Five series of new neo-
tanshinlactone analogues were designed, synthesized, and evaluated in various biological 
assays as potential anti-breast cancer agents. Lead compounds 108-110 and 113 are shown 
in Figure 7-1. The SAR conclusions for neo-tanshinlactone analogues can be summarized 
as follows (Figure 7-1): 
(1) C-4 position is critical for both potency and selectivity. The order of potency with 
various substituents against SK-BR-3 was ethyl = 2-bromoethyl = propyl > methyl = 
methoxy > fluoro = hydrogen > isopropyl > ethoxy > hydroxyl, OAc, and 2-
dimethylaminoethoxy. Analogues with isopropyl, propyl and methoxy groups showed 
high selectivity against different breast cancer cell lines.  
(2) Aromatic ring-A > non-aromatic ring-A 
(3)      The order of potency for C-17 position was methyl > ethyl > hydrogen, while the order 
of potency for C-16 position was hydrogen > methyl.  
(4)       Pyridinone ring is not favored for ring-B.  
(5)       Lactone ring-C is essential for activity.  
(6)       Ring-D is preferably an unsaturated furan ring. 
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Figure 7-1. SAR summary of neo-tanshinlactone analogues and lead compounds  
 
7.1.2  Discovery of Novel Compounds with New Scaffolds as Anti-Breast Cancer 
Agents 
We studied the individual contribution of the A-, B-, C-, and D-rings of 90 to the 
selective activity against breast cancer cells. Scaffolds 1-5 were designed by breaking 
bonds 1-5 respectively (Figure 7-2). We demonstrated that aromatic rings A and D were 
important for the cytotoxic activity. Importantly, this study indicated that a simplified neo-
tanshinlactone skeleton obtained by removal of ring-B still retained potent activity when the 
proper functional groups were present. Moreover, we discovered that ring-C could be 
opened through hydrolysis of the ester bond, without losing the desired biological activity. 
Based on this study, two novel chemical entities were discovered and developed as 
selective anti-breast cancer agents. 
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Figure 7-2. Scaffolds 1-5 derived through structure simplification of 
neo-tanshinlactone (90) 
 
7.1.2.1 Design, Synthesis, and Biological Evaluation of Novel 2-(Furan-2-yl) 
naphthalen-1-ol and Tetrahydronaphthalene-1-ol Derivatives as Potent and Selective 
Anti-Breast Cancer Agents 
We designed and developed 2-(furan-2-yl) naphthalen-1-ol (FNO) derivatives, a new 
class of anti-breast cancer agents. Further optimization led to 172, 173, and 181 as new 
lead compounds with better selectivity than neo-tanshinlactone analogue 91. Interestingly, 
compound 178 showed broad in vitro cytotoxicity against human cancer cell lines tested, 
suggesting a different mechanism of action from its structural derivatives. Conformational 
searches and dihedral energy analyses of 172 and 178 suggested that intramolecular 
hydrogen bonding was important to form a rigid conformation and improved the in vitro 
anticancer selectivity of 172. In addition, we further designed tetrahydronaphthalene-1-ol 
(TNO) derivatives and evaluated their antitumor activity. Compound 186 showed the highest 
potency with ED50 values of 0.23 µg/mL against SK-BR-3 and 0.49 µg/mL against ZR-75-1. 
These results established two new scaffolds as promising structures for the development of 
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investigational anti-breast cancer agents. 
 
 
Figure 7-3. SAR summary of 2-(furan-2-yl) naphthalen-1-ol & Tetrahydronaphthalene-
1-ol derivatives and lead compounds 
 
7.1.2.2 Novel Substituted 6-Phenyl-4H-furo[3,2-c]pyran-4-one Derivatives as Potent 
and Highly Selective Anti-Breast Cancer Agents 
Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives were designed and 
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synthesized as promising anti-breast cancer agents. Promising lead compounds 198-201, 
211, 213, and 215 showed potent inhibition against the SK-BR-3 breast cancer cell line. The 
ED50 values of the two most potent analogues (213 and 215) against SK-BR-3 were 0.08 
and 0.14 µg/mL, respectively. More importantly, 213 and 215 showed extremely high cancer 
cell line selectivity, being approximately 100- to 250-fold more potent against SK-BR-3 
compared with six additional tested cancer cell lines. Preliminary SAR studies led to the 
following observations.  
(1)    3’-Methyl, methoxy, ethoxy, and hydroxy groups, but not a 3’-fluoro group, could 
increase potency.  
(2)      Among di-substituted phenyl compounds, 2’-methyl, 2’-methoxy, 4’-methyl, 4’-methoxy, 
5’-methyl, and 5’-hydroxy groups decreased potency; while a 4’-hydroxy or 5’-
methoxy group increased potency.  
(3)       Current modifications in ring-C and -D were not preferred.  
 
145 
 
 
Figure 7-4.SAR summary of 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives and lead 
compounds 
 
7.1.3   Mechanism of Action Studies and Preliminary in vivo Evaluation of 4-Ethyl Neo-
tanshinlactone (91) 
Enzyme assays suggested that 91 significantly suppressed CK2α1, ABL, and AKT1, 
while 178 showed higher inhibition activity against CDC42BPB, PKG1β, and SGK1. The 
results will guide our future explorations of the mechanisms of action. In addition, we 
demonstrated that 4-ethyl neo-tanshinlactone (analogue 91) is a potent and selective anti-
breast cancer agent in vivo. Compound 91 at 10 mg/kg showed significant antitumor activity 
against human ZR-75-1 breast ductal carcinoma xenograft, but was not active against PC-3 
human prostate adenocarcinoma and MDA-MB-231 breast ductal carcinoma xenografts.  
 
7.2       Perspectives for Future Studies 
7.2.1    Further Exploration of SAR of Neo-tanshinlactone Analogues 
Our further modification will focus on modifying ring-D of neo-tanshinlactone 
analogues 238-241 to study the SAR and develop new leads. Scheme 7-1 shows the 
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synthetic methodologies that we will use to achieve these goals. A similar synthetic route 
has been reported by Hsung’s group.1 
Scheme 7-1. Synthetic pathway to designed neo-tanshinlactone analogues 238-241 
 
7.2.2   Design and Development of Novel 2-(Furan-2-yl) naphthalen-1-ol Derivatives as 
Anti-Breast Cancer Agents  
Previous studies have indicated that the two functional groups (OH and COOH) 
resulting from an opened lactone ring-C are critical to anti-breast cancer activity and 
selectivity. We will explore different ether and ester substituents in new analogues 244-247 
to find optimal lead compounds (Scheme 7-2). 
Scheme 7-2. Synthetic pathway to designed 2-(furan-2-yl) naphthalen-1-ol and 
tetrahydronaphthalene derivatives 244-247 
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7.2.3   Design and Development of Novel Substituted 6-Phenyl-4H-furo[3,2-c]pyran-4-
one Derivatives as Potent and Selective Anti-Breast Cancer Agents 
(1) C-6 substituents play important roles in the anti-breast cancer activity of this 
compound class. To identify the SAR and find optimized substituents at this position, we will 
introduce different alkyl and heterocyclic groups, including methyl, ethyl, isopropyl, pyridine, 
and pyrimidine.2 (2) Our study results also indicated that the orientation, ring size, and 
dihedral angle between rings could affect the anti-breast activity. We will insert a linker, such 
as a double bond, to find the best arrangement and combination of the rings. The syntheses 
of these new compounds are feasible based on prior studies (Scheme 7-3).3 
Scheme 7-3. Synthetic pathways to designed 4H-furo[3,2-c]pyran-4-one derivatives 
250 and 255 
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7.2.4   Design and Development of Novel Substituted 4-Amino-2H-benzo[h]chromen-2-
one Derivatives as Anticancer Agents 
In our most recent study, compounds 256-257 were designed, synthesized, and 
assayed against a panel of human tumor cell lines. As seen in Table 7-1, 256 showed potent 
antitumor activities against all cancer cell lines tested, while 257 was only moderately active. 
The results indicated that 4-amino-2H-benzo[h]chromen-2-one derivatives might have a 
different mechanism of action. In addition, Roma et al. reported that similar compounds 
displayed inhibition activity of DNA synthesis and cell growth in HeLa cell line.4 More 
analogues will be synthesized as shown in Scheme 7-4 to discover new leads, establish the 
SAR, and explore the mechanism of action.5  
Table 7-1. Cytotoxicity of compounds 256-257 against tumor cell lines 
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 SK-BR-3 ZR-75-1 MDA MB-231 A549 DU145 KB KB-vin
256 1.41 0.60 1.25 0.98 1.00 0.70 0.94 
257 5.9 6.2 >20 6.0 5.5 7.3 6.7 
 
Scheme 7-4. Synthetic pathways to designed 4-amino-2H-benzo[h]chromen-2-one 
derivatives 259 
 
 
N-Methoxy-N-methyl-2-(2-oxo-2H-benzo[h]chromen-4-ylamino)acetamide (256). 
57% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 3.33 (s, 3H, NCH3), 3.82 (s, 3H, OCH3), 4.17 
(d, J = 3.9 Hz, 1H, NCH2), 5.36 (s, 1H, COCH), 7.27-7.72 (m, 4H, aromatic), 7.85-7.88 (m, 
1H, aromatic), 8.57-8.61 (m, 1H, aromatic); MS for ([M+H]+): 313. 
2-(7-Ethyl-2-oxo-2H-benzo[h]chromen-4-ylamino)-N-methoxy-N-methylacetami 
de (257). 33% yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.5 Hz, 3H, CH2CH3), 
3.12 (q, J = 7.5 Hz, 2H, CH2CH3), 3.33 (s, 3H, NCH3), 3.82 (s, 3H, OCH3), 4.17 (d, J = 3.9 
Hz, 2H, NCH2), 5.35 (s, 1H, COCH), 6.46 (br, 1H, NH), 7.48-7.61 (m, 3H, aromatic), 7.90 (d, 
J = 9.0 Hz, 1H, aromatic), 8.48 (d, J = 8.1 Hz, 1H, aromatic); MS for ([M+H]+): 341. 
7.2.5   Mechanism of Action Studies and In Vivo Evaluation of Lead compounds 91, 
178, and 213 as Anti-Breast Cancer Agents 
Future mechanism of action studies will focus on 91 and 178. In collaboration with Dr. 
Eva Lee's laboratory, 91 was tested on both BRCA1/p53 and wild-type mouse models. 
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Seven to ten days of daily injection of 0.1 mg of 91 dramatically reduced ductal branching of 
the mammary gland. BRCA1 is the first cloned breast cancer tumor susceptibility gene that 
is expressed in all cells. BRCA1 mutations mainly lead to breast and ovarian cancers.6 
Based on these results, we will extensively explore the interaction of 91 with progesterone, 
kinases, and aromatases. Because 178 showed higher inhibition activity against CDC42BPB, 
PKG1β, and SGK1, further studies will focus on the related pathways. In a collaborative 
study with Dr. Che-Ming Teng at National Taiwan University, preliminary in vivo data 
demonstrated that compound 91 is a potent and selective anti-breast cancer agent. 
Compounds 91, 178, and 213 have been synthesized on a gram scale, and will be 
examined in vivo for efficacy, toxicity, and dose effect. This study will also be performed in 
collaboration with Dr. Teng. 
7.2.6    Ligand-based Drug Design and Development  
In our research, we developed five different but related classes of anti-breast cancer 
agents: neo-tanshinlactone, 2-(furan-2-yl) naphthalen-1-ol (FNO), 6-phenyl-4H-furo[3,2-
c]pyran-4-one (AFPO), tetrahydronaphthalene-1-ol (TNO), and 4-amino-2H-benzo[h] 
chromen-2-one derivatives (ABO). We established SAR with more than 100 analogues. To 
construct an informative SAR model, improve further drug design, and discover novel 
chemical entities with desired pharmacological properties, we will use molecular modeling 
studies to pursue quantitative structure-activity relationships (QSAR). QSAR is a well-known 
and useful method for drug discovery and development. Firstly, we will generate models with 
different QSAR methods, such as kNN,7 and validate them with test sets. Secondly, the best 
models will be applied for virtual screening. Meanwhile, the generated QSAR models will be 
utilized for ligand-based drug design.  
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